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Question: Foamy viruses (FV), and in particular PFV, have emerged in 
recent years as attractive gene therapy vector candidates. Since the 
lack of knowledge on molecular events in FV replication is a major hur-
dle for broader usage of foamy virus vectors, we aimed at elucidating 
PFV biology by investigating interactions of its capsid protein, Gag, 
with host cell components.
Methodology and result: To this end, we identified members of the 
mammalian PLK family as PFV Gag interactants in a commercial yeast-
two-hybrid (Y2H) screen and validated these results in detailed Y2H 
experiments for PLK1–3. In the yeast system, the intact PLK kinase and 
substrate recognition motifs were required for interactions with PFV 
Gag, in which a unique S224-T-P226 motif served as a PLK binding deter-
minant. PFV Gag mutants harbouring alanine substitutions of STP resi-
dues (iSTP) or phosphomimetic mutations of the T225 (pmSTP) failed 
to interact with PLK1–3 in yeast. These findings were corroborated by 
colocalization studies of ectopically expressed, fluorescently tagged 
proteins in mammalian cells, where mCherry-tagged PFV Gag was able 
to recruit eGFP-tagged PLK1 and 2 to condensed mitotic chromatin in 
an STP motif-dependent manner.
When characterizing PFV virions containing wild type or STP mutant 
Gag proteins, we observed that the mutations did not interfere with 
particle assembly, release or reverse transcription, but led to a 70  % 
titer reduction relative to wild type in single-round infection experi-
ments. These replication defects became more prominent in the rep-
lication-competent PFV context. Therefore, the lack of Gag STP mutant 
interaction with PLK proteins upon viral entry into host cells was likely 
underlying this replication deficit. This hypothesis was strengthened 
by the finding that enzymatic PLK inhibition in host cells during trans-
duction with wild type PFV mimicked the replication phenotype of 
PFV STP mutants. In addition to the overall reduced infectivity of the 
mutants, we also observed that the STP mutations in particle-asso-
ciated Gag lead to differential sensitivity to integrase inhibition by 
dolutegravir and resulted in decreased integration efficiency.
Conclusions: Taken together, our results demonstrate that PLK pro-
teins influence PFV replication by virtue of their interaction with the 
Gag protein, ensuring timely and efficient transduction.
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species of viral capsids during synchronized HIV‑1 infection
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After viral-to-cellular membrane fusion, a nucleoprotein complex 
enclosing the viral genome and composed of viral as well as cellular pro-
teins is released in the cell cytoplasm. The behavior of viral cores once 
inside the cell is notoriously difficult to apprehend especially given the 
metamorphic nature of these structures over time. To better understand 
the behavior of HIV-1 capsids, we have developed a novel assay that we 
named EURT, forEntry/Uncoating assay based on core-packagedRNA 
availability andTranslation. This novel entry-uncoating assay is based on 
the degree of exposure of a virion core-packaged mRNA reporter to the 
translation machinery of the target cell and it provides a measure of the 
status of viral capsids, as reporter RNA translation is prevented in hyper-
stable viral capsids. Using EURT, we highlight here that two kinds of 
viral cores coexist during HIV-1 infection: one that we define as open, in 
which the viral genome is readily accessible to the cytoplasmic environ-
ment and to the translation machinery and another that we define as 
close, in which access to the RNA is prevented until viral capsid is desta-
bilized. The results we have obtained so far indicate that the former 
species represents a dead-end product of infection, likely derived from 
improper or inefficient assembly of infectious virion units. Interestingly, 
IFNα that negatively impacts HIV-1 replication increases the proportion 
of open viral cores to the detriment of closed ones, suggesting a core-
destabilizing activity driven by interferon-regulated proteins. These and 
other results examining the relationship between core opening and 
reverse transcription will be presented.
Work in our laboratory is supported by the ANRS and Sidaction.
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HIV-1 must travel through the cytoplasm to reach the nuclear enve-
lope (NE) of an infected cell, transport through a nuclear pore to enter 
the nucleus, and integrate its genome into the chromosomal DNA of 
the host cell. Recently, we have labeled HIV-1 virions with APOBEC3F 
fused to yellow fluorescent protein (A3F-YFP), which remains stably 
associated with viral complexes, and visualized the viral complexes 
in infected cells to gain new insights into the early stages of viral 
replication. We showed that reverse transcription is not required for 
nuclear import of HIV-1 complexes, indicating that alterations in the 
viral capsid (CA) structure that accompany reverse transcription are 
dispensable for their nuclear import. We found that HIV-1 CA muta-
tions that altered the stability of the viral core significantly reduced the 
association of viral complexes with the nuclear envelope (NE) and their 
nuclear import. In addition, we found that nuclear viral complexes 
remain near NE and are not randomly distributed in the nuclei.
The dynamics of HIV-1 association with the NE and nuclear import 
in infected cells are not well understood. To gain insights into the 
dynamics of HIV-1 association with the NE, we analysed A3F-labeled 
HIV-1 complexes in living cells, and observed that most contacts 
between HIV-1 and NE form transient associations while few form sta-
ble associations, which are essential for nuclear import. Furthermore, 
HIV-1 capsid and host Nup358 played critical roles in forming the sta-
ble associations. Additionally, we observed the translocation of viral 
complexes from the cytoplasm to the NE during nuclear import. We 
determined that viral complexes have long residence times at the NE 
prior to import. After import, viral complexes exhibit a brief fast phase 
as they move away from the point of entry, followed by a long slow 
phase, suggesting they are associated with chromatin and/or other 
nuclear macromolecules. These studies provide novel insights into 
the dynamics of HIV-1 NE association, nuclear import, and nuclear 
movements.
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Human papillomavirus protein E4 potently enhances the 
susceptibility to HIV infection
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Sexually transmitted infections of the anogenital tract are important 
cofactors for HIV transmission, and acute infections by mucotropic 
human papillomaviruses (HPV) enhance the risk of HIV acquisition. 
Little is known about the molecular mechanisms involved in this 
increased susceptibility.
Here we show that the abundant E4 protein, which is encoded by both 
oncogenic and non-oncogenic HPV types, drastically enhances HIV 
infection. E4 is expressed in HPV-infected, ultimately disintegrating 
keratinocytes in the outermost cell layers of the anogenital mucosa. 
N-terminally cleaved forms of E4 self-assembled into cationic, inter-
mediate amyloid fibrils that captured and concentrated cell-free HIV 
particles, protecting their infectivity and promoting their envelope-
independent binding and envelope-dependent fusion to primary 
target cells. E4 drastically lowered the virus titer required for produc-
tive HIV infection in lymphoid organ cultures ex  vivo and infection 
enhancement occurred efficiently in vaginal fluid. Moreover, HIV-
permissive target cells were found to be recruited into HPV-induced 
lesions in the anogential mucosa.
Thus the concept emerges that aggregating cleavage products origi-
nating from body fluids, including semen, and from co-infecting 
pathogens can alone or in combination modulate the susceptibility to 
sexual transmission of HIV. In conjunction with the observational epi-
demiological evidence these findings provide a molecular rationale to 
extend anti-HPV vaccine programs to individuals at risk for HIV acquisi-
tion. The development of a new generation of broad-range vaccines 
that protect from infection with all circulating, oncogenic and non-
oncogenic mucosal HPV types may lower the global incidence of HIV 
infection.
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After retroviral infection of a target cell, during the early phase of rep-
lication, the HIV-1 genomic viral RNA is reverse transcribed by the viral 
reverse transcriptase (RT) to generate the double-stranded viral DNA 
that interact with viral and cellular proteins to form the pre-integration 
complex (PIC). Viral integrase (IN) is a key component of the PIC and 
is involved in several steps of replication notably in reverse transcrip-
tion, nuclear import, chromatin targeting and integration. Viral com-
ponents such as IN cannot perform these functions on their own and 
need to recruit host cell proteins to efficiently carry out the different 
processes. IN is a disordered protein showing high inter-domain flex-
ibility. This flexibility accounts for IN ability to interact with multiple 
partners allowing its multiple functions in viral replication. Yet the 
molecular mechanisms and dynamics of these processes, the role of 
cellular co-factors as well as of post-translational modifications remain 
largely unknown.
To produce and purify proteins participating in these transient macro-
molecular complexes we develop new technologies for high molecu-
lar weight transient complexes production as well as for functional 
and structural analysis. We demonstrated that the low solubility and 
inter-domain flexibility can be circumvented by forming stable and 
specific complexes with substrates such as DNA or protein co-factors 
and by post-translational modifications (PTMs). We purified HIV-1 IN 
alone and in complex with viral and cellular proteins produced in E. 
coli, insect and mammalian cells (Levy et al. 2016, Nature Communica-
tions 7:10932). Comparison of IN purified from E. coli, insect and mam-
malian cells production showed that IN purified from mammalian cell 
production showed higher solubility, increased 3′ processing activity 
as well as 5 PTMs (one phosphorylation and four acetylation). Mutant 
of the phosphorylated and acetylated sites were generated and their 
effect on viral replication and 3′ processing are analysed. Structural 
analysis of acetylation in the IN catalytic core domain suggest that 
acetylation participate in the modulation of IN multimerization.
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Regulation of retroviral integration by RNA polymerase II associated 
factors and chromatin structure
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HIV-1 integration occurs in highly Pol II transcribed and spliced regions 
of the chromatin thanks to the interaction between the retroviral 
intasome and the cellular tethering factor LEDGF/p75. These regions 
of the host genome are enriched in transcription and remodeling 
factors that are expected to modulate the chromatin access to the 
incoming intasome and its functional association with the targeted 
nucleosome. Since this final step has been shown to be regulated 
by both intasomes and chromatin structure we investigated these 
regulation processes focusing on the analysis of the IN/nucleosome 
interaction and on the role of the cellular proteins associated with 
the Pol II transcription apparatus. We found that HIV-1 IN specifically 
binds to the amino-terminal tail of human histone H4, a major com-
ponent of the nucleosome. This interaction was found required for 
optimal association and integration onto nucleomes. Functional 
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and structural analysis of this interaction led us to validate the pres-
ence of an unedited histone tail binding motif in the CTD of HIV-1 IN 
that behaves as an ancestral SH3/β-chromobarrel chromatin-reader 
domain and point out the critical role of the IN/H4 association during 
the retroviral integration process. Additionally, the analysis of the role 
of Pol II associated remodeling factors on this functional association 
led us to found that FACT (facilitates chromatin transcription) complex, 
a chromatin remodeler associated with Pol II and recently reported 
to bind LEDGF/p75, can regulate the access to the nucleosome and 
histone tails to the incoming intasomes. Mechanistic studies indicate 
that FACT generates partially dissociated nucleosomes structures that 
are highly favored substrates for HIV-1 integration. This partial nucleo-
some dissociation decreases the chromatin density in the vicinity of 
the integration site and, thus, allows the final association between 
intasomes and the targeted nucleosome. Consequently, our work 
highlights new host/pathogen interactions that could constitute novel 
and attractive targets for future potential therapeutic applications in 
addition to provide a better understanding of this crucial integration 
step of the retroviral replication.
Session 3: Transcription and latency
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Background: Cellular permissiveness to HIV infection is highly hetero-
geneous across individuals, as well as across cells from the same indi-
vidual. To investigate the major source of this difference and identify 
biomarkers, we developed a novel pipeline based on single-cell analy-
sis, where (i) cellular heterogeneity was evaluated at transcriptome 
level, and (ii) HIV permissiveness was correlated to cell surface protein 
expression.
Methods: Activated CD4+ T cells from a high and low permis-
sive donor were used for single-cell RNA-seq analysis (fluidigm C1™ 
technology).
Activated cells from the high permissive donor were infected with a 
GFP encoding HIV-based vector. Expression of 332 cell surface pro-
teins (LegendScreen™) was assessed by FACS and correlated with GFP 
expression.
Candidate biomarkers were validated in activated cells sorted accord-
ing to their protein expression level and infected by HIV vector.
Results: Transcriptomic profiles of 85 high and 81 low permissive 
single cells were successfully obtained. Transcriptional heterogeneity 
observed at single-cell level identified TCR-mediated cell activation as 
a major determinant of cellular heterogeneity.
Cell surface expression analysis of 332 proteins identified 76 candi-
dates correlating with successful HIV infection, including CD25, a typi-
cal activation marker.
Candidate biomarkers of HIV permissiveness were selected based on 
correlations between gene expression and activation (single-cell RNA-
Seq) and between surface protein expression and HIV permissiveness 
(LegendScreen™), and tested for their ability to capture permissive 
cells.
Eleven candidate biomarkers were successfully validated, showing 
enrichment of HIV permissive cells.
Conclusions: In this study, we developed a single-cell pipeline to 
investigate cell heterogeneity and identify gene candidates affect-
ing HIV permissiveness. Our data showed that, at the single-cell level, 
the status of cellular activation was the major driver of cell heteroge-
neity towards HIV permissiveness. Moreover, we identified several 
cell surface biomarkers characterizing the HIV permissive cell. This 
single-cell analysis pipeline represents a valuable tool for biomarker 
identification.
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To identify key steps of the HIV-1 life cycle that are dependent on cap-
sid (CA), we have developed differential high throughput chemical 
screening. The CA point mutation N74D makes HIV-1 independent of 
several host factors. Taking advantage of this phenotype, CD4+ T cells 
were co-infected with two HIV-1 vectors (WT-GFP and N74D-mCherry), 
which were identical except for the CA N74D mutation. Compound 
libraries were screened to find molecules that selectively inhibited 
infection of WT over N74D, which, by implication, should affect directly 
or indirectly the interaction between host factors and HIV-1 CA.
We found that digoxin selectively inhibited infection of WT in both 
CD4 T cell lines and primary memory CD4 T cells, repressing HIV-1 
gene expression. The antiretroviral activity of digoxin was dependent 
on the Na/K ATPase. To identify the mechanism of digoxin selectiv-
ity, we infected CD4 T cells with WT or N74D virus in the presence of 
digoxin then analysed in parallel the cellular transcriptional profile by 
RNAseq and integration site selection by deep sequencing. RNAseq 
showed that digoxin up-regulated 221 genes and down-regulated 336 
genes ≥fourfold. Within the up-regulated genes, the main biological 
functions affected by digoxin were regulation of cell cycle, chromatin 
remodeling, RNA processing, cell survival. Within the down-regulated 
gene group, the main biological functions impinged by digoxin were 
antigen presentation, T cell activation and metabolism. Two main 
gene networks down-regulated by the drug were CD40L and CD38 
markers of T cell activation.
We examined >400,000 unique integration sites and discovered that 
WT virus had a stronger bias relative to N74D virus to integrate within 
or near genes susceptible to down-regulation by digoxin. Of those, 
integration within or near genes involved in T cell activation was two-
fold more frequent for WT virus than N74D virus and 3.8-fold more fre-
quent than integration near any gene. Thus WT virus is more sensitive 
to digoxin than N74D because it integrates more frequently within or 
near genes down-regulated by the drug. We discovered a functional 
connection between integration preference and T cell activation and 
metabolism that is dependent on CA, which may affect the establish-
ment of latency and the control of viral reactivation.
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Bovine leukemia virus (BLV), the etiologic agent of enzootic bovine 
leucosis, is a B-lymphotropic oncogenic retrovirus closely related 
to the human T cell leukemia virus I and II (HTLV-I and II). It is widely 
accepted that BLV latency, due to the RNA polymerase II (RNAPII) 
5′LTR-driven transcriptional and epigenetic repression, is a viral strat-
egy used to escape from the host immune system and contribute to 
tumor development. However, by deep sequencing and bioinformat-
ics analysis, a highly expressed BLV micro-RNA (miRNA) cluster has 
been recently reported, suggesting that the silencing dogma in BLV 
transcriptional regulation is only partially correct. In addition, these 
viral miRNAs are produced through a non-canonical process, involving 
RNA polymerase III (RNAPIII).
In this report, we used chromatin immunoprecipitation assays to dem-
onstrate the in vivo recruitment of a bona fide RNAPIII complex to the 
BLV miRNA cluster both in BLV-latently infected cell lines and in ovine 
BLV-infected primary cells, through a canonical type 2 RNAPIII pro-
moter. In addition, by specific knockdown of the RPC6 RNAPIII subu-
nit, we showed a direct functional link between RNAPIII transcription 
and BLV miRNAs expression. Furthermore, in BLV-latently infected cell 
lines and in ovine BLV-infected primary cells, we showed that both the 
tumor- and the quiescent-related isoforms of RPC7 RNAPIII subunits 
were recruited to the miRNA cluster, consistent with previous stud-
ies showing that the viral miRNAs are transcribed at all stages of BLV 
disease. Epigenetically, we demonstrated that the BLV miRNA cluster 
was enriched in positive epigenetic marks in agreement with the high 
expression level of the viral miRNAs previously reported. Interestingly, 
we also demonstrated the in vivo recruitment of RNAPII at the 3′LTR/
host genomic junction, associated with positive epigenetic marks. 
Functionally, we showed that the BLV LTR exhibited a strong antisense 
promoter activity and identified cis-acting elements of an RNAPII-
dependent promoter. Finally, we provided evidence for an in vivo colli-
sion between RNAPIII and RNAPII convergent transcriptions.
Taken together, our results provide new insights into alternative ways 
used by BLV to counteract silencing of the viral 5′LTR promoter.
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Method: Early after HIV-1 acquisition, cellular viral reservoirs are 
formed containing latent, but infectious, HIV-1. Cells belonging to 
these latent reservoirs can, when activated, reestablish new viral 
infections in the absence of antiretroviral therapy (ART). How latently 
infected cells are activated in patients is still unclear. To examine 
whether cellular signaling between cells can activate latent HIV-1, we 
co-cultured tissue-specific immune cells, including a large panel of 
dendritic cell subsets with latently infected cells. Next, we measured 
reversal of HIV-1 latency using our in  vitro latency model. Moreover, 
by using specific signaling pathway inhibitors we determined which 
intracellular signaling pathways are important for reversion: making 
latent HIV replication competent upon cell–cell contact.
Results: Our results demonstrate that blood or genital tract den-
dritic cells do not activate latent provirus in effector T-cells, whereas 
gut or lymphoid dendritic cells induce virus production from latently 
infected effector T-cells. Dendritic cells were also able to activate latent 
HIV-1 in resting T cells from patients as measured with the virus out-
growth assay. We could show that activation was not triggered via 
classical T-cell stimulation pathways, but that activation occurred via 
the mTORC1 pathway.
Conclusion: In this study, we show that HIV-1 provirus residing in the 
effector T-cells is activated from latency by tissue-specific dendritic cell 
subsets and other immune cells with remarkably different efficiencies. 
Our results suggest that the observed rapid depletion of T cells in the 
gut can be attributed to the large quantities of gut dendritic cells that 
constantly promote virus propagation from latently infected cells.
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Background: HIV RNA is known to contain a large number of cis-act-
ing sequences such as the TAR stem loop, packaging signal and the 
Rev responsive element with which HIV controls its lifecycle.
Methods: Bioinformatics analysis across HIV sequences has identified 
regions with high sequence homology to motifs associated with sub-
cellular trafficking of RNA in other systems. The motifs were synony-
mously mutated in HIV and viral replication kinetics examined.
Results: Upon disruption of these elements, we observed a phe-
notypic effect on virus replication manifest as a slow virus growth 
rate but showed cell type specificity, being most apparent in physi-
ologically relevant T cells but not commonly used cell lines. This effect 
seems to act at the early stage of the virus life cycle as the overall 
production of HIV-1 Gag protein is reduced leading to a diminished 
amount of intracellular viral protein.
Conclusions: Studies to date implicate a transcriptional or post-transcrip-
tional defect involving members of the ESCRT group of cellular proteins.
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Different organisms show differences in the frequency of occurrence 
of synonymous codons (codon usage bias). In contrast to humans, HIV 
uses in general the most A-rich codon for a certain amino acid. Codon 
usage influences protein production on various levels, starting from 
gene expression over RNA metabolism to translation.
Previous studies of our group showed that adapting the gag gene to 
human codon usage (huGag) led not only to a significantly increased 
protein production but also caused independency of Rev, an acces-
sory protein of HIV which mediates the export of unspliced and incom-
pletely spliced HIV mRNAs. The aim of this work is to gain insight into 
the effects of codon adaptation on gag expression, especially regard-
ing length and position. For this, subgenomic gag reporter constructs 
were generated that extend the humanized part of the gene stepwise 
from 5′end to 3′end as well as from 3′end to 5′end. Those constructs 
were then transfected into HEK293T cells. Gag expression was investi-
gated on protein level by p24 ELISA as well as on RNA level by North-
ern blot analysis and qPCR.
It became apparent that humanization of the very 5′ end is necessary 
for enhanced protein production and Rev-independent expression. 
Moreover, increasing the length of the humanized sequence starting 
from the 5′ end directly correlated with p24 levels. Contrary to that, 
such a correlation is lacking for constructs humanized progressively in 
3′ to 5′ direction. Interestingly, even humanization of the whole gag 
except of the 5′part remained Rev-dependent and thus did not show 
enhanced gag expression. Inhibition of Rev-mediated export with 
LMB confirmed the Rev-independency of huGag and showed that 
Rev-dependency decreased with increasing length of the optimized 
sequence part. Relative quantification of the RNA levels corroborated 
the results obtained on protein level. The existence of cryptic splicing 
products could be ruled out by Northern Blot analysis.
In summary, codon adaptation of the 5′ part of HIV gag seems to 
be necessary for enhanced and Rev-independent Gag expression. 
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Clarification of the underlying molecular mechanisms could help to 
understand how HIV benefits from the deviant codon usage.
Session 5: Assembly & release
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Transmission of Human T-cell leukemia virus type 1 (HTLV-1) between 
CD4+ T-cells requires cell–cell contacts and remodeling of the host cell 
cytoskeleton. The viral transactivator Tax is crucial for formation of the 
virological synapse (VS), a specialized cell–cell contact. At the VS, polar-
ized budding of virions into synaptic clefts and transfer of viral biofilms 
to target cells takes place. Furthermore, HTLV-1 is transmitted via cel-
lular protrusions. The actin-bundling protein Fascin is Tax-dependently 
upregulated in HTLV-1-infected T-cells and important for the forma-
tion of protrusive structures. Here, we report that Fascin is required for 
HTLV-1 transmission. Repression of endogenous Fascin by short hairpin 
RNAs or delocalization of Fascin by nanobodies impaired virus trans-
mission and release using single-cycle replication-dependent HTLV-1 
reporter vectors in 293T cells. Beyond, HTLV-1 release and cell-to-cell 
transmission were enhanced by Tax-induced Fascin in Jurkat T-cells in 
co-culture with Raji/CD4+ B-cells. In chronically HTLV-1-infected T-cells, 
virus release, transfer of gag p19 to target cells and transactivation of 
co-cultured reporter T-cells was decreased upon knockdown of Fascin. 
Spotting the mechanism, confocal laser scanning microscopy revealed 
that Fascin and actin accumulate at cell–cell contacts suggesting that 
Fascin enhances T-cell conjugate formation. However, Fascin was not 
necessary for Tax-induced T-cell aggregation as exploited by automatic 
image analysis and flow cytometry-based aggregation assays. Yet, Fas-
cin potentially regulates dissemination of infected cells as knockdown of 
Fascin reduced adhesion of HTLV-1-infected MT-2 cells. Immunofluores-
cence analysis of cell–cell-contacts between HTLV-1-positive MS-9 cells 
co-cultured with Jurkat T-cells revealed the following: (1) short Fascin-
containing protrusions extend from infected cells and clutch target cells, 
(2) Fascin and gag localize in long-distance cellular protrusions in close 
proximity or partially co-localize, and (3) clusters of Fascin are inter-
spersed by clusters of gag reminiscent of viral biofilms. Taken together, 
we found that endogenous and Tax-induced Fascin is crucial for HTLV-1 
transmission, potentially by redirecting viral proteins to budding sites.
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We recently reported that the T cell immunoglobulin and mucin 
domain (TIM) proteins inhibit release of HIV-1 and other enveloped 
viruses by interacting with virion- and cell-associated phosphatidylser-
ine (PS) (Li et al., PNAS 111, 2014). In this study, we demonstrate that 
the Nef proteins of HIV-1 and other lentiviruses antagonize TIM-medi-
ated restriction. We show that TIM-1 exhibits stronger inhibition of 
the release of Nef-deficient relative to Nef-expressing HIV-1 particles 
and that ectopic expression of Nef relieves this restriction. Consistent 
with this finding, knockdown of endogenous TIM-3 in human PBMCs 
effectively enhances the production of Nef-deficient HIV-1 particles. 
HIV-1 Nef does not appear to downregulate TIM-1 expression on the 
cell surface, nor does it disrupt TIM-1 incorporation into HIV-1 virions. 
Interestingly, we observed that coexpression of SERINC3 and SERINC5 
potentiates TIM-1 inhibition of HIV-1 release, and that depletion of 
SERINC proteins in viral-producer cells rescues TIM-mediated inhibi-
tion of HIV-1 release. These results suggest that SERINCs are involved 
in TIM-mediated restriction of HIV-1 release. In addition to HIV-1 Nef, 
the Nef proteins of simian immunodeficiency virus (SIV) strains and 
HIV-2 also antagonize the antiviral activity of TIM-1, suggesting an 
evolutionarily conserved role of the lentiviral nef gene in antagoniz-
ing TIMs. Collectively, our work reveals a new role for lentiviral Nef in 
antagonizing TIM, and highlights a complex interplay between lentivi-
ral Nef and cellular restriction by TIMs and SERINCs.
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Human Immunodeficiency Virus Type 1 (HIV-1), the causative agent of 
Acquired Immunodeficiency Syndrome (AIDS), has currently infected 
35 million people and caused 1.5 million deaths in 2013 with no cure 
available. 85 % of all new infections occur following sexual intercourse 
where semen is the main vector of HIV-1 transmission. Instead of being 
a passive carrier, semen enhances HIV infectivity, an activity that is 
attributed to amyloid fibrils present in semen. These fibrils self-assem-
ble from peptides derived from prostatic acidic phosphatase (PAP) or 
semenogelins where SEVI (Semen-derived Enhancer of Virus Infec-
tion) formed from PAP248–286 is the best characterised. The cationic 
surface of semen amyloid allows capturing negatively charged HIV-1 
virions and increases attachment to and thus infection of target cells. 
Interestingly, HIV-1 particles are relatively labile and have a reported 
half-life of only a few hours in serum, probably due to gp120 shedding 
and membrane rupture induced by shearing forces. We hypothesized 
that amyloid, by binding and concentrating, may stabilize virions 
resulting in a prolonged infectious half-life. We thus performed HIV-1 
decay kinetics in buffer, and in the presence of SEVI or human semen 
at 37  °C. We found that the infectious half-life of HIV-1 in buffer was 
2.5 ± 1.3 h, independent on the virus concentration used. Incubation 
with physiological concentrations of SEVI increased infection rates and 
additionally extended the viral half-life to 12.1 ±  2.7  h (p  <  0.0001). 
This effect was observed using lab adapted NL4-3 as well as trans-
mitted/founder (T/F) HIV-1 variants. Furthermore, HIV-1 incubated in 
semen reached half-lives up to 10.2 ±  3.2  h (p  <  0.0001). This effect 
was abrogated by depleting semen of amyloid, suggesting it accounts 
for the observed phenomenon. Normalizing for initial infection rates 
revealed that the extended half-lives in the presence of SEVI or semen 
are independent of infectivity enhancing effects. Conclusively, semen 
increases HIV infection not only by promoting attachment of virions 
to target cells but also by increasing the infectious half-life. Conse-
quently, antagonizing semen amyloid might not only lower the infec-
tivity but also the stability of HIV-1 particles in semen, and might find 
application in microbicides designed to impede HIV spread.
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Background: Retroviruses can infect an organism at mucosal surfaces 
after sexual and mother to child transmission. They can also be trans-
mitted horizontally through contact with body fluids such as blood, 
semen and saliva of retrovirus-infected individuals. Irrespective of the 
path retroviruses take to establish an infection within the host, retrovi-
ruses pass through secondary lymphoid organs such as lymph nodes 
and the spleen. Unfortunately, the critical events and the mechanism 
leading to the initial infection and subsequent spread of retroviruses 
at secondary lymphoid organs are currently unknown.
Results: Here, we show that sinus-lining macrophages of second-
ary lymphoid tissue contribute to establish infection by lymph- and 
blood-derived human immunodeficiency virus and murine leuke-
mia virus. We identify the I-type lectin CD169/Siglec-1 to mediate 
Env-independent capture of retroviral particles followed by efficient 
trans-infection of permissive lymphocytes in peripheral lymph nodes 
and spleen. Using blocking antibodies and mice lacking CD169, we 
demonstrate that CD169-dependent trans-infection is required for the 
establishment of viral infection in mice. Applying intravital microscopy 
and EM tomography we visualize the formation of infectious synapses 
between CD169+ macrophages and target cells and subsequent virus 
transmission across cell–cell contacts in vivo.
Conclusions: Our results highlight the central role of CD169-express-
ing macrophages in retrovirus transmission and identify trans-infec-
tion as an important mechanism to establish retrovirus infection 
in  vivo. Given the strategic position of CD169+ macrophages at the 
interface between extracellular body fluids such as lymph and blood 
to lymphoid tissues, our data suggest that retroviruses spread in vivo 
by a combination of cell-free spread within extracellular fluid followed 
by the CD169-dependent capture of cell-free virus and efficient trans-
infection of permissive lymphocytes.
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The presence of a vpu gene and the lack of Nef-mediated downmodu-
lation of the T cell receptor (TCR) CD3 distinguish HIV-1 and its simian 
precursors from primate lentiviruses that replicate efficiently in their 
natural host without causing disease. For example, SIVagm from Afri-
can Green Monkeys (AGMs), which does not encode vpu but down-
modulates CD3, is generally not pathogenic in its natural host species. 
Here, we generated HIV-1-like derivatives of SIVagm containing a func-
tional vpu and/or an HIV-1 nef allele. Although all chimeric viruses rep-
licated with similar efficiencies in cell culture, their replication fitness 
in infected AGMs was strikingly different. While insertion of vpu alone 
prevented SIVagm infection in vivo, insertion of HIV-1 nef attenuated 
viral replication after acute infection. SIVagm containing both vpu and 
HIV-1 nef maintained high viral loads for more than 4  years without 
causing disease, whereas individual introduction of vpu disrupted and 
of HIV-1 nef impaired viral replicaton in AGMs. Thus, Vpu and Nef coop-
erate to allow efficient viral replication in vivo and host factors seem 
to play a key role in the non-pathogenic course of SIVagm infection in 
AGMs.
To study the genetic and functional evolution of Vpu and Nef in the 
AGMs infected with SIVagm or the chimeric variants thereof, the 3′ 
halves of the viral genomes were amplified by single-genome ampli-
fication (SGA). The great majority of the PCR fragments contained 
intact vpu and nef ORFs, and sequence alignments revealed that these 
accessory genes were highly conserved. All Vpus tested were active 
in downmodulating CD4, NTB-A and CD1d. Furthermore, all AGM-
derived vpu alleles suppressed NF-kB activation, reduced AGM Teth-
erin cell surface expression and promoted infectious virus release. The 
nef alleles maintained the functional properties of the parental SIVagm 
and HIV-1 nef genes. Notably, none of the HIV-1 nef alleles became 
active in downmodulating CD3 or in counteracting AGM tetherin, irre-
spectively of the presence of a vpu gene.
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Human induced pluripotent stem cells (hiPSCs) can differentiate into 
every cell type of the adult body and hold substantial promise for 
regenerative medicine and as in vitro models of disease and develop-
ment. However, reprogramming and subsequent cultivation of hiP-
SCs can induce genetic and epigenetic abnormalities that can result 
in tumorigenic hiPSCs. Thus, it is unclear if hiPSCs or their derivatives 
are safe for administration. Genomic mutations may undermine their 
use in regenerative medicine. Activation of the human endogenous 
mobile retrotransposons LINE-1 (Long Interspersed Element-1, L1), 
Alu and SVA has the potential to cause such mutations. In differenti-
ated cells, L1 is primarily suppressed by methylation of its CpG-rich 
promoter, but we show that reprogramming triggers transcription of 
functional L1 elements via demethylation and specific transcription 
factors that are absent from differentiated cells. To investigate if the 
observed L1 activation in hiPSCs leads to L1-mediated mobilization, 
we applied retrotransposon capture-sequencing (RC-seq) to 8 hiPSC 
lines, their parental cells and human embryonic stem cell lines (hESCs). 
We identified, mapped and validated individual L1, Alu and SVA de 
novo retrotransposition events that occurred during reprogramming 
into hiPSCs and cultivation of hiPSCs and hESCs, and timed the period 
during hiPSC cultivation when individual de novo insertions occurred. 
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Each hiPSC was estimated to carry ~1 L1 de novo insertion. As ~50 % of 
all de novo retrotransposition events occurred in protein-coding genes 
that are actively transcribed in hiPSCs, including genes playing roles 
in oncogenesis, development or signal transduction, we investigated 
effects of these intronic insertions on host gene expression in hiPSCs. 
To exemplify the consequences of even short intronic L1 de novo inser-
tions, we analysed effects of the 390-bp L1 de novo insertion L1-dn13 
in CADPS2 intron 7 on CADPS2 transcription in hiPSCs, and demon-
strate significant interference of L1-dn13 with allelic CADPS2 gene 
expression. Our experiments demonstrate incidence, and functional 
impact of reprogramming-activated endogenous retrotransposition 
in hiPSCs and imply consequences for the biological safety of hiPSC-
derived cell therapies.
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NF‑κB activation induces expression of human endogenous 
retrovirus and particle production
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Question: Human endogenous retroviruses (HERVs) are prevalent in 
the human genome, mainly as defective proviruses or solo long termi-
nal repeats (LTRs). The presence of HERVs can potentially alter human 
gene expression since the LTRs contain binding sites for numerous 
transcription factors, as well as for steroid hormone and nuclear recep-
tors. While these sites have been predicted by sequence analysis, they 
have not been shown to be functional in vivo.
Methods: In order to assess the responsiveness of these binding sites, 
we used a cell line that is known to be permissive for HERV expres-
sion. The human embryonic carcinoma cell line, NCCIT, has been 
demonstrated to express HERVs and to produce mature particles. This 
is likely facilitated by the loss of the usual epigenetic suppression of 
HERV expression, such as by global hypomethylation that is frequently 
observed in cancer cells. The cells were treated with drugs, hormones 
and cytokines, then HERV-K env and pol expression was analysed by 
quantitative PCR (qPCR).
Results: We found that the cytokines interleukin-1α (IL-1α) and 
tumour necrosis factor α (TNFα), as well as the Toll-like receptor-4 
(TLR4) ligand lipopolysaccharide (LPS), increased HERV transcription in 
the NCCITs. Further, these ligands dramatically increased HERV-K parti-
cle production by these cells.
Conclusions: Since these ligands activate innate immune signalling 
pathways to the transcription factor nuclear factor-κB (NF-κB), we 
hypothesise that the HERV-K LTRs are responsive to NF-κB binding. 
Thus, pro-inflammatory conditions could lead to increased HERV-K 
expression if the LTRs are de-repressed for other reasons, such as in the 
context of cancer.
Session 7a and b: Innate sensing & intrinsic immunity
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SAMHD1 is a critical HIV-1 restriction factor in non-dividing, myeloid 
and resting CD4+ T cells. As a dNTPase, SAMHD1 reduces dNTP levels 
below those required for reverse transcription. The restrictive activ-
ity of SAMHD1 is negatively regulated by phosphorylation: in cycling 
cells, SAMHD1 is phosphorylated at T592 and unable to restrict HIV-1 
infection. Upon entry into a non-cycling state, T592 phosphorylation is 
lost and SAMHD1 rendered active against HIV-1.
SAMHD1 is phosphorylated by CDKs/cyclin A2, but the phosphatase 
acting on SAMHD1 is currently unknown. Using tandem affinity purifi-
cation followed by MS analysis, we identified the Aα subunit of protein 
phosphatase 2A (PP2A) to potentially interact with SAMHD1. PP2A 
holoenzymes are composed of a scaffolding (A), catalytic (C) and vari-
able regulatory (B) subunit, which can be recruited out of 4 different 
families. Specific PP2A holoenzymes are known to reverse CDK1-medi-
ated phosphorylation events at the end of mitosis—consistent with 
the fact that SAMHD1 loses T592 phosphorylation rapidly upon entry 
into G1, as we could observe in synchronized HeLa ‘Kyoto’ cells using a 
thymidine block/release protocol.
After pull-down of PP2A-B55α trimers, SAMHD1 was specifically 
enriched. In line with this observation, only PP2A-B55α trimers were 
able to efficiently remove SAMHD1 phosphorylation at T592 in in vitro-
dephosphorylation assays. We verified the specificity as (i) the inhibi-
tor okadaic acid prevented dephosphorylation by PP2A and (ii) the 
protein phosphatase 1 (PP1) had no influence. Upon incubation with 
equilibrated units of de novo purified PP2A dimers or PP1, MS-based 
quantification of (non-)phosphorylated SAMHD1 peptides revealed 
that only PP2A dimers were able to remove phosphorylation at T592 
in  vitro. Furthermore, silencing of PP2A-B55α trimers in  vivo using 
specific siRNAs led to increased T592 phosphorylation in HeLa ‘Kyoto’ 
cells. To characterise dephosphorylation at T592 at M/G1 transition in 
more detail, we chemically induced exit from mitosis in HeLa ‘Kyoto’ 
cells and observed impaired T592 dephosphorylation upon silenc-
ing of PP2A-B55α trimers. Taken together, we determined PP2A-B55α 
holoenzymes responsible for dephosphorylating SAMHD1 during M/
G1 transition and rendering SAMHD1 active against HIV-1.
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In contrast to activated CD4 T cells, resting CD4 T cells from periph-
eral blood are highly resistant to productive HIV-1 infection. Infection 
of resting CD4 T cells is restricted at the level of reverse transcription. 
This block can be overcome by virion-packaged Vpx proteins that tar-
get SAMHD1 for proteasomal degradation and elevate cellular dNTP 
pools. Here we find that Vpx proteins from distinct SIV lineages, SIVrcm 
and SIVmnd-2, enhanced the HIV-1 susceptibility in the absence of 
SAMHD1 degradation or elevation of dNTP pools in resting CD4 T cells, 
but not macrophages. This infection enhancement was paralleled by 
a dramatic increase of RT intermediates and total HIV-1 cDNA. Single 
amino acid changes enabled the prototypic SAMHD1-degrading Vpx-
mac239 to enhance early post-entry step of HIV infection in rcm/mnd2-
like fashion. Importantly, Vpx enhanced HIV infection of resting PMBCs 
of an AGS patient that lacks expression of functional SAMHD1. These 
results demonstrate that Vpx, in addition to SAMHD1, overcomes a 
previously unappreciated post-entry restriction of HIV-1 that is specific 
to resting CD4 T cells.
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SAMHD1 acts as a dNTP triphosphohydrolase and blocks the replica-
tion of retroviruses and retroelements in nondividing cells. Here, we 
use SAMHD1 knockout mice to analyze the regulation and the mecha-
nism of SAMHD1 restriction and to determine the impact of SAMHD1 
on antiviral sensing. Previously, we found that the lack of SAMHD1 trig-
gers a spontaneous upregulation of IFN-inducible genes (ISGs) in vari-
ous murine cell types. We therefore infected SAMHD1 knockout mice 
lacking the type I IFN receptor (IFNAR) with HIV reporter virus and ana-
lysed splenocytes of the mice 72  h postinfection. We found a strong 
increase in infected splenocytes of SAMHD1/IFNAR KO mice compared 
to SAMHD1 KO mice, suggesting an IFN-depended antiviral mecha-
nism in the absence of SAMHD1 in  vivo. In addition, we found that, 
similar to human SAMHD1, the antiviral activity of mouse SAMHD1 
is regulated through phosphorylation and is limited to nondividing 
cells. Comparing the susceptibility to infection with intracellular dNTP 
levels and SAMHD1 phosphorylation showed that both functions are 
important determinants of the antiviral activity of murine SAMHD1. 
In contrast, we found the proposed RNase activity of SAMHD1 to be 
less important and could not detect any effect of mouse or human 
SAMHD1 on the level of incoming viral RNA. Our findings show that 
murine SAMHD1 blocks retroviral infection at the level of reverse tran-
scription and is regulated through a cell cycle-dependent phospho-
rylation at threonine 603. Together, we show that the antiviral block 
mediated by murine SAMHD1 is mechanistically similar to what is 
known for the human protein, making the SAMHD1 KO mouse model 
a valuable tool to study the impact of SAMHD1 on the replication of 
different viruses in vivo.
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Question: So-called host cell restriction factors (RFs) potently sup-
press HIV-1 replication in cell lines and primary cell culture models. In 
theory, RFs might represent attractive targets for the development of 
novel antiviral treatment strategies but their importance for virus con-
trol in vivo is controversial.
Methods: Here, we profiled the expression of RFs including p21, 
SAMHD1 and Tetherin in primary blood-derived mononuclear cells 
(PBMC) from untreated, therapy-naïve HIV-1 patients and quantified 
cellular infection levels.
Results: There was overall no correlation between the expression of 
the individual RFs and HIV-1 control versus progression in patients. 
However, we identified a T cell population that was negative for intra-
cellular CD2 and expresses low levels of SAMHD1, p21 and the recently 
identified inhibitor of HIV-1 infectivity SerinC5. CD2-negative T-cells 
with low RF expression levels were highly HIV-infected in compari-
son to their CD2+ counterparts and the extent of CD2-negative T-cell 
infection was a marker of HIV-1 progression. Altogether, we report an 
association of RF expression levels with the extent of HIV-1 infection in 
primary T cells directly isolated from untreated patients.
Conclusions: Our study supports the in  vivo importance of RFs for 
HIV-1 control and highlights RFs as promising targets for therapeutic 
intervention.
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Upon HIV infection, reverse transcribed DNA present in the cytoplasm 
can be sensed by cellular pattern recognition receptors, resulting 
in the induction of antiviral type I IFN and expression of interferon-
stimulated genes that exert numerous antiviral functions. Specifically, 
upon DNA binding, the protein cyclic GMP-AMP Synthase (cGAS) syn-
thesizes the unique second messenger cGAMP that binds to STING 
to activate downstream IFN signaling. It has been proposed that this 
signaling pathway is engaged upon HIV infection, especially in the 
absence of TREX1, a cellular exonuclease that degrades excess viral 
DNA that escapes the viral core. However, HIV-1 perfectly inhibits and 
evades intrinsic immune responses. Most of these studies have been 
performed with cell-free HIV-1 particles.
We established an HIV-1 cell-to-cell transmission model using HIV-
1-infected human PBLs and autologous macrophages as donor and 
target cell populations, respectively. Upon cell-to-cell transmission, 
HIV-1 infection led to a robust interferon response, an observation 
which was not recapitulated in assays using cell-free HIV-1 particles 
although the resulting percentage of infected target macrophages 
was in a similar range as in the condition of cell-to-cell transmission. 
Specifically, IFN-beta mRNA expression and release of bioactive type I 
IFN in the culture supernatant were induced.
To understand the specific signatures of the cellular responses to each 
infection mode, the expression of known cellular key players was 
decreased using siRNA in target macrophages showing that this IFN 
induction required STING, but not cGAS. Moreover, direct contact of 
donor and target cells and functional HIV-1 Env-mediated fusion were 
necessary. HIV-1-infected PBLs, but not their cell-free virions, con-
tained SVPDE-sensitive, IFN-inducing small molecules, most conceiv-
ably cGAMP. These data are in line with intercellular transfer of cGAMP 
from infected PBLs to target macrophages, where cGAMP binds to 
STING and triggers a type I IFN induction in a fashion that bypasses the 
necessity of functional cGAS in macrophages.
We propose that, in HIV-1-infected tissues, cGAMP-mediated innate 
immunity spreads predominantly via direct cell–cell contacts that result 
in cytoplasmic mixing of HIV-1-infected and neighboring target cells.
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Perturbation of innate RNA and DNA sensing by human T cell 
leukemia virus type 1 oncoproteins
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Chin‑Ping Chan1, Dong‑Yan Jin1 
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Human T-cell leukemia virus type 1 (HTLV-1) chronically infects 5–20 
million people worldwide, causing adult T-cell leukemia (ATL) and 
tropical spastic paraparesis in a small subset of them. Interferon (IFN) 
α is a key innate immune effector and its combination with zidovu-
dine, which is a nucleoside reverse transcriptase inhibitor, is the rec-
ommended standard first-line therapy for ATL. It is thought that viral 
RNA and proviral genome in HTLV-1-infected cells are sensed by the 
host sensor proteins to induce type I IFNs. Exactly how HTLV-1 perturbs 
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this induction remains to be fully understood. In this study we report 
on the perturbation of innate RNA and DNA sensing by HTLV-1 onco-
proteins Tax and HBZ. The induction of IFN-β production was blunted 
in HTLV-1-transformed ATL cells and in T lymphocytes freshly infected 
with HTLV-1. Interestingly, HTLV-1 oncoproteins Tax and HBZ displayed 
differential activity to perturb innate RNA sensing mediated by RIG-I 
and PACT as well as innate DNA sensing mediated by cGAS, cGAMP and 
STING. The perturbation occurred at a step prior to IRF3 activation since 
neither Tax nor HBZ was capable of suppressing the activity of a domi-
nant active phosphomimetic IRF3 mutant IRF3-5D. Tax and HBZ were 
found to associate with TBK1, IKKε, STING and IRF3. In vitro phosphoryl-
ation assay indicated the suppression of TBK1-mediated phosphoryla-
tion of IRF3 and other substrates by Tax. Taken together, our findings 
suggested that HTLV-1 oncoproteins Tax and HBZ differentially modu-
late innate RNA and DNA sensing in infected cells. Our findings might 
reveal new strategies and compounds that could be used to improve 
IFN-based anti-HTLV-1 and anti-ATL therapy. Supported by HKRGC 
(HKU171091/14M, HKU271215/15 and C7011-15R), HMRF (HKM-
15-M01 and 15140682) and SK Yee Medical Research Fund (2011).
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HIV-1 is transmitted primarily across mucosal surfaces and rapidly 
spreads within the intestinal mucosa during acute infection. The type 
I interferons (IFNs) likely serve as a first line of defense, but the relative 
expression and antiviral properties of the 12 IFNα subtypes against 
HIV-1 infection remain unknown. We evaluated the expression of all 
IFNα subtypes in HIV-1-exposed plasmacytoid dendritic cells and 
PBMC of HIV-infected individuals. We also determined the relative anti-
viral potency of each IFNα subtype ex vivo using the human intestinal 
Lamina Propria Aggregate Culture or an PBMC model. IFNα8, IFNα6, 
IFNα14, IFNα17, and IFNα21 were the most potent in restricting HIV-1 
infection in  vitro. IFNα2, the clinically-approved subtype, and IFNα1 
were both highly expressed but exhibited relatively weak antiviral 
activity. The relative potencies correlated the induction levels of HIV-1 
restriction factors Mx2 and Tetherin/BST-2.
We also demonstrate in a humanized mouse model that, when deliv-
ered at the same high clinical dose, the human IFNα14 subtype has 
very potent anti-HIV-1 activity in  vivo whereas IFNα2 does not. In 
both post-exposure prophylaxis and treatment of acute infections, 
IFNα14 but not IFNα2 significantly suppressed HIV-1 replication and 
proviral loads. Whereas ineffective IFNα2 therapy was associated with 
CD8+ T cell activation, successful IFNα14 therapy was associated with 
increased intrinsic and innate immunity including significantly higher 
induction of tetherin and MX2, increased APOBEC3G signature muta-
tions in HIV-1 proviral DNA, and higher frequencies of TRAIL + NK cells. 
These results identify IFNα14 as a potent new therapeutic that operates 
via mechanisms distinct from antiretroviral drugs. The ability of IFNα14 
to reduce both viremia and proviral loads in vivo suggests that it has 
strong potential as a component of a cure strategy for HIV-1 infections.
O27 
Vpu‑mediated counteraction of tetherin is a major determinant 
of HIV‑1 interferon resistance
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HIV-1 groups M, N, O and P are the result of independent zoonotic 
transmissions of SIVs infecting great apes in Africa. Among these, 
only Vpu proteins of pandemic HIV-1 group M strains evolved potent 
activity against the restriction factor tetherin which inhibits virus 
release from infected cells. Thus, effective Vpu-mediated tetherin 
antagonism may have been a prerequisite for the global spread of 
HIV-1. To determine whether this particular function enhances primary 
HIV-1 replication and interferon resistance, we introduced mutations 
into the vpu gene of HIV-1 group M and N strains to specifically disrupt 
their ability to antagonize tetherin, but not other Vpu functions, such 
as degradation of CD4, down-modulation of CD1d and NTB-A, and 
suppression of NF-κB activity. Lack of particular human-specific adap-
tations reduced the ability of HIV-1 group M Vpu proteins to enhance 
virus production and release from primary CD4+ T cells at high levels 
of type I IFN from about fivefold to twofold. Interestingly, transmitted-
founder HIV-1 strains exhibited higher virion release capacity than 
chronic control HIV-1 strains irrespective of Vpu function, and group 
M viruses produced higher levels of cell-free virions than an N group 
HIV-1 strain. Thus, efficient virus release from infected cells seems to 
play an important role in the spread of HIV-1 in the human population 
and requires a fully functional Vpu protein that counteracts human 
tetherin.
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DNA repair protein Rad18 restricts HIV‑1 and LINE‑1 life cycle
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Introduction: Long interspersed element type 1 (LINE-1, L1) is a mobile 
genetic element comprising about 17 % of the human genome. L1 uti-
lizes an endonuclease to insert L1 cDNA into the target genomic DNA, 
which induces double-strand DNA breaks (DSBs). Likewise, human 
immunodeficiency virus-1 (HIV-1) integration induces DSBs in the 
human genome and activates DNA damage signaling pathway result-
ing in a recruitment of DNA repair protein(s). This may facilitate HIV-1 
and L1 integration in the human genome. Therefore, host DNA repair 
machinery has been involved in both HIV-1 and L1 life cycle.
Results: In this study, we have demonstrated that Rad18 post-rep-
lication repair protein restricts both HIV-1 and L1 life cycle. Notably, 
HIV-1 infection or L1 retrotransposition efficiency was enhanced in the 
Rad18 deficient or the knockdown cells. In contrast, overexpression of 
Rad18 strongly suppressed L1 retrotransposition as well as L1-medi-
ated Alu retrotransposition. The RING-finger and the Rad6 (E2 ubiq-
uitin-conjugated enzyme)-binding domains but not the Polη-binding 
domain were required for the inhibitory effect on L1 retrotransposi-
tion, suggesting that the ubiquitin E3 ligase activity of Rad18 is impor-
tant for regulation of L1 mobility. Furthermore, Rad18 sequestered 
L1 ORF1p in RAD18-nuclear bodies and bound with L1 ORF1p. Simi-
larly, HIV-1 integrase colocalized with Rad18 in Rad18-nuclear bodies 
and bound with Rad18, indicating an interaction of Rad18 with HIV-1 
integrase. Moreover, we found that Rad18 suppressed the late step of 
HIV-1 replication.
Conclusion: Altogether, these results suggest a potential role of 
Rad18 DNA repair protein in HIV-1 life cycle and L1 retrotransposition 
process.
O29 
Natural mutations in IFITM3 allow escape from post‑translational 
regulation and toggle antiviral specificity
Alex Compton, Nicolas Roy, Françoise Porrot, Anne Billet, Nicoletta Casar‑
telli, Jacob Yount, Chen Liang, Oliver Schwartz 
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The interferon-induced transmembrane (IFITM) proteins protect host 
cells from diverse virus infections. IFITM also incorporate into HIV-1 
virions and inhibit virus fusion and cell-to-cell spread, with IFITM3 
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showing the greatest potency. Here we report that amino-terminal 
mutants of IFITM3 preventing ubiquitination and endocytosis are 
more abundantly incorporated into virions and exhibit enhanced inhi-
bition of HIV-1 fusion. An analysis of primate genomes revealed that 
IFITM3 is the most ancient antiviral family member of the IFITM locus 
and has undergone repeated duplication in independent host line-
ages. Some IFITM3 genes in non-human primates, including those 
that arose following gene duplication, carry amino-terminal muta-
tions that modify protein localization and function. This suggests 
that “runaway“IFITM3 variants could be selected for altered antiviral 
activity. Furthermore, we show that adaptations in IFITM3 result in a 
trade-off in antiviral specificity, as variants exhibiting enhanced activ-
ity against HIV-1 poorly restrict Influenza A virus. Overall, we provide 
the first functional evidence that variation in IFITM3 genes may boost 
the antiviral coverage of host cells and provide selective functional 
advantages.
Session 8: Adaptive immunity & immune evasion
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Question: During HIV-1 infection, a constant interplay of antibodies 
and the autologous viral quasi-species shapes the developing anti-
body response and potentially leads to viral escape. A better under-
standing of these co-evolutionary processes is urgently needed 
both for designing a vaccine scheme eliciting an effective antibody 
response and for preventing viral escape in passive immunisation with 
broadly neutralising antibodies (bnAbs). Of particular importance is 
the right dosage of these bnAbs as too low concentrations may lead 
to fast escape of the virus. Thus, we study here at which antibody con-
centrations a viral escape variant can outcompete its viral ancestor, 
referred to as mutant selection window (MSW).
Methods: To determine the MSWs of an ancestor/escape pair in 
respect to a specific bnAb, we analysed experimentally derived inhi-
bition measures (IC50) with a mathematical model. As within-host 
viral transmission can happen via free-virus transmission and through 
direct spread between infected and target cells (cell–cell transmis-
sion), we calculated the MSW for both transmission routes. With the 
MSW framework, we characterised the selective pressure of a bnAb 
lineage leading to viral escape in the HIV-infected individual CAP256 
using in vivo-derived longitudinally sampled virus strains and isolated 
autologous bnAbs. We identified potential CAP256 ancestor/escape 
pairs based on the viral phylogeny.
Results: We found that escape mutants can out-compete their sen-
sitive ancestral strains for wide concentration ranges in both trans-
mission pathways. The MSW of these viral pairs in respect to the 
autologous bnAbs additionally allowed us to identify (i) which autol-
ogous virus strain will be out-competed (ii) which strain could be a 
possible ancestor of an escape variant and (iii) whether escape pre-
dominantly occurs via free virus or cell–cell transmission.
Conclusions: Our method provides important implications for anti-
body-based treatment strategies and vaccine design. Not only will the 
MSW framework allow the selection of the appropriate antibody dos-
age to suppress the development of escape mutants but, in addition, 
may help to design a vaccine scheme that mimics the co-evolutionary 
processes of a natural HIV-1 infection leading to a protective broadly 
neutralising antibody response in uninfected individuals.
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Interferons (IFN) are cytokines that are fundamental to innate and 
adaptive immune responses and are named so by their ability to 
“interfere” with viral replication. The family of human IFN-alpha’s 
(IFN-α) is encoded on chromosome 9 and comprises 13 different sub-
types [1]. These molecules signal through the IFN-α receptors 1 and 2, 
prompting Jak/Stat activation and induction of interferon stimulated 
genes (ISGs) [2]. IFN-α 1 and 2 were the first two alpha subtypes char-
acterised [3]. IFN-α2 has a higher specificity and activity than IFN-α1 
and so became the prototype IFN for most subsequent studies. Data 
reporting the anti-viral effects of the other subtypes is sparse.
Here we analysed 12 IFN family members and 6 mutant IFN variants, 
engineered to have various binding efficiencies, for their ability to 
inhibit HIV-1 replication in primary human cells such as peripheral 
blood mononuclear cells, purified CD4+ T-cells as well as monocyte 
derived macrophages. We tested a range of concentrations (10 U/ml, 
100 U/ml and 1000 U/ml) for each of the IFNs. We found a significant 
difference in activities of the natural IFN variants at lower dosages, 
which was lost at higher concentrations. Similarly, at lower dosages, 
the IFN mutants with stronger (60×) binding affinity showed a higher 
inhibition than the mutants with lower (40×) affinity. However, this 
difference was also reduced with increasing concentrations, indicating 
that differential antiviral efficacies between IFN subtypes can be com-
pensated for with higher amounts. These results are consistent with 
RNA-seq, differential expression and biological network analyses of 
IFNα-2, IFNα-14 and IFN mutant stimulated macrophages at high and 
low doses.
Together, these observations bring into focus the importance of 
understanding putative differential IFN antiviral activity as a function 
of binding affinity, potency and dosage.
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Persistence of latent, replication-competent HIV provirus is the main 
impediment towards a cure for HIV/AIDS. Therefore, different therapeutic 
strategies to eliminate this latent reservoir are currently being explored. 
Persistence is in part a consequence of proviral integration. LEDGF/p75 
acts as the pivotal chromatin tethering-factor targeting HIV integra-
tion into active transcription units through its interaction with HIV-1 
integrase. We investigated the role of integration site selection in the 
establishment of HIV persistence employing LEDGF/p75 knockout cells. 
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To evaluate whether the reactivation potential of the quiescent proviral 
reservoir was dependent on integration site selection during reservoir 
establishment, LEDGF/p75 WT and KD/KO cell lines were infected with 
HIVNL4.3-tCD34 or a double reporter virus that allowed direct visualization 
of the quiescent pool by FACS analysis. We show for the first time that 
LEDGF/p75 depletion hampers HIV-1 reactivation in cell culture.
Next we demonstrate that LEDGINs, a novel class of integration inhibi-
tors inhibiting the interaction between HIV integrase and the LEDGF/
p75 host cofactor, relocate 3D nuclear location and retarget HIV pro-
viral integration out of transcription units, resulting in a HIV reservoir 
that is refractory to reactivation by different latency-reversing agents 
both in cell lines an primary CD4+ T-cells. We here propose a novel 
strategy to reduce the functional HIV reservoir during primary HIV 
infection by means of drug-induced retargeting of HIV integration and 
support the potential of these drugs to reduce the likeliness of viral 
rebound. Pushing the provirus into quiescence could drive the basic 
reproduction number of HIV below a threshold required for sustained 
infection even after treatment interruption.
O33 
NKG2D‑mediated clearance of reactivated viral reservoirs by natural 
killer cells
Permission for the publication has not been granted.
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Inhibition of HIV reactivation in brain cells by AAV‑mediated 
delivery of CRISPR/Cas9
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Several recent studies demonstrated that the CRISPR-associated 
endonuclease Cas9 can be used for guide RNA (gRNA)-directed, 
sequence-specific cleavage of HIV proviral DNA in infected cells. We 
here demonstrate profound inhibition of HIV-1 replication by harness-
ing T cells with Cas9 and an antiviral gRNA. However, the virus rapidly 
and consistently escaped from this inhibition. Sequencing of the HIV-1 
escape variants revealed nucleotide insertions, deletions and substi-
tutions around the Cas9/gRNA cleavage site that are typical for DNA 
repair by the non-homologous end-joining (NHEJ) pathway. We thus 
demonstrate the potency of CRISPR-Cas9 as an antiviral approach, 
but any therapeutic strategy should consider these viral escape 
options. We will present several combinatorial therapeutic approaches 
designed to block virus escape. More specifically, we tested the simul-
taneous attack by different guide RNAs on HIV-1 DNA, but also the 
combinatorial attack on both HIV-1 RNA and DNA forms by combining 
RNAi and CRISPR-Cas approaches.
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The use of heterologous immunisation regimens, and the employ-
ment of various improved vector systems as well as antigen designs, 
has proven to lead to vigorous increases in immunogenicity in the 
assessment of HIV-1 vaccine candidates in non-human primates. In 
order to resolve interdepencies between different delivery modali-
ties, we compared three different poxvirus boost regimens after a 
DNA prime. Three groups of rhesus macaques were each immunized 
with the same DNA vaccine encoding for Gag, PolNef, and gp140 at 
weeks 0, 4 and 8. At week 20, the groups were boosted either (i) by 
administering the poxviral replication-competent NYVAC-KC-vector by 
scarification, or (ii) by i.m. injection, or (iii) by i.m. injection of the rep-
lication-deficient NYVAC-vector, carrying the same antigens. Finally, 
macaques were boosted with adjuvanted, recombinant gp120 pro-
tein at weeks 28, 32, and 49 in order to enhance humoral responses. 
The regimen elicited very potent CD4+ and CD8+ T cell responses in 
a well-balanced manner, peaking 2  weeks after the NYVAC-boost. T 
cell responses subsequently declined and were hardly influenced by 
subsequent protein boosts. T-cells were broadly reactive and poly-
functional, with high fractions of cells secreting all three cytokines 
assessed. All animals exhibited antigen-specific humoral responses 
already after the poxvirus boost, that by trend slightly increased fol-
lowing protein administration. Polyclonal reactivity of IgG antibodies 
was highest against C clade Env-proteins, yet with substantial cross-
reactivity towards other clades. Serum IgA responses were absent. 
Substantial ADCC activity, and very high ADCVI activity were observed 
in sera obtained after the last protein boost.
As no differences were evident between the groups, it can be con-
cluded that the potent priming induced by the DNA vaccine initially 
framed the epitope specificity and polyfunctionality of the T cell 
responses in a way that the subsequent poxvirus boost only led to an 
increase in the response magnitudes without skewing the quality. This 
emphasizes the importance of selecting the best mixture of vector sys-
tems in heterologous vaccination regimens.
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Pretreatment with antibodies targeting the HIV-1 Env protein has been 
shown to prevent systemic infection in non-human primate models 
for AIDS. To investigate whether these antibodies can block infection 
of the “first cell” at the viral portal of entry, genetically tagged chal-
lenge viruses based on simian immunodeficiency virus (SIV) were 
constructed. They use HIV-1 Env for entry into target cells during the 
first replication cycle, but switch to SIV Env for all subsequent rounds 
of infection. Macaques were passively immunized with the HIV-1 Env 
specific neutralising antibody PGT121 a day before rectal exposure to 
the switching challenge virus. Ten days after viral inoculation a 100-
fold reduction of HIV-1 Env-mediated infection events was observed 
in various organs and blood compared to control animals treated 
with a HIV-unrelated antibody. A lesser level of inhibition of infection 
was also detected against a HIV Env pseudotype, which is resistant to 
PGT121 neutralisation. Thus, antiviral antibodies can reach sufficient 
levels at mucosal surfaces to provide sterilizing immunity in a very 
strict sense.
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HIV broadly neutralising antibodies (bNAbs) confer protection fol-
lowing passive immunisation, but the mechanisms that allow these 
humoral immune responses to evolve in a fraction of infected indi-
viduals is unclear. Features of bNAbs suggest that extensive germinal 
center (GC) reactions are required to drive these unusual super-high 
affinity responses required to drive broad viral neutralisation. How-
ever, the mechanisms that underlie this extensive affinity maturation 
are poorly understood. Given that antigens are delivered to follicular 
dendritic cells (FDCs), the key antigen presenting cells in the GC, in the 
form of antibody immune complexes, here we speculated that key fea-
tures of immune complexes may drive enhanced affinity maturation. 
Thus using a set of high-throughput, comprehensive Fc-characterizing 
assays that capture the remarkable biodiversity of antibody Fc-effec-
tor functions, linked to multivariate computational tools, we profiled 
differences in immune complex (IC) biology among individuals that 
develop neutralising antibodies (“neutralizers”) in an unbiased man-
ner. “Neutralizers” possessed higher Fc-mediated antibody effector 
functions, HIV-specific antibody titers, and overall enhanced binding 
to Fc-receptors as compared to subjects that did not possess broadly 
neutralising antibodies. Interestingly, enhanced antibody effector 
function in “Neutalizers” was not associated with overall changes in 
antibody subclass distribution but was associated with the selective 
production of antibodies that were more highly sialylated. Interest-
ingly, ICs generated with “neutralizer” antibodies drove enhanced 
antibody class switch and affinity maturation following immunisation 
of mice compared to ICs generated with “non-neutralizer” antibod-
ies. Moreover, ICs generated with solely sialylated antibodies dem-
onstrated en equally enhanced capacity to drive B cell maturation by 
class switch, to expand GC B cell numbers, and drive enhanced anti-
body affinity maturation. These data argue that the generation of par-
ticular antigen-specific sialylated Fc-profiles drives enhanced antibody 
maturation, potentially contributing the prolonged affinity maturation 
required for the evolution of broadly neutralising antibody responses. 
Thus rational vaccine design strategies that induce enhanced sia-
lylated HIV-specific antibodies may enhance affinity maturation and 
therefore accelerate the induction of broadly neutralising antibodies 
against HIV.
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Question: How Murine Leukemia virus (MLV) travels from the cell 
membrane towards the nucleus, and the mechanism of nuclear entry 
of MLV viral DNA in dividing cells, still remain unclear. It seems likely 
that the MLV preintegration complex (PIC) interacts with cellular pro-
teins to perform those tasks. We have recently published that micro-
tubule motor cytoplasmic dynein complex (DC) and its regulator 
proteins interact with MLV preintegration complex at early stages of 
infection, suggesting a direct interaction between the incoming viral 
particles and the DC, and have shown an essential role for the dynein 
regulators dynactin and NudEL on MLV infection.
Methods: Here we show a shRNA screening of the dynein chains on 
MLV infection.
Results: We found that silencing or over expressing a specific light 
chain of the cytoplasmic DC profoundly reduced the efficiency of 
infection and increases the infection of MLV in a dose dependent 
manner, respectively. The block of restriction was determined to be 
in a step after reverse transcription, but before nuclear entry, by MLV 
reporter viruses, without altering traffic of cellular components.
Conclusions: We propose that the light chains of the cytoplasmic 
DC are an important piece of the host machinery needed for MLV 
infection.
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Introduction: Broadly neutralising antibodies (bnAbs) against enve-
lope structures of HIV-1 are promising candidates for antiviral proph-
ylaxis or therapy. We hypothesized that peptides mimicking the 
complementarity-determining regions (CDRs) of the bnAb b12, which 
recognizes the CD4 binding site of the HIV-1 envelope glycoprotein 
gp120, may be able to inhibit the entry of HIV-1 into target cells in a 
b12-related fashion.
Methods: Peptides presenting the sequences of the heavy chain CDRs 
of b12 were synthesized by solid-phase synthesis. The virus neutral-
ising activity of b12 itself, as well as the paratope mimetic peptides, 
was tested using a reporter cell line. To further clarify the mechanism 
of inhibition, the proviral clone HIV-1NL4-3 was sequentially passaged in 
increasing concentrations of either b12 or paratope mimetic peptides. 
After obtaining resistant viruses, they were sequenced and analysed 
for cross-resistance against each inhibitor.
Results: The paratope mimetic peptides were found to specifically 
recognize the b12 antigen, i.e. gp120 from b12-susceptible HIV-1, but 
not gp120 from b12-resistant HIV-1. Furthermore, the peptides were 
able to inhibit HIV-1 infection in cellular infections assays, at micro-
molar concentrations. A peptide with mutations at key amino acids 
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within the three CDR loops was inactive. Viruses resistant against 
b12 and the paratope mimetic peptide, respectively, occurred after 
15 and 6 passages, respectively. b12 selected one mutation (V370E), 
located directly in the CD4 binding site, while the mutations induced 
by the paratope mimetic peptide were in the vicinity of this site. The 
b12-resistant virus was also resistant against the paratope mimetic 
peptide. Vice versa, cross-resistance was also evident, but less 
pronounced.
Conclusion: Peptides which mimic the CDRs of the broadly neutral-
ising antibody b12, exhibit antiviral activity. Ongoing chemical and 
structural optimization of the peptides is expected to enhance their 
antiviral activity, demonstrating the therapeutic potential of antibody 
paratope mimics.
P3 
Investigating cellular pathways involved in the transmission 
of HIV‑1 between dendritic cells and T cells using RNAi screening 
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Background: Dendritic cells (DC) are thought to be amoung the ear-
liest targets of HIV-1 infection and act as a ‘Trojan Horse’ concealing 
the virus from the innate immune system and delivering it directly to 
T-cells via virological synapses to promote infection.
Question: DC studies have led to the identification of several restric-
tion factors and cellular structures that aid viral transmission, however 
work still needs to be done on how the virus is trafficked through the 
cell to the virological synapse and how the virus evades degradation 
within DC.
Method: Advancements in RNAi screening libraries allows the investi-
gation of multiple pathways which could potential be involved in viral 
transmission such as cell signalling. A high-throughput method has 
been developed using On-Target SMART pool siRNA (Dharmacon) in 
Monocyte derived dendritic cells (MDDC) to investigate the transfer of 
HIV-1 from DC to T-cells.
Results: Initial membrane traffic screening results analysed using net-
work mapping software (Cytoscape 3.3.0) implicates a role of several 
genes involved in vesicle mediated transport at both the plasma and 
vesicle membrane and a role for actin cytoskeleton organisation in DC 
to T-cell HIV transfer.
Conclusion: The discovery of potential cellular targets involved in 
HIV-1 transmission between DC and T-cells could potentially lead to 
the discovery of potential drug targets to be developed to combat 
HIV-1 infection in the future.
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Background: HIV entry is mediated through the retroviral envelope, 
CD4 and chemokine receptors (majorly CXCR4, CCR5). Co-receptor tro-
pism plays a crucial role in HIV transmission and pathogenesis. HIV-1 
co-receptor tropism is extensively studied; however scarce data exists 
on tropism exhibited during HIV-2 and HIV-1&2 dual infections from 
endemic regions. In the present study, we determined co-receptor tro-
pism amongst Indian drug naïve patients with HIV-1 (n =  10); HIV-2 
(n = 12) and HIV-1&2 dual infection (n = 13) confirmed by ELISA and 
Western Blot.
Methods: PBMC co-cultures using patient’s PBMCs were carried out 
and virus growth confirmed by various assays viz. for i) HIV-1: HIV-1 
p24 antigen capture ELISA on culture supernatants and IFA on infected 
cells; ii) HIV-2: ExaVir™ load, TZM-bl infectivity assay on culture super-
natants for CPE and IFA on infected cells; iii) HIV-1&2 dually infected 
viral cultures: presence of HIV-1 was confirmed by HIV-1 p24 antigen 
capture ELISA; independent IFAs were carried out for HIV-1 and HIV-2 
and overall infection was assessed using TZM-bl infectivity assays 
and ExaVir™ load (Fig. 1). Co-receptor tropism was determined using 
GHOST cell assays in co-receptor specific cell lines (GHOST CXCR4; 
GHOST CCR5); the results were confirmed microscopically for syncyt-
ium formation and on FACS using FLOWJO software for green flores-
cence protein production under the control of HIV tat.
Results: Our results suggest that amongst ten HIV-1 drug naïve pri-
mary isolates one isolate was CXCR4 tropic, four were CCR5 tropic and 
five were dual tropic viruses. Of twelve HIV-2 drug naïve primary iso-
lates, eight were CCR5 tropic and four were dual tropic. In case of HIV-
1&2 dually infected primary isolates, seven were CXCR4 tropic and six 
were dual tropic viruses (Fig. 2).
Conclusion: During the early stage of HIV infection, the transmitting 
virus is almost invariably CCR5 tropic. In contrast to these findings our 
data suggests 50 % existence of dual tropism in Indian HIV-1 and HIV-2 
infection. Although we report in vitro phenotypic co-receptor tropism 
for the first time on Indian HIV-1&2 dual infections, it is difficult to 
attribute our findings to the independent tropism of the two viruses, 
as it is a preliminary baseline finding that needs further genotypic 
confirmation.
Fig. 1 Confirmation of HIV‑2 and HIV‑1 and 2 virus isolations
Fig. 2 Results of co‑receptor tropism
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Questions: Understanding how cellular proteins participate in HIV-1 
replication provides insights into the mechanisms of individual steps 
of retroviral replication, and may identify potential novel antiviral tar-
gets. In this study we evaluated the contribution of the calcium- and 
integrin-binding 2 (CIB2) protein, previously identified by RNAi screen-
ing as a potential helper factor, and its homolog, CIB1.
Methods: Jurkat cells and primary CD4+ T-lymphocytes were trans-
duced by lentiviral vectors expressing shRNA targeting either CIB1 or 
CIB2, resulting in efficient and specific knockdown of expression of 
these proteins.
Results: HIV-1 replicated with significantly lower efficiency in trans-
duced cells, identifying CIB1 and CIB2 as non-redundant HIV-1 helper 
factors. By exploring individual steps of virus replication in CIB1- or 
CIB2-knockdown cells, we determined that CIB1 and CIB2 are required 
for efficient HIV-1 entry into target cells, both for CCR5- and CXCR4-
tropic viruses. Also, both the cell-free and cell-associated entry path-
ways were affected by CIB proteins depletion. In contrast, knockdown 
of CIB1 and CIB2 had no impact on the infectivity of HIV-1 virions 
pseudotyped with the VSV-G envelope in either Jurkat cells or CD4+ 
T-lymphocytes. We found no evidence that the level of CIB1 and CIB2 
expression influenced cell viability, cell proliferation, receptor-inde-
pendent viral binding to the cell surface, later steps involved in the 
transport and uncoating of the viral capsid, nuclear import and inte-
gration, or the production, export and infectivity of progeny virions. 
CIB1 and CIB2 knockdown were found to reduce the expression of 
surface receptors implicated in HIV-1 infection, including CCR5, CXCR4 
and integrin α4β7.
Conclusions: In this study we have shown CIB1 and CIB2 knockdown 
significantly inhibited HIV-1 replication, specifically affecting the viral 
entry step. CIB1 and CIB2 knockdown reduced the expression of sur-
face receptors implicated in HIV-1 infection, suggesting at least one 
mechanism through which these proteins may promote viral infection.
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Covariation is an essential evolutionary process leading to the coevo-
lution of parts of proteins and genomes. In organisms that are subject 
to strong selective pressure, coevolution is central to keep the balance 
between the opposite requirements of antigenic variation and reten-
tion of functionality. Being the viral component the most exposed to 
the environment, the envelope glycoprotein gp120 of HIV-1 consti-
tutes the main target of the immune response raised against this virus. 
This is also reflected by the fact that its more external portions are 
characterised by extensive sequence heterogeneity leading to broad 
antigenic variation. We are interested in the study of coevolution 
within the HIV-1 envelope through the functional characterisation of 
chimerical envelopes of primary isolates of HIV-1 group M.
We observe that a single polymorphism, present at the level of the 
viral population in the conserved internal region C2, is sufficient to 
totally abolish Env functionality when inserted in an exogenous enve-
lope backbone. Two main alterations of the functionality of the enve-
lope are responsible for the loss of functionality: a decrease in the 
proportion of trimeric forms and a post-CCR5 binding defect, likely 
due to an interference with the subsequent conformational changes 
that lead to membrane fusion. We also observed that a complete 
restoration of functionality can be achieved by compensatory poly-
morphisms introduced at the level of the external and hypervariable 
region V3. Interestingly, this is accompanied by a change in antigenic 
profile and in the response to treatment with membrane-fusion 
inhibitors.
Altogether, these results indicate that (1) coevolution between V3 and 
C2 can control the formation of trimeric spikes on the viral particles, 
(2) even if two V3 loops bind CCR5 with similar affinity, the subsequent 
steps required to carry out membrane fusion can have markedly differ-
ent outcomes, suggesting that the modes of binding can be different. 
(3) Finally, these results suggest that variable regions, besides harbour-
ing intrinsic extensive antigenic diversity themselves, can also contrib-
ute to sequence diversification in more structurally constrained parts 
of the gp120, further increasing the genetic flexibility of the protein.
This research was supported by Sidaction and the ANRS.
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The recognition of a cell-surface protein or a group of surface proteins 
and their specific interaction with the viral envelope protein represent 
the first stage and one of the key events of the viral infection pro-
cess. For the human endogenous retrovirus HERV-K(HML-2), the cel-
lular receptor(s) which mediate entry of the virus have not been yet 
identified.
We have generated a fusion protein comprising a codon-optimized 
version of the reconstituted envelope glycoprotein of HERV-K113 (Ori-
CoEnvgp42) and the Fc-region of the human immunoglobulin pro-
tein (h-IgG). This fusion-protein is secreted from transfected cells and 
can be easily purified. OriCoEnvgp42-IgG interferes profoundly with 
the HERV-K(HML-2) virus/receptor interaction and inhibits virus entry 
in a concentration-dependent manner. In order to shed light on the 
receptor binding site of HERV-K(HML-2) Env, we aligned the protein 
sequence with the Env sequence of the most closely related Betaretro-
virus, mouse mammalian tumor virus (MMTV). This allowed the puta-
tive HERV-K(HML-2) Env receptor binding site (RBS) to be predicted, 
based on the MMTV Env RBS. RBS mutants were then generated from 
a C-terminal truncated HERV-K(HML-2) Env and the OriCoEnvgp42. 
The RBS mutants Env_D139A and Env_Δ144–153 were expressed at 
wild-type levels, but in contrast to the reconstituted original Env did 
not facilitate entry of pseudotyped lentiviruses, indicating a defect in 
receptor binding. However, mutants derived from the OriCoEnvgp42-
IgG fusion protein still interfered with the entry of reporter viruses 
pseudotyped with the reconstituted HERV-K(HML2) Env.
These data suggest the presence of additional, relevant RBS sequences 
and should help the complete RBS of HERV-K(HML-2) to be character-
ised. The OriCoEnvgp42-IgG fusion protein will be a very useful tool in 
elucidating the mechanisms of cell-entry by the virus.
Topic 2: Reverse transcription & integration
P8 
The R263K/H51Y resistance substitutions in HIV integrase decreases 
levels of integrated HIV DNA over time
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Background: HIV DNA that is integrated into cells can persist indefi-
nitely within HIV-positive individuals, even when they are successfully 
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treated with antiretroviral therapy (ART). This persistence of integrated 
HIV DNA within reservoirs contributes to an inability to achieve viral 
eradication.
No patient treated with the integrase inhibitor dolutegravir (DTG) in 
first-line therapy has ever developed resistance to this drug. Our group 
showed in culture that DTG can select for a R263K mutation in Inte-
grase that confers low-level DTG resistance. Although rare, failure in 
treatment-experienced, integrase inhibitor-naïve individuals who are 
treated with DTG is associated with the emergence of the R263K sub-
stitution in integrase as well as plasma viral loads that are lower than 
those observed when treatment failure occurs with ART regimens that 
do not contain DTG. This is likely due to the fact that R263K confers 
only low-level resistance against DTG and also decreases both viral 
replication capacity and viral integrase activity in short-term infectivity 
assays. We sought to determine the effect of the DTG-specific R263K 
resistance substitution on integration during long-term infection.
Methods: We measured HIV integration by Alu-mediated QPCR 
over 5  weeks of infection of Jurkat cells with WT, R263K and H51Y/
R263K viruses. Levels of integration were measured every week 
and expressed relative to integration of the WT virus after week 1. 
Means ± standard deviations were calculated and Student’s t test was 
used to evaluate significance of differences.
Results: The R263K substitution impaired HIV integration over time 
and was associated with a progressive decline in levels of integrated 
HIV DNA in peripheral blood mononuclear cells. Even further impair-
ments were noted if both the R263K and H51Y substitutions were 
simultaneously present and this is because H51Y further impairs viral 
replication and integrase activity at the same time that it only slightly 
increases levels of drug resistance against DTG.
Conclusions: This raises the possibility that emergence of the R263K/
H51Y substitutions in individuals who experience treatment failure 
with DTG might result in a progressive decline in the size of the viral 
reservoir. Further studies to study this hypothesis are underway in SIV-
infected macaques.
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Retrovirus replication requires that the virus integrate a DNA copy 
of its genome into the host chromosomal DNA. Although there are 
numerous published studies that describe the distribution of retro-
virus integration sites, there is no large publicly available centralized 
database that contains the available integration site information. Cur-
rently, most of the retrovirus integration site information is found in 
supplementary materials, which makes retrieving it for meta-analyses 
difficult. Thus, a comprehensive database that includes information 
about integration sites is critically needed.
We have built the NCI Retrovirus Integration Database (RID, Fig. 3) to 
record integration site information for all retroviruses, including HIV-1, 
HTLV, and MLV. RID is an in-progress MySql based relational database. 
Briefly, it has tables to store host, virus and subtypes, sample/patient 
and tissue and demographics information without (for integration 
sites in humans) revealing personally identifiable information. Chro-
mosome, integration site, associated genes, exon/intron information, 
provirus orientation, and the references from which the information 
was collected are provided on the database. Additionally, we built 
several tools into the database to facilitate mapping of the integra-
tion sites to USCS genome browser, to plot the integration site pat-
terns on a chromosome (Fig.  4), and to display provirus LTRs in their 
inserted genome sequence for PCR/probe design. We also created a 
robust, user friendly website that allows users to query the database 
and analyze the data dynamically. All the integration sites are mapped 
to human genome build hg19 for easy comparison between different 
datasets.
In conclusion, we have created a relational database to store compre-
hensive retrovirus integration information. This information will facili-
tate the retrieval and analysis of the published integration datasets. 
The database is available for public use. For a link, see https://rid.ncif-
crf.gov.
P10 
The small molecule 3G11 inhibits HIV‑1 reverse transcription
Thomas Fricke1,2, Silvana Opp1, Caitlin Shepard3, Dmitri Ivanov4, Baek 
Kim3, Jose Valle‑Casuso1, Felipe Diaz‑Griffero1 
1Albert Einstein College of Medicine, Department of Microbiology & 
Immunology, New York City, NY, United States; 2International Institute of 
Molecular and Cell Biology, Laboratory of Structural Biology, Warszawa, 
Poland; 3Emory University, Department of Pediatrics, Atlanta, GA, United 
States; 4University of Texas Health Science Center, Department of Bio‑
chemistry, San Antonio, TX, United States
Correspondence: Thomas Fricke
Retrovirology 2016, 13(Suppl 1): P10
The small molecule 6-(tert-butyl)-4-phenyl-4-(trifluoromethyl)-1H,3H-
1,3,5-triazin-2-one (3G11) was discovered as a small molecule that 
potentially targets capsid and inhibits infection of replication compe-
tent HIV-1 on a cell-based screen using the T cell line MT-4. Here we 
Fig. 3 NCI Retrovirus Integration Database
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showed that 3G11 specifically and potently blocks HIV-1 infection. By 
contrast, 3G11 did not block other related retroviruses such as HIV-2, 
simian immunodeficiency virus (SIVmac), bovine immunodeficiency 
virus (BIV), feline immunodeficiency virus (FIV), equine infectious 
anemia virus (EIAV), N-tropic murine leukemia virus (N-MLV), B-tropic 
murine leukemia virus (B-MLV) and Moloney murine leukemia virus 
(Mo-MLV). Although NMR experiments revealed that 3G11 binds to 
the HIV-1 capsid (Fig.  5), functional experiments (fate of the capsid 
assay and capsid stability assay) suggested that capsid is not the viral 
determinant for sensitivity to 3G11. Analysis of DNA metabolism by 
real-time PCR revealed that 3G11 blocks the formation of HIV-1 late 
reverse transcripts during infection. In agreement, an in  vitro primer 
extension assay revealed that 3G11 blocks the enzymatic activity of 
HIV-1 reverse transcriptase as strong as nevirapine (Fig.  6) Overall, 
we described a novel non-nucleoside reverse transcription inhibitor 
(NNRTI) that blocks HIV-1 infection.
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Background: HIV-1 integration is regulated by cellular cofactors 
acting at early and late steps of the process. The cellular DNA repair 
recombinase hRAD51 has been shown to interact with HIV-1 integrase 
and restrict integration both in  vitro and in  vivo. This finding paved 
the way for the development of new antiviral strategies based on 
the stimulation of hRAD51 recombination activity. However, hRAD51 
has also been shown to stimulate HIV-1 expression by enhancing LTR 
transcription. This complicates any therapeutic strategies based on 
hRAD51 modulation without pre-existing knowledge of the regulatory 
functions of this recombinase in HIV-1 replication. In order to better 
determine the role of hRAD51 in virus replication, we here performed 
biochemical and pharmacological analyses on its regulatory activity 
during the step of HIV-1 integration.
Results: We show here in in  vitro experiments that activation of 
hRAD51 inhibits the viral integrase. This effect on integrase activity 
is abolished when the recombinase is inhibited. This indicates that 
hRAD51-mediated inhibition of integration is closely linked to the 
promotion of DNA repair and recombination activities of the protein. 
Interestingly pharmacological cellular analyses demonstrate that cells 
with high intracellular hRAD51 concentrations or activity prior de novo 
infection are more resistant to early steps of the integration process 
whereas when hRAD51 was activated during integration this step was 
strongly promoted (Fig. 7).
Conclusions: The presented data indicate an unexpected opposite 
regulatory function of hRAD51 on early and late stages of the integra-
tion process. In addition to providing new information about the regu-
lation of HIV-1 integration by hRAD51 our data may form the basis for 
improved and novel antiviral approaches aiming to modulate intracel-
lular hRAD51 activity or concentrations.
Fig. 4 Pattern plotting result. a One dataset, b comparison of two 
datasets
Fig. 5 (Left) model of 3G11 bound to HIV‑1 capsid. Most affected 
residues are shown in red and less affected in orange. (Right) model 
of the 3G11‑bound CA hexamer viewed from the interior of the core 
particle
Fig. 6 3G11 blocks HIV‑1 reverse transcriptase activity. 32P‑labeled 
17‑mer primer annealed to 40‑mer RNA template was extended by 
HIV‑1 RT with varying concentrations of 3G11, Nevirapine was also 
used for comparison
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Carrying out the integration of the viral DNA into the host cell genome, 
HIV-1 integrase (IN) is crucial for viral replication. As such, it constitutes 
an appealing target for the development of antiviral drugs. However, 
the architecture of the IN tetramer has so far only been inferred by 
combining information obtained on individual parts of the protein. 
Retention of functionality in proteins presenting sequence variability, 
as HIV proteins, relies on the existence of coevolution networks that 
allow counterbalancing the potential deleterious effects of one muta-
tion by the introduction of compensatory mutations in other positions 
of the protein. Since the positions harbouring the mutations are struc-
turally and functionally related, this provides information about the 
arrangement of the protein.
We study coevolution networks in the IN in order to understand the 
architecture of the tetramer. To this end, we constructed chimerical IN 
between primary isolates of HIV-1 groups M and O and analysed their 
functionality by infection in culture. The rationale is that, if coevolu-
tion networks were perturbed, functionality could be impaired. We 
observed a decrease of integration efficiency for certain IN chimeras. 
Systematic replacement of residues that differ between wt and chi-
merical IN defined a motif of 4 residues, constituted of 2  K residues 
and 2 polar amino acids, that is required for integration. The motif is 
conserved within group M and within group O but differs between 
the two groups. When less than 2  K are present, the functionality of 
the protein is severely impaired, while for 2 or more K functionality is 
restored, irrespective of their positions. Structural data suggest that 
they could interact with the target DNA.
These results are relevant from at least two standpoints. One is the def-
inition of an essential motif for IN functionality that could be responsi-
ble for the recognition of the cellular DNA. The other is the remarkable 
possibility of permutation of the position where the K residues can be 
present without affecting IN functionality. This feature allows concili-
ating sequence diversification in HIV-1 and preservation of functional-
ity. Establishing the function of these motifs appears now essential for 
improving our understanding of the mechanisms of HIV integration.
This research was supported by Sidaction.
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The human Ku heterodimer consists of two subunits: Ku70 and Ku80. 
Its main function is the binding of DNA ends produced by double-
strand DNA brakes during the first steps of the NHEJ repair process. Ku 
can also take part in transcription regulation, telomere maintenance, 
protein turn-over and cytoplasmic DNA-sensing. Reportedly, Ku partic-
ipates in the HIV-1 replication and favors different stages of the HIV-1 
life cycle, such as the formation of 2-LTR circles, integration and tran-
scription of proviral DNA. Viral replication is reduced in cells depleted 
of either component of Ku and this effect is more pronounced during 
the early stages of viral replication (Zheng 2011; Manic 2013). How-
ever, an exact mechanism by which Ku affects the replication of HIV-1 
is unclear. It has been proposed, that the binding of Ku70 to HIV-1 inte-
grase (IN) protects the latter from proteasomal degradation.
We have shown that a stable complex can be formed between recom-
binant Ku70 and IN with a Kd ~ 70 nM. Using a set of E. coli expressed 
deletion mutants of both Ku70 and IN and the GST pull-down assay we 
localized the binding sites within both proteins. The binding of Ku70 
with IN relies at least on two sites in the proteins structure. Specifically, 
the Ku70(1–250) contacts with an α-helix located in the 160–230 IN 
region. This observation is supported by the fact that IN with alanine 
substitutions in positions Q209, E212 and L213 shows a weaker bind-
ing with Ku70 and does not bind Ku70(1–250) completely (Fig. 8).
The data obtained from experiments on recombinant purified proteins 
were confirmed by expressing C-terminal HA-tagged full-length IN 
and its various deletion mutants in HEK 293T cells with or without a 
WT Ku70-3FLAG and truncated variants. The coexpression with Ku70 
stabilized IN, while the IN expression in cells that were knocked down 
of Ku70 was reduced. Also, the overexpression of Ku70 diminishes the 
association of IN with 20S proteasome as shown by immunoprecipita-
tion of transfected cell lysates.
The work was supported by RFBR grant 14-04-00833
Fig. 7 Activation of hRAD51
Fig. 8 Triple HIV‑1 IN mutant Q209A/E212A/L213A loses its ability 
to bind Ku70. a IN catalytic and C‑terminal domains with mutated 
amino acids marked in red. b Western Blot analysis of the complex 
formation between recombinant GST‑Ku70(1–250) and two recombi‑
nant His6‑IN variants: WT and mutant
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Retroelements’ (RE) activity is a huge source of genetic innovation in 
human somatic cells. At the present time somatic RE insertions were 
found in normal and malignant cells of different origin. Despite of 
rapid development of high-throughput sequencing technologies all 
current methods for somatic RE insertions identification still have two 
major limitations: (1) ability to analyze only small number of cells due 
to low enrichment of DNA library by target sequences; (2) high rate of 
false positive results because of ligation and amplification procedures. 
In this study we developed a new method for identification of rare 
somatic RE insertions in human genome. Applying of DNA Normalisa-
tion procedure with duplex-specific DNAse from Kamchatka Crab pro-
vides additional (to PCR or capture enrichment) 20× enrichment for 
somatic insertions. Fragmentation genomic DNA before amplification 
by restriction nucleases instead sonication enables accurate filtering 
of false positive. Introduction of Unique Molecular Identifiers (UMI) in 
each target molecule before all steps of enrichment enables to unam-
biguously quantify the number of cells bearing a certain somatic inser-
tion. This method was used for identification of somatic insertions of 
AluYa5 elements in 25,000 nuclei from NeuN+ (neurons) and NeuN− 
(glia) fraction from human dentate gyrus. We found 32 highly confi-
dent somatic insertions in NeuN+ fraction and 84 somatic insertions 
in NeuN− fraction. Our results show that somatic insertions of AluYa5 
elements occurs only in small percent of cells and probably more 
frequently in glia cells then in neurons. Thus, the developed method 
could be employed to identify somatic insertions which are present in 
a small subpopulation of cells (Figs. 9, 10).
The reported study was funded by RFBR according to the research project 
No. 16-34-01100-mol_a and No. 16-04-00779 and Russian President’s 
Fallowship No. SP-4059.2016.4.
Topic 3: Transcription and latency
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nuclear translocation of NF‑κB
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BCA2 (breast cancer-associated gene 2) is an E3 ubiquitin ligase that 
serves as a co-factor in the restriction imposed by Tetherin on HIV-1. 
We recently demonstrated that BCA2 also has Tetherin-independent 
activity. In particular, BCA2 targets HIV-1 Gag for lysosomal degrada-
tion, impairing virus assembly. Since many antiviral factors modulate 
the NF-κB pathway, we sought to explore if BCA2 is harnessing this 
innate signaling cascade to further limit HIV-1.
Here we show for the first time that BCA2 is induced by NF-κB-
activating cytokines and that its up-regulation provides a negative 
feedback on NF-κB. Mutagenesis analyses indicated that the catalytic 
domain of BCA2 is critical to suppress NF-κB signaling. Besides being 
an E3 ubiquitin-ligase, BCA2 may also act as an E3 SUMO-ligase, 
since it physically interacts with UBC9—an E2 SUMO enzyme. UBC9 
mediates the SUMOylation of IκBα, which in turn impairs the nuclear 
translocation of NF-κB. To explore if BCA2 participates in this process, 
we assessed IκBα’s post-translational modifications and the subcel-
lular distribution of NF-κB components. Remarkably, the levels of 
SUMOylated IκBα increased in cells overexpressing BCA2 whereas its 
phosphorylation levels diminished. Conversely, depletion of UBC9 or 
BCA2 led to a significant reduction of SUMOylated IκBα and a corre-
sponding increase in its phosphorylation levels. In vitro SUMOylation 
studies revealed that BCA2 enhances IκBα SUMOylation, demonstrat-
ing for the first time that BCA2 serves as a SUMO-ligase in the regu-
lation of the NF-κB pathway. Consistent with this, BCA2 blocked the 
nuclear translocation of NF-κB.
Since HIV-1 needs NF-κB to enhance its replication, we examined the 
biological implication of the BCA2-dependent inhibition of this path-
way in HIV-1 infectivity. BCA2 reduced the transcriptional activity 
of HIV-1 by twofold 6  h post-infection and this effect was more pro-
nounced at later time points. In fact, the BCA2-mediated inhibition 
of NF-κB accounts for 70 % of its overall antiviral activity and causes a 
fivefold defect in virus replication. Thus, our findings demonstrate that 
BCA2 is an important barrier to HIV-1 by affecting multiple steps of its 
replication cycle. Not only does BCA2 prevent assembly and release 
of nascent virions, but also impairs HIV-1 at the transcriptional level 
(Fig. 11).
Fig. 9 Immunofluorescent sorting of nuclei from human dentate 
gyrus
Fig. 10 Scheme of DNA libraries preparation
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Post-transcriptional regulation of HIV-1 replication is finely controlled 
by viral and host factors. Among the former, Rev controls the export of 
unspliced viral RNAs from the nucleus and their expression in the cyto-
plasm or incorporation into new virions. Taking advantage of a novel 
proteomic approach we previously identified the nuclear matrix pro-
tein MATR3 as a Rev co-factor (Kula et al. Retrovirology 2011; Kula et al. 
Virology 2013). To investigate the functional role of MATR3 in viral rep-
lication we depleted or over-expressed MATR3 in Jurkat cells and pri-
mary PBLs in the context of HIV infection. We confirmed that MATR3 is 
a positive regulator of viral replication acting at a post-transcriptional 
level by affecting nuclear-cytoplasmic translocation of Rev-dependent 
transcripts. By applying the same approach to J-Lat cells, a well-estab-
lished model for the study of latency, we observed that MATR3 deple-
tion was not affecting transcriptional reactivation of the integrated 
provirus upon TNFα stimuli, but was causing a defect in Gag produc-
tion. Following these observations, we hypothesized that MATR3 could 
be involved in the establishment of HIV-1 post-integrative latency. 
Indeed, mechanisms acting at the post-transcriptional level have been 
greatly overlooked in favour of transcriptional pathways. Experiments 
in resting PBLs confirmed that MATR3 was almost undetectable in rest-
ing PBLs but could be promptly upregulated upon cellular stimula-
tion with PHA. However, drugs such as SAHA or DSF, which are potent 
transcriptional activators of HIV-1 transcription, were poor inducers of 
MATR3 providing a rationale for their inability to fully reactivate the 
virus. These data have been confirmed in cells derived from patients 
under cART and are being evaluated in a model of latency based on 
direct infection of resting PBLs.
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Introduction: To comprehensively characterise the intricate role of 
the viral-host interface in HIV-1 gene expression and silencing, we 
performed a series of system-wide proteomic screenings, which col-
lectively revealed cross-talk between HIV-1 Tat, the key viral regula-
tory protein and transactivator, and the SUMOylation system. Given 
that Small Ubiquitin-like Modifier (SUMO) is a reversible covalent 
post-translational modification (PTM) targeting chromatin-associated 
factors and regulating epigenetic silencing, we investigated the mech-
anisms by which HIV-1 Tat could intersect with the SUMO pathway to 
promote HIV-1 gene reactivation.
Results: The HIV-1 promoter is dynamically associated with SUMO. 
We investigated the SUMO chromatin profile of the integrated HIV-1 
Promoter in J-LAT cells using ChIP-qPCR. Under basal conditions, the 
silenced HIV-1 promoter is enriched in SUMO-1 and SUMO-2/3, while 
TNF-alpha stimulation or SAHA-mediated de-repression resulted in a 
decrease of SUMO-1 and SUMO-2/3 from the HIV-1 promoter.
SENP3 is a co-factor of Tat-mediated reactivation of the HIV-1 pro-
moter. We previously identified SENP3, a cysteine protease that catal-
yses SUMO removal, to be part of the Tat nuclear interactome. Here, 
we describe that SENP3 depletion has no impact on basal HIV-1 gene 
expression in J-LAT models, while SENP3 knockdown impaired HIV-1 
promoter reactivation by up to 40 % in a Tat-dependent context.
Tat physically recruits SENP3 to the HIV-1 promoter. Co-immunopre-
cipitation in the presence and absence of SUMO protease inhibitors 
suggests that SUMO PTMs enhance the stability of the Tat-SENP3 
complex formation. In parallel, ChIP-qPCR revealed that Tat promotes 
SENP3 association with the HIV-1 promoter, where it can control the 
level of SUMO2/3 associated with the HIV-1 promoter.
Conclusion: Our findings expand the repertoire of PTMs at the HIV-1 
LTR and suggest that HIV gene silencing can be regulated by dynamic 
SUMOylation at the epigenetic level. In this context, we propose that 
Tat intersects with the SUMO pathway via interacting and recruiting 
SENP3 to the HIV-1 promoter, where it can de-SUMOylate chromatin 
associated factors and support Tat-mediated transactivation of the HIV 
promoter.
P18 
Conservation in HIV‑1 Vpr guides tertiary gRNA folding 
and alternative splicing
Ann Baeyens1, Evelien Naessens1, Anouk Van Nuffel1, Karin Weening1, 
Anne‑Marie Reilly1, Eva Claeys1, Wim Trypsteen2, Linos Vandekerckhove2, 
Sven Eyckerman3, Kris Gevaert3, Bruno Verhasselt1 
1Ghent University, Clinical Chemistry, Microbiology, and Immunology, 
Ghent, Belgium; 2Ghent University and Ghent University Hospital, Internal 
Medicine, Ghent, Belgium; 3VIB Medical Biotechnology Center, Ghent, 
Belgium
Correspondence: Ann Baeyens
Retrovirology 2016, 13(Suppl 1): P18
Vpr is a pleiotropic accessory protein, dispensable for HIV-1 propaga-
tion in T cell lines, but important to establish infection of resting cells, 
like macrophages. Despite this apparent redundancy, Vpr is highly 
conserved among different isolates. To study Vpr-host protein interac-
tions in a fully replicating virus, we constructed an NL4-3 HA/FLAG-Vpr 
virus. Surprisingly, viral production and replication were defective, due 
to aberrant splicing of genomic RNA. This defect was not protein-but 
RNA-based and sequence dependent, thus proposes that not only 
protein, but also RNA sequence conservation is imposed on the Vpr 
encoding region of HIV. Simulation of genomic RNA folding suggests 
that introduction of the tag sequence induced an alternative folding 
structure in a region enriched in splice sites and splicing regulatory 
sequences. To test this, alternative tagging strategies were evaluated 
in silico and NL4-3 HA/His6-Vpr was selected as a valid alternative. 
Indeed, in vitro infectivity and mRNA splice pattern improved although 
did not return to wild-type values. This implies that sequence-specific 
Fig. 11 Biological implication of the BCA2
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modifications may interfere with tertiary mRNA folding to skew the 
alternative splicing balance. To test if tertiary mRNA folding is con-
served in the RNA sequence, we studied NL4-3 Vpr U213C, a silent 
mutation in all three reading frames. The U213 site is 99 % conserved 
and its mutation affected mRNA folding, mRNA splicing balance and 
infectivity. In long-term culture, this mutation reversed, which restored 
infectivity. From these results we conclude that sequence conserva-
tion in Vpr preserves tertiary mRNA folding, important to balance viral 
splicing and replication.
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The clonality of latent HIV has been inferred from viral sequences 
derived from various sources, including proviruses, residual viraemia 
of patients stable on treatment, and rebound viraemia in patients who 
have undergone treatment interruption. It has also been deduced 
from the integration sites of infected cells. It is unclear whether these 
data accurately reflect reactivatable latent viruses.
We studied viruses reactivated from latently infected cells. Resting 
CD4 T cells isolated from a patient stable on treatment underwent 
limiting dilution and were subsequently activated with PHA, IL-2 and 
irradiated PBMC followed by co-culture with SupT1-CCR5 feeder cells 
for 21  days. The supernatant was harvested for viral RNA. Amplicons 
were generated from a region in Gag and one in Env and analysed by 
Sanger sequencing. To control for sequence variations acquired during 
culture, SupT1-CCR5 cells were infected with NL4-3 and underwent the 
same limiting dilution, culture, RNA isolation and sequencing. Pairwise 
comparisons were performed to obtain p-distances. The p-distances 
obtained from NL4-3 infected SupT1-CCR5 cells were used as refer-
ences. Each pair of patient derived viral sequences was considered 
different if the p-distance was higher than that of the corresponding 
region of the reference sequences.
We obtained 32 sequences of reactivated latent viruses from a single 
patient.19 distinct sequences could be distinguished from the Gag 
region. The remaining 13 sequences segregated into five groups con-
taining up to four sequences. However, when the Env regions of these 
13 sequences were analysed, only one ‘clonal’ group of two sequences 
remained. 30/32 reactivated latent viruses were distinct. If the thresh-
old p-distance for two sequences to be considered distinct was set at 
the maximal (rather than average) p-distance observed in the refer-
ence set, 26/32 of reactivated latent viruses could still be considered 
distinct.
These data suggest that the majority of reactivatable latent viruses 
are genetically distinct. Our data show that the phylogenetic structure 
of reactivatable latent viruses is wholly different from that of residual 
viraemia, where a single ‘predominant plasma clone’ can account for 
over 50 % of all sequences observed.
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Latent infection of long-lived memory CD4+ T cells is a major bar-
rier to the eradication of HIV-1. Reactivation of these transcriptionally 
silent proviruses is the basis of therapeutic approaches aimed at cure, 
but despite maximal activation a significant proportion of viruses are 
not reactivated from latency (Ho et al. 2013).
We examined published sequences from non-induced proviruses 
found in patient samples. All sequences contained mutations in a 
recently described exonic splice enhancer (ESE) involved in the regu-
lation of tat mRNA splicing (Erkelenz et al. 2015). By comparison with 
over 2000 subtype B sequences deposited in the Los Alamos data-
base we identified mutations that are highly enriched in the latent 
sequences. We hypothesised that mutations in this region could result 
in inefficient splicing of tat mRNA preventing the establishment of the 
Tat-TAR feedback loop and leading to silencing.
One of the mutations corresponding to a G to A mutation at position 
5817 in HXB2 was found in 11/18 (60 %) of the latent sequences but 
only 10 % of subtype B sequences.
To investigate this further, we cloned this and other mutations affect-
ing splicing into the HIV proviral clone NL4-3 and an NL4-3 based vec-
tor expressing GFP in env, and examined the replicative capacity of the 
mutant viruses compared to wild type. We also studied the effect of 
these mutations on viral RNA splicing patterns and the dynamics of 
viral gene expression in a primary cell model of latency. Results of our 
studies will be presented.
References
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Background: To accelerate HIV cure research and the identification of 
new Latency Reversing Agents (LRAS), we need to develop new tools 
with high-screening capacity. Here we report a new specific and highly 
sensitive RT-qPCR method to measure variation in HIV gene expres-
sion directly from a mixture of latently infected primary T cells and 
supernatant bypassing the need of cumbersome cell isolation, and 
RNA extraction and purification steps.
Specificity and versatility: Our method is based on a one-step RT-
PCR followed by a Taqman probe qPCR (RT-PCR/qPCR) strategy target-
ing either regions flanking Tat intron or the 3′ polyadenylated LTR of 
the viral RNA genome. Our assay was optimal to accurately measure 
changes in the production of total polyadenylated and/or multiply-
spliced viral RNAs with high specificity and reproducibility.
Medium/high-throughput format: Primary T cell model of HIV-1 
latency adapted from the Planelles Model were cultured in a 96-well-
plate format with 100,000 cells per well and treated with LRAs or 
activators. With this layout we successfully achieved quantification of 
HIV-1 RNAs directly from 10  µl (10,000 cells) of unprocessed mixture 
cell/supernatants or cell free supernatant with PCR efficiency steadily 
and strictly above 1.8.
Sensitivity: The sensitivity of our assay can be adjusted to low pro-
viral load by increasing the number of PCR cycles during the first RT-
PCR step. We successfully detected LRA-mediated reactivation of HIV 
gene expression with as little as 1 % of HIV infected cells.
Our assay facilitates medium/high throughput LRA screening in a 
96-well plate format, using as little as 10,000 primary T cells latently 
infected with HIV per point, and bypassing costly and laborious RNA 
extraction/purification while capitalising on the fast, sensitive and 
reproducible RT-PCR/qPCR quantification system.
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Background: Integration of retroviral genome into the host DNA is a 
key step of retroviral replication cycle ensuring efficient expression of 
retroviral genes. Proviral expression is influenced by numerous factors 
including epigenetic environment at the site of proviral integration 
being one of the most important factors affecting proviral transcrip-
tional activity. Transcription of the integrated provirus is frequently 
silenced resulting in the establishment of latently infected cells. The 
silencing of proviral transcription can be classified as early and late 
according to the timing when the silencing occurs. Here we present 
novel approach designed to study the population of early silenced 
proviruses.
Methods: Our approach for detection of early silenced proviruses 
consists of reporter cell line and specially designed retroviral vector. 
Both, the reporter cell line and the vector encode marker for retrovi-
ral expressional activity. While vector-encoded marker refers to actual 
expressional activity of the provirus, cell line-encoded marker is acti-
vated early after start of the proviral expression and can be detected 
independently of current proviral expressional activity. We refer to the 
single cell line-encoded marker-positive cells as early silenced provi-
rus-bearing cells. Nondefective, expression-competent proviruses can 
be also detected in the double negative population corresponding 
to immediately silenced proviruses. Using this approach, we define, 
isolate and study populations of early silenced proviruses of vec-
tors derived from diverse retroviruses including ASLV, MLV and HIV-1. 
Defining
Conclusion: This novel assay provides a tool for quantification of 
immediately, early and late silenced proviruses. Further analysis of 
these distinct populations of integrated proviruses offers a valuable 
dataset for detailed analysis of factors involved in these various means 
of provirus transcriptional silencing.
Topic 4: RNA trafficking & packaging
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Background: The dimer initiation site/dimer linkage sequence (DIS/
DLS) region of HIV is located on the 5′ end of the viral genome and 
suggested to form complex secondary/tertiary structures. Within this 
structure, stem-loop 1 (SL1) is believed to be most important and an 
essential key to dimerization, since the sequence and predicted sec-
ondary structure of SL1 are highly stable and conserved among vari-
ous virus subtypes. In particular, a 6-base palindromic sequence is 
always present at the hairpin loop of SL1 and the formation of kissing-
loop structure at this position between the two strands of genomic 
RNA is suggested to trigger dimerization. Although the higher-order 
structure model of SL1 is well accepted and perhaps even undoubted 
lately, there could be stillroom for consideration to depict the func-
tional SL1 structure while in vivo (in virion or cell).
Results: In this study, we performed several analyses to identify the 
nucleotides and/or basepairing within SL1 which are necessary for 
HIV-1 genome dimerization, encapsidation, recombination and infec-
tivity. We unexpectedly found that some nucleotides that are believed 
to contribute the formation of the stem do not impact dimerization 
or infectivity. On the other hand, we found that one G–C basepair 
involved in stem formation may serve as an alternative dimer inter-
active site (DIntS). We also report on our further investigation of the 
roles of the palindromic sequences on viral replication. Collectively, we 
aim to assemble a more-comprehensive functional map of SL1 on the 
HIV-1 viral life cycle.
Conclusions: We discovered several possibilities for a novel structure 
of SL1 in HIV-1 DLS. The newly proposed structure model suggested 
that the hairpin loop of SL1 appeared larger, and genome dimeriza-
tion process might consist of more complicated mechanism than pre-
viously understood. Further investigations would be still required to 
fully understand the genome packaging and dimerization of HIV.
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The foamy viral genome encodes four central purine-rich elements 
localized in integrase encoding sequence of pol. Previously, we have 
shown that the first two of these RNA elements are required for pro-
tease dimerization and activation. The third element was described 
to be essential for gag expression indicating that it might serve as 
RNA export element. Here, we show that this element is not respon-
sible for the export of genomic and pol RNAs, but encodes a splice 
enhancer element, which acts negatively on env splicing. Thus, recruit-
ment of a positive splice factor surprisingly results in intron retention, 
whereas the deletion of this element promotes complete splicing of 
almost all LTR derived transcripts to an env 3′ splice site localized in 
pol. We show that this inhibition of splicing is achieved by overlapping 
splice enhancer and branch point sequences, which influence branch 
point recognition and SF1/mBBP binding. Separation of branch point 
and the splice enhancer sequences by insertion of a few nucleotides 
restored splicing to the env 3′ splice site similar to the deletion of the 
enhancer element in the wild-type context. In summary, we provide 
evidence that splice enhancer might act negatively on splicing by 
blocking the recognition of essential splice signals.
Topic 5: Assembly & release
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The Human T-cell leukemia virus type 1 (HTLV-1)-encoded acces-
sory protein p8 induces cellular conduits, which are thought to facili-
tate transfer of p8 to target cells and virus transmission. Host factors 
interacting with p8, enhancing p8 transfer, and HTLV-1 transmission 
are unknown. Here, we report that vasodilator-stimulated phospho-
protein (VASP) is a novel interaction partner of p8. VASP contains an 
Ena/VASP homology 1 (EVH1) domain that targets the protein to focal 
adhesions. Functionally, VASP prevents elongating actin-filaments 
from capping thereby promoting filament elongation. Bioinformatics 
identified a proline-rich sequence stretch in p8, which may interact 
with EVH1 domains of host proteins like VASP. The predictions were 
verified by co-immunoprecipitation experiments. VASP and p8 co-
precipitated not only after co-expression in 293T and Jurkat T-cells, 
but also after mixing of lysates expressing VASP and p8 individually. 
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Co-precipitation could be blocked by peptides mimicking the pre-
dicted EVH1 binding motif in p8, but not by a control peptide, which 
covers also a proline-rich sequence stretch, but which was not pre-
dicted as an EVH1-binding motif. Mutational studies revealed that the 
EVH1-domain of VASP is necessary, but not sufficient for the interac-
tion with p8. Beyond, deletion of the G- and F-actin binding domains 
within VASP significantly diminished co-precipitation of p8. Immu-
nofluorescence analysis identified areas of partial co-localization of 
VASP with p8 at the plasma membrane and in protrusive structures 
between T-cells. Co-culture experiments revealed that p8 is trans-
ferred between Jurkat T-cells via VASP-containing conduits. Repression 
of both endogenous and overexpressed VASP by small hairpin RNAs 
strongly reduced p8 transfer. Taken together, we identified VASP as a 
novel interaction partner of p8, which is important for transfer of p8 
to target cells and could thus contribute to the formation of cellular 
conduits to promote HTLV-1 transmission.
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Human T-cell leukemia virus type 1 (HTLV-1) infects CD4+ T-cells pref-
erentially via cell-to-cell transmission requiring reorganization of the 
cytoskeleton as well as expression of the viral key-player and oncopro-
tein Tax. Collagens are not only part of the basal membrane but also 
represent an important component of the viral biofilm, which depicts a 
fundamental route of transmission. Thus, we asked, (1) if and what type 
of collagens are expressed in HTLV-1-infected T-cells and (2) whether 
these collagens are (up)regulated by Tax. Making use of microarrays, 
RT-PCR, qPCR, western Blot, luciferase assays and immunofluores-
cence analysis, we found that Col4α1 (COL4A1) and Col4α2 (COL4A2) 
are the only collagens to be upregulated in the presence of Tax in 
three independent systems. Being transcribed from a shared and com-
mon bidirectional promoter, COL4A1 and COL4A2 are translated into 
individual α-chains that finally assemble to heterotrimers (α1α1α2), 
underlying several posttranslational modification steps. Both COL4A1 
and COL4A2 transcripts and Collagen4 protein (COL4) can be shown to 
be upregulated in HTLV-1-positive T-cell lines. However, COL4 protein 
was only detectable in HTLV-1-infected cell lines that produce virions, 
suggesting that COL4 either contributes to viral transmission or plays 
its major role upon cellular transformation. Mechanistically, we found 
that Tax induces COL4A1 and COL4A2: (1) Repression of Tax in a Tax-
transformed T-cell line led to a significant reduction of COL4A1/A2. (2) 
Overexpression of Tax in Jurkat T-cells led to an induction of COL4A1/
A2. This finding was further supported by luciferase-based promoter 
studies indicating that Tax activates the COL4A1 and, to a less extent, 
the COL4A2 promoter. (3) COL4A1/A2 increased in a time-dependent 
manner in a Tax-inducible T-cell line. Results obtained from Tax-mutants 
suggest that both Tax-induced CREB and NF-κB signaling are crucial for 
Tax-mediated transcriptional induction of COL4A1/A2. Though, merely 
the NF-κB pathway seems to play a predominant role in stabilizing 
and maintaining Tax protein itself whereas CREB-signaling appears to 
be dispensable. Taken together, we identified COL4A1 and COL4A2 as 
novel cellular targets of Tax, potentially leading to an improved under-
standing of HTLV-1 transmission.
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Particle formation and budding from infected cells are fundamentally 
different in foamy viruses (FVs) compared to the orthoretroviruses. 
Unlike in other retrovirus, Env is required to interact with the Gag N 
terminus for particle release and Gag in capsids assembled at the 
microtubule organizing center (MTOC) and in released particles is not 
cleaved in the canonical MA, CA and NC proteins.
While Primate Foamy Virus (PFV) Gag has been characterised with 
respect to particle formation, genome packaging and budding, central 
and C-terminal sequences of non-primate FV Gag are less character-
ised and their contribution to capsid formation and release has so far 
not been analysed. We have recently shown that the feline FV (FFV) 
Gag N terminus is required for MTOC targeting, capsid assembly, RNA 
and Pol packaging and subsequent Gag processing at a C-terminal 
site. To study the importance of the Gag C-terminus for assembly and 
budding, C-terminally truncated FFV Gag variants were analysed. With 
the exception of a 7.5 kDa C-terminal domain, most of Gag is neces-
sary for capsid assembly and Env-dependent particle release. Sucrose 
gradient analyses of cytosolic extracts of HEK293T cells transfected 
with wt and truncated Gag constructs allowed identification of dif-
ferent assembly and maturation intermediates like soluble Gag, cap-
someres and capsids.
The intactness of the highly conserved FV Gag motif QPQRYG was 
essential for capsid assembly in truncated Gag expression constructs 
while amino acid replacement mutagenesis of QPQ and RYG of this 
motif plus conserved upstream Y and R residues in the FFV provi-
rus showed wt capsid formation and budding but strongly reduced 
particle infectivity. We assume that gross deletions in the C-terminal 
nucleic-binding domain of Gag interfere with unspecific RNA binding 
required for capsid formation which is in other retroviruses orches-
trated by membrane targeting of Gag. In contrast, the more subtle 
changes in the Gag QPQRYG motif and the adjacent chromatin bind-
ing site may for instance interfere only with genome encapsidation, 
reverse transcription and/or integration. Studies are underway to iden-
tify and characterise the underlying mechanisms.
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Question: The youngest family of human endogenous retroviruses, 
HERV-K(HML-2), is biologically active and is able to produce viral par-
ticles, at least under certain circumstances such as malignant diseases. 
Using a reconstituted HERV-K(HML-2) sequence (oriHERV-K113), we 
recently showed that human Staufen-1 protein is an interaction part-
ner of the accessory Rec protein. Similar to the situation for HIV-1 Rev, 
the action of HERV-K(HML-2) Rec, together with host cell factors, is 
essential for virus particle production.
Methods: The capsid protein (p27-CA) domain from the oriHERV-K113 
gag sequence was expressed in E.coli and used to immunize rabbits. 
A monoclonal antibody to HERV-K113 Gag (Boller et  al. 2008) was 
used as the basis for a HERV-K(HML-2) p27-CA antigen-capture ELISA 
(AC-ELISA). HEK 293T cells were transfected with molecular clones of 
various exogenous retroviruses and of oriHERV-K113 and virus lysates 
analysed using the p27-CA AC-ELISA. Mutations preventing Rec splic-
ing were introduced into the full length molecular clone of oriHERV-
K113 by site-directed mutagenesis to generate oriHERV-K113Drec.
Results: The new AC-ELISA was shown to be sensitive and specific for 
the p27-CA of HERV-K(HML-2). Deletion of Rec resulted in drastically 
impaired virus production that could be restored by providing Rec 
in trans. Moreover, addition of Staufen-1 (a previously identified cel-
lular interaction partner of Rec) together with Rec in trans resulted 
in even higher virus levels by oriHERV-K113Drec than those with 
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oriHERV-K113 alone. Whereas co-transfection with a full-length HIV-1 
molecular clone had no significant influence on oriHERV-K113 particle 
production, HIV-1 Rev alone in trans could rescue particle expression 
by oriHERV-K113Drec.
Conclusions: The HERV-K(HML-2) p27-CA AC-ELISA is a useful tool 
for monitoring virus production in  vitro. Deletion of Rec significantly 
inhibits viral particle production but this can be overcome by Rec and 
also by HIV-1 Rev in trans. However, there is also evidence for an addi-
tional, Rec-independent mechanism of HERV-K(HML-2) enhancement 
by Staufen-1.
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Although HIV-2 does not encode a vpu gene, the ability to antagonize 
BST-2 is conserved in some HIV-2 isolates where it is controlled by the 
Env glycoprotein. We previously reported that a single amino acid dif-
ference between the lab-adapted ROD10 and ROD14 Envs controlled 
the Vpu-like activity. In this study we investigated how conserved the 
Vpu-like activity is in primary HIV-2 isolates. We found that almost half 
of the 35 tested primary HIV-2 Env isolates obtained from 8 different 
patients exhibited Vpu-like activity. Interestingly, each HIV-2 patient 
harbored a mixed population of viruses with or without Vpu-like activ-
ity. Vpu-like activity and envelope function varied significantly among 
Env isolates. However, there was no direct correlation between these 
two Env functions suggesting they evolve independently. In compar-
ing the Env sequences from one HIV-2 patient we found that similar 
to the ROD10/ROD14 Envs a single amino acid change (T568I) in the 
ectodomain of the TM subunit was sufficient to confer Vpu-like activity 
to an inactive Env variant. Surprisingly, however, absence of Vpu-like 
activity was not correlated with absence of BST-2 interaction. Taken 
together, our data suggest that maintaining the ability to antagonize 
BST-2 is of functional relevance not only to HIV-1 but to HIV-2 as well. 
Our data show that as with Vpu, binding to BST-2 is important but not 
sufficient for antagonism. Finally, as observed before, the Vpu-like 
activity in HIV-2 Env can be controlled by very subtle changes in the 
TM subunit.
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During and after budding of the HIV-1 virion, the structural polypro-
tein Gag undergoes cleavage by the viral protease in a precisely coor-
dinated manner, leading to structural maturation of the virus core, 
enabling the particle to become infectious. Mutation of an RNA stem-
loop (SL1) in the 5′ untranslated region of the virus genome, which is 
involved in genome dimerization and packaging, causes a delay in the 
final step of Gag proteolytic processing, preventing correct particle 
maturation and severely reducing infectivity. To investigate whether 
dimerization is a requirement for correct Gag processing, as it appears 
to be in HIV-2, we analysed Gag processing in three SL1 mutants with 
minimal to severe dimerization defects, and found no correlation 
between the phenotypes. We found that mutation of a neighbouring 
structure (SL3), which is the key determinant of genome packaging, 
also exhibits a delay in Gag processing, suggesting that proper Gag 
processing is dependent on efficient packaging rather than genome 
dimerization. Impaired Gag processing is also a characteristic pheno-
type of late domain mutants, where deletions of conserved motifs in 
the p6 domain of Gag disrupt interactions with members of the host 
ESCRT machinery (TSG101 and ALIX) which are hijacked by the virus 
for budding. We observed that both SL1 and SL3 mutations cause 
budding defects, suggesting that genomic RNA packaging and virus 
budding are linked. It has been demonstrated that ALIX can bind to 
the nucleocapsid domain of Gag in an RNA-dependent manner. Using 
an assay where ALIX is overexpressed to rescue inefficient budding 
of a late domain mutant, we found that introduction of an SL1 muta-
tion alongside the late domain mutation reduces the ability of ALIX 
to rescue the budding defect. These data are consistent with a model 
whereby genomic RNA packaging is important for efficient maturation 
and budding of virus particles.
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As the C-terminal part of the Pr55 Gag polyprotein, the HIV-1 p6 pro-
tein regulates the final abscission step of nascent virions from the 
cell surface by the action of its two late (L-) domains which recruit 
Tsg101 and ALIX, components of the endosomal sorting complex 
required for transport (ESCRT). Besides its essential role in virus bud-
ding there is increasing evidence that the 52 aa p6, in addition to the 
canonical membrane targeting signals in matrix, governs interaction 
of Gag with the cytoplasmic face of the plasma membrane. Mutation 
of the highly conserved Ser-40 to Phe (S40F) in p6, a mutation fre-
quently occurring in patients with treatment failure, disturbs CA-SP1 
processing, reduces infectivity and replication capacity, while virus 
release remains unaffected. Others found that S40F causes forma-
tion of filopodia-like structures enabling cell to cell transmission of 
the virus.
Furthermore, S40F-mutation augments K48-linked polyubiquitination 
of Gag, its entry into the ubiquitin proteasome system (UPS) and into 
the MHC-I antigen pathway. Phe-40, together with Tyr-36, causes the 
formation of a hydrophobic patch within the C-terminal α-helix of p6, 
providing a molecular rationale for the enhanced membrane associa-
tion of S40F Gag, as shown by membrane flotation assays, NMR spec-
troscopy, and surface plasmon resonance studies.
Furthermore, we found that mutation of the 7 highly conserved glu-
tamic acids within p6 to alanine (E0A), causes defective virus budding 
and, like the S40F mutant, leads to an enhanced polyubiquitina-
tion and subsequent entry of Gag into the UPS corresponding to an 
increased MHC-I antigen presentation of Gag derived epitopes. In 
addition, like for the S40F mutant, the CA-SP1 processing of the E0A 
mutant is impaired, also resulting in loss of infectivity and impaired 
virus replication.
The cumulative data support a model in which p6, either by hydro-
phobic (S40F) or electrostatic (E0A) interactions with the plasma mem-
brane, acts, in addition to matrix, as a membrane targeting domain of 
Gag. The extended exposure to a membrane-resident E3-ligase com-
plex, comprising, among others, CCDC8 and Cul7, might augment the 
polyubiquitination, entry into the UPS, and thus the immunogenicity 
of Gag. However, the localization and biological function of p6 after 
maturation of Gag still remains enigmatic.
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Topic 6: Pathogenesis & evolution
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Random mutations, which afford virus evasion of intrinsic host and 
therapeutically administered opposition, rarely provide direct survival 
adaptations and more often have deleterious effects by directly per-
turbing interfaces central to intrinsic protein folding or extrinsic inter-
actions essential for crafting viral protein assemblies. Mutant proteins 
may regain functional stability and folding by employing either, or 
both, an intrinsic mechanism, through the accumulation of coevolved 
mutations that induce compensatory conformational changes, or by 
an extrinsic mode via the interaction with molecular chaperoning pro-
teins promoting the acquisition of the functional folded state.
Cross-family differences and interspecies subtleties can aid highlight-
ing resistance-mechanisms accessible by mutational adaptation of 
challenged viruses. Exploring how related viruses coevolved in their 
natural environment can, therefore, highlight crucially conserved 
patterns and uncover conceivable latent escape routes potentially 
accessible to emergent viral strains. We determined the structure of 
capsid from feline immunodeficiency virus (FIV) and revealed that 
the functional structure is preserved through spatial correlations of 
coevolved substitutions, which when otherwise uncoupled and indi-
vidually substituted into HIV-1 capsid impairs virus infectivity. This 
example illustrates an intrinsic mechanism during viral adaptation. The 
extrinsic mechanism of protein adaptation will be illustrated by dis-
cussing the structural and molecular basis of lentiviral Vif flexibility in 
exploiting various chaperoning cofactors during evasion of APOBEC3 
cellular-restriction.
The ability to circumvent deleterious effects of mutations affords 
viruses an important survival advantage by exploiting alternative, but 
functionally equivalent, patterns when the default ones are blocked.
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Question: HIV-1 entry into cells is linked to the ability of gp120 to use 
at least one of the coreceptors CCR5 (R5) or CXCR4 (X4). However, a 
mixed viral quasispecies is present in natural infection competing 
for permissive cells. During progression of the disease the shift from 
R5-to-X4 is explained by selectivity of cell reservoirs and selective 
immune responses but the direct impact of a single virus on the sup-
pression or enhancement of other X4- or R5-viruses is not completely 
elucidated. Cells, productively infected by HIV-1 release viral particles 
as well as the gp120 envelope into body fluids. Thus, soluble gp120 
(sgp120) will compete for receptor binding with other virus variants.
Methods: To study viral infection in the presence of soluble gp120 
(sgp120) we have constructed pairs of R5- and X4-tropic viruses with 
high and low infectivity and the corresponding sgp120. We preferen-
tially mutated N-glycosylation sites in and around the gp120 V3 loop 
and introduced arginine residues close to the N-glycosylation site pre-
sent in the V3 loop (Fig. 12).
Results: For X4-tropic virus, mutated N-glycosylation sites lead to 
enhanced infectivity and for R5-tropic viruses, their lack leads to 
loss of R5-specific infectivity. We demonstrated, that R5-tropic virus 
was suppressed by heterologous sgp120 derived from R5-viruses of 
higher infectivity. Thus, the R5-tropic “best-fit” can block infection of 
other R5-tropic rivals. In X4-specific infection we also demonstrated 
neutralisation of viruses by sgp120 with the same coreceptor tro-
pism. Here, viruses of a higher efficiency were able to enhance their 
X4-tropic rivals. Another support of infection was observed for 
R5-tropic infection in the presence of sgp120 derived from X4-virus. 
R5-tropic infection was strongly enhanced by X4-sgp120. This cross-
enhancement was linked to the presence of heparan sulphate proteo-
glycans (HSPG) on the surface of CCR5+ target cells. Effects of R5-virus 
enhancement and suppression were studied for HIV-1 subtype B, A 
and C envelopes in the background of the NL4-3 laboratory strain. We 
demonstrated that the N-glycan g15 within the V3 loop played a role 
in selection of X4- and R5-tropic viruses and arginine amino acids sur-
ounding the g15 N-glycosylation site.
Conclusion: We propose, that soluble X4- and R5-gp120 is supporting 
the R5-tropic viral “best fit”.
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Question: The cytoplasmic tail (CT) of the transmembrane envelope 
glycoprotein (gpTM) of HIV-2 includes amino acids (aa) sequences sim-
ilar to lentiviral lytic peptides (LLP) described in other lentiviruses [1, 
2]. Within the putative LLP-2 region, we previously observed insertions 
of 3 or 7 aa in sequences deduced from plasma viral RNA of sympto-
matic HIV-2 infected individuals [3]. Based on these observations, we 
reproduced the insertions in a molecular clone to assess their impact 
on replicatve fitness and cell death.
Methods: Using a molecular clone of the HIV-2 ROD reference strain, 
site-directed mutagenesis experiments allowed the generation of 
plasmids with the insertion I787SQS or I787FRSLQRA in Env. After trans-
fection in HEK293T cells, the resulting viral particles were used to 
infect H9 cells. Viral release was quantified by RT-qPCR at three and six 
days post-infection. Cell viability was assessed with the percentage of 
living cells using a CASY cell counter.
Fig. 12 Suppression of viral infection by +g15 R5‑topic viruses (sub‑
type A V3 loop). Gp120 of the +g15 type was neutralizing the −g15 
mutant (NL‑V3A‑g12, 13, 14, 15, 16, black bars). Such an effect was not 
observed using the −g15 gp120 on the +g15 virus. +g15 = pres‑
ence of the N‑glycan within the V3 loop; −g15 = lack of the V3 
loop N‑glycan, V3A = subtype A V3 loop, gp120–918 = a subtype B 
R5‑tropic gp120 used for comparison
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Results: Compared to the control wild-type ROD virus, the clone with 
a 7 aa insertion in the LLP-2 region (M1) enhanced viral release ten 
times (Fig. 13). Cell viability was 20 % more impaired compared to the 
wild type (Fig. 14). The effect of the 3 aa insertion (M2) was milder, with 
a non-significant trend to enhance viral release and cell death com-
pared to the wild-type.
Conclusions: A 7 aa insertion including positively charged aa in the 
putative LLP-2 enhances viral replication and cell death in  vitro. The 
insertions in the Env CT observed in vivo in samples from disease pro-
gressors may therefore be involved in the higher viral load observed 
in these individuals. Further investigations are needed to assess the 
effect of the lytic peptide on cell death. This study may open the way 
to the development of laboratory diagnostic tools related to disease 
progression.
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Combination antiretroviral therapy (ART) suppresses HIV-1 replica-
tion and improves immune function. Considerable proportion of HIV-
infected individuals receiving ART fail to increase CD4+ T-cell counts 
sufficiently. Incomplete restoration of CD4+ T-cell count during viro-
logically successful ART is a major predictor of morbidity and mortality. 
For better understanding of HIV-1 pathogenesis and improved design 
of curative strategies, it is important to determine whether the degree 
of HIV-1 persistence, measured early on ART, can predict subsequent 
immunological response to the long-term therapy and whether HIV-1 
persistence correlates with host biomarkers of immune dysfunction. 
Viral (total and episomal HIV-1 DNA, unspliced and multiply spliced 
[total and tat/rev] cell-associated HIV-1 RNA) and host (CD4+ and CD8+ 
T-cell activation, proliferation, senescence, apoptosis, exhaustion, 
thymic migration, and CD4+ and CD8+ T-cell subsets) biomarkers were 
longitudinally measured in a cohort of 28 HIV-infected patients at 0, 
12, 24, 48, and 96 weeks of virologically suppressive ART. No baseline 
HIV-1 marker was predictive of CD4+ T-cell count at 96 weeks of ART. 
However, at 12 weeks of ART, cell-associated HIV-1 unspliced to multi-
ply spliced-total (US/MS) RNA ratio, despite not being associated with 
baseline CD4+ T-cell count, strongly negatively correlated with both 
absolute CD4+ T-cell count at 96 weeks of ART (rho = −0.56, P = 0.004) 
and with relative increase in CD4+ T-cell count between baseline and 
96 weeks of ART (rho = −0.55, P = 0.004). Moreover, US/MS RNA ratio 
at 12 weeks ART strongly positively correlated with markers of CD4+ 
T-cell activation (CD4+/CD38+/HLA-DR+: rho  =  0.63, P  =  0.001) and 
apoptosis (CD4+/Annexin-V+/FAS+: rho  =  0.59, P  =  0.002). Because 
HIV life cycle involves a temporal shift from the production of multiply 
spliced to the production of unspliced RNA species, higher US/MS RNA 
ratio in a patient might reflect the higher frequency of HIV-infected 
cells in the later stages of viral life cycle, which is characterised by 
expression of viral proteins and presentation of antigens. Such cells 
could exert pressure on the host immune system, causing persistent 
immune activation and apoptosis and contributing to poor immuno-
logical response to ART.
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Question: HIV-1 infections by subtype B account for about 12  % of 
infections worldwide. Evidence is rapidly accumulating that there is 
a significant difference in natural progression and response to HAART 
among subtypes. Gross deletion in the HIV nef gene (gΔnef) is associ-
ated with slow progression in subtype B-infected patients (B). To date, 
there is no such data in patients infected with non-B subtypes (non-B).
Methods: To investigate whether there is a difference in natural pro-
gression, response to Korean red ginseng (KRG), and proportion of 
gΔnef among Korean subclade of subtype B (KSB) (n = 103), subtype 
B (n =  39), and non-B (n =  124) infected patients in the absence of 
HAART, we compared rate of decrease of CD4+ T cells (CD4) and the 
proportion of gΔnef and also with control. We amplified nef gene by 
nested-PCR and determined 4508 nef sequences (Fig. 15).
Results: Monthly decrease of CD4 was significantly faster in non-B 
(9.4  ±  14/μL) than 4.1–4.2/μL in B and KSB-infected patients 
(P  <  0.001). Overall proportion of gΔnef was 4.4, 7.9, and 12.2  % in 
non-B, subtype B, and KSB infected patients, respectively (P  <  0.01). 
One-hundred and sixty-three patients were treated with KRG 
(3797 ± 4901 g) over 85 ± 63 months and their monthly decrease of 
CD4 was significantly slower (4 ±  6/μL) than 10 ±  17/μL in 82 KRG-
naïve patients (P < 0.001). KRG treatment significantly slowed decrease 
of CD4 in non-B and KSB patients and significantly increased propor-
tion of gΔnef from 2.1 and 3.7 % at baseline to 12.6 and 17.1 % after 
Fig. 13 Absolute quantification of viral release from infected H9 cells 
at 3 and 6 days post‑infection [n = 3 independent experiments, p 
value <0.05 (*) and <0.01 (**)]
Fig. 14 Percentage of living cells after 3 and 6 days post‑infection 
(n = 3 independent experiments)
Fig. 15 There were significant differences in monthly decrease of 
CD4, proportion of gΔnef, and rate of variation among 3 subtypes
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12 months in subtype B and KSB patients, respectively (P < 0.001). In 
contrast, KRG treatment did not affect the gΔnef in non-B. However, 
the proportion of sequences with premature stop codon was similar 
among 3 subtypes (0.5–2.0 %). Sequence identity over 6 years was sig-
nificantly higher in KSB (97.8 ± 1.1 %) than subtype B (96.1 ± 1.6 %) 
(P  <  0.01) and non-B (96.8  ±  1.5  %) (P  <  0.01). The sequence iden-
tity 97.8  ±  1.1  % was also higher than 96.4  ±  2.0  % in KSB control 
(P  <  0.01). Taken collectively, 23 long-term slow progressors (LTSPs) 
was detected in KRG treated patients only (P < 0.01) and its proportion 
was higher in KSB patients than in non-B patients (P < 0.01).
Conclusions: Decrease of CD4 and proportion of gΔnef are affected 
by subtypes and KRG treatment. Faster decrease of CD4 in non-B 
patients than in KSB patients is supported by significantly lower gΔnef 
and higher variation in non-B than KSB.
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Background: Germ cell tumors and particularly seminomas reflect the 
epigenomic features of their parental primordial germ cells, includ-
ing the genomic DNA hypomethylation and expression of pluripotent 
cell markers. Because the DNA hypomethylation might be a result of 
TET dioxygenase activity, we examined expression of TET1–3 enzymes 
and the level of their product, 5-hydroxymethylcytosine, in a panel of 
histologically characterised seminomas and non-seminomatous germ 
cell tumors. Simultaneously, we analysed the expression of ERVWE1 
endogenous retrovirus whose spliced form codes for envelope gly-
coprotein called Syncytin-1. Syncytin-1 has fusogenic ability and its 
expression is restricted to placenta under physiologic conditions.
Results: We found highly increased expression of TET1 dioxygenase 
in most seminomas and a strong TET1 staining in seminoma cells. 
Isocitrate dehydrogenase 1 and 2 mutations were not detected sug-
gesting the enzymatic activity of TET1. The levels of 5-methylcytosine 
and 5-hydroxymethylcytosine in seminomas were found decreased in 
comparison to non-seminomatous germ cell tumors and healthy tes-
ticular tissue. Seminomas further displayed significant increase in both 
spliced and non-spliced forms of ERVWE1 in comparison to healthy 
controls. Importantly, the promoter of ERVWE1 in seminomas con-
tained low levels of DNA methylation.
Conclusions: We propose TET1 expression as a marker of seminoma 
and mixed germ cell tumor. Furthermore, the endogenous retrovirus 
ERVWE1 was consistently overexpressed in seminomas. In contrast to 
the CpG island methylator phenotype observed in a fraction of tumors 
of various types, we suggest the anti-methylator phenotype in semi-
nomas is maintained by TET1 demethylation activity.
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Endogenous retroviruses are genomic elements formed by germline 
infiltration by originally exogenous viruses. These molecular fossils 
provide valuable information about the evolution of the retroviral family. 
Lentiviruses are an extensively studied genus of retroviruses infecting a 
broad range of mammals. Despite a wealth of information on their mod-
ern evolution, little is known about their origins. This is partially due to 
the scarcity of their endogenous forms. Recently, an endogenous lenti-
virus, ELVgv, was discovered in the genome of the Malayan colugo (order 
Dermoptera). This represents the oldest lentiviral evidence available and 
promises to lead to further insights into the history of this genus.
In this study, we analysed ELVgv integrations at several genomic loca-
tions in four distinct colugo specimens covering all the extant derm-
opteran species. We confirmed ELVgv integrations in all the specimens 
examined, which implies that the virus originated before the dermop-
teran diversification. Using a locus-specific dermopteran substitution 
rate, we estimated that the proviral integrations occurred 21–40 mil-
lion years ago. Using phylogenetic analysis, we estimated that ELVgv 
invaded an ancestor of today’s Dermoptera more than 60 million years 
ago. We also provide evidence of selective pressure on the TRIM5 anti-
viral restriction factor, something usually taken as indirect evidence of 
past retroviral infection. Interestingly, we show that TRIM5 was under 
strong positive selection only in the common dermopteran ancestor 
and that this period could coincide with ELVgv activity. In summary, we 
describe the evolutionary history of the oldest known lentiviral lineage 
and propose its coevolution with the TRIM5 host restriction factor.
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The general profile of endogenous retroviruses (ERVs) in the domes-
tic horse (Equus cabalus) genome has been described, but a thor-
ough Characterisation is lacking. We used an in silico approach based 
on data mining and phylogenetic analysis to profile equine ERVs 
in depth. We identified a total of 1384 ERV loci in the horse genome 
that disclosed a robust phylogenetic relationship to retroviral reverse 
transcriptase (RT) genes. Through phylogenetic and genomic analy-
ses of these loci we derived an overview of equine ERV diversity. We 
inferred that there are at least 8 distinct, major lineages of ERVs in the 
equine germ line, and recovered consensus proviral genome struc-
tures for each of these. One highly divergent ERV lineage, which we 
provisionally refer to as ‘EqERV-u1’, was observed to be unique to the 
family Equidae. We show that EqERV-u1 is intermediate to Alpha- and 
Betaretroviruses in phylogenetic trees, and identify 46 distinct EqERV-
u1 proviruses, including 17 with intact genomes. Interestingly, we 
observed two distinct genome structures among intact EqERV-u1 
copies: a classical (type I) structure in which a dUTPase gene is located 
between the pro and pol coding domains, and a type II structure—
unique to EqERV-u1—in which a dUTPase gene occurs upstream of 
gag. We dated the activity of the EqERV-u1 lineage over time using a 
molecular clock-based approach, revealing that it has been active rela-
tively recently (i.e. within the past 1–5 million years), even though it 
may have entered the equid germline >18 million years ago. Analysis 
of published E.cabalus transcriptome data revealed that one EqERV-u1 
provirus on chromosome 29 is actively transcribed in a tissue-specific 
manner. This provirus exhibits the unusual type II genome structure.
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During the 20th century a confluence of socio-epidemiological fac-
tors combined to facilitate the emergence of retrovirall pathogens 
in humans. However, the influence of anthropogenic factors on the 
emergence of retroviral infections in non-human species has not 
been evaluated to the same extent. Small ruminant lentiviruses 
(SRLVs) cause chronic, persistent infections in populations of domes-
tic sheep (Ovis aries) and goats (Capra hircus) throughout the world. 
Here, we trace the origins and history the SRLV pandemic. To investi-
gate the ancient history of SRLVs, we performed a serology and DNA 
sequencing-based investigation of SRLVs diversity in the Fertile Cres-
cent region, where domestication of sheep and goats is thought to 
have originally occurred. Screening of 886 sheep and goats in Jordan 
and Lebanon revealed a relatively high prevalence of infection (~21 %) 
and an elevated level of viral genetic diversity compared to other 
regions of the world. Furthermore, using sequences obtained via this 
screen, we show that currently circulating SRLV genotypes reveal evi-
dence of ancient, inter-genotype recombination. These data support 
the hypothesis that SRLVs disseminated out of Western Asia during 
the early Neolithic period. However, by using phylogenetic and phylo-
geographic approaches to analyze SRLV sequences sampled from 600 
distinct infections in 30 different countries, and spanning a period of 
64 years, we show that pandemic spread of SRLVs did not occur until 
the 20th century. We integrate the findings of our analysis with histori-
cal and epidemiological evidence to propose a geographic sequence 
and timeline for the emergence of the SRLV pandemic. We identify the 
Colonial expansion of European nations during the ‘Age of Imperialism’ 
(~1870–1950), and the associated development of novel agricultural 
systems, as having played a key role in enabling the global spread of 
SRLV infection.
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Background: The first reported cases of HIV-1 infection in South Africa 
occurred in 1982, which was initially spread by MSM. Almost 7 million 
people are living with HIV-1 infection in South Africa and 2 separate 
epidemics have been described. The majority of these infections are 
caused by HIV-1 subtype C, spread through heterosexual contact. The 
minor subtype B epidemic in South Africa was, in the past, transmitted 
via MSM. We recently described the detection of new BC URFs circulat-
ing in the country. This indicates that both epidemics are still co-cir-
culating in South Africa, but only 6 HIV-1 subtype B NFLGs sequences 
have been previously characterised.
Methods: Ten samples were selected for NFLG amplification. Seven of 
the samples were obtained from the late 1980s, while the other three 
samples were from more recent infections. The NFLG amplification was 
performed using a PCR protocol designed to target two overlapping 
5.5  kb fragments. There after samples were sequenced through con-
ventional “Sanger” sequencing and next-generation sequencing (NGS) 
using the Illumina MiSeq platform. The samples were subtyped using 
the REGA, COMET, RIP and jpHMM online tools. Multiple sequence 
alignments were done using MAFFT and then codon aligned. Maxi-
mum likelihood phylogenetic trees were constructed in Geneious 9 
and MEGA.
Results: The six 1980s samples were obtained from MSM in the West-
ern Cape South Africa. The others obtained were from a 16  year old 
heterosexual teenager in Gauteng, one woman from the Eastern Cape 
and one woman from the Western Cape. Two of the subtype B NFLG 
sequences obtained cluster with reference subtype B strains from the 
1980s. Three sequences cluster more closely with reference strains 
from the late 1990s. Another sequence was identified as a unique BC 
recombinant strain.
Discussion: We have detected and characterised HIV-1 subtype B 
strains circulating in South Africa since the early 1980s to 2000s. This 
subtype B epidemic crossed over into the heterosexual population, 
as indicated by infection of both children and women in the differ-
ent provinces of South Africa of concern is the characterisation of the 
newly described subtype BC URF strains. We will continue to monitor 
the HIV-1 subtype B epidemic in the heterosexual population in South 
Africa.
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The restriction factor tetherin inhibits the release of enveloped viruses 
and imposes a barrier for efficient spread of HIV in the human popu-
lation. The direct precursors of HIV-1, SIVcpz and SIVgor, use their 
Nef protein to antagonize the tetherin orthologue of their respec-
tive hosts. Because of a five amino acid deletion in its cytoplasmic 
tail, human tetherin is resistant to SIV Nef. Overcoming this hurdle 
may have been a prerequisite for effective spread of HIV-1 in humans. 
Pandemic HIV-1 group M strains acquired Vpu-mediated anti-tetherin 
activity during human adaptation to overcome this hurdle. In con-
trast, HIV-1 group O Vpus do usually not counteract human tetherin. 
Instead, the accessory Nef protein of group O viruses evolved the abil-
ity to target a region adjacent to the deletion to antagonize tetherin in 
humans. Here, we demonstrate that the infectious molecular clone of 
HIV-1 O RBF206 utilizes both Nef and Vpu to antagonize human teth-
erin. Using FACS analyses and virus release assays, we show that the 
RBF206 Vpu is as efficient as the group M NL4-3 Vpu in reducing cell 
surface levels of human tetherin and promoting virus release. Unlike 
that of NL4-3, the RBF206 Vpu also efficiently antagonizes the second 
shorter isoform of humans tetherin that lack the first 12 amino acids. 
In the NL4-3 context, both Nef and Vpu reduce cell surface levels of 
human tetherin in infected PBMCs and promote virus release in 293T 
cells. Our data suggest that HIV-1 group O is still adapting to human 
tetherin and further illustrate the enormous capacity and plasticity of 
Vpu and Nef proteins in counteracting cellular defense mechanisms.
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Increasingly scientific evidence underline retroelements and in par-
ticular human endogenous retroviruses (HERVs) as important players 
in cell plasticity, transformation and tumour progression. Expression of 
the HERV-K, especially the HML-2 family, was found elevated in mela-
noma and has been suggested to be implicated in the etiopathogene-
sis of the disease. We previously demonstrated that HERV-K activation 
and viral particles production were associated to aggressiveness and 
immune evasion of metastatic melanoma cells. However, mela-
noma consists of heterogeneous cell populations whose biological 
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properties remain poorly characterised. In this context, phenotype-
switching and cancer stem cell (CSC) models of melanoma progres-
sion are driven by genetic and epigenetic signalling, depending from 
microenvironment changes. Therefore, we investigated the potential 
role of HERV-K in cellular plasticity and stemness features of mela-
noma cells under modification of the microenvironment. To this aim, 
melanoma cell lines were exposed to different culture conditions; 
HERV-K dependency of cell phenotypic modifications, stem cell mark-
ers expression and metastatic features were evaluated. The study 
demonstrated that the plasticity features of melanoma cells were cor-
related and dependent to HERV-K activation. During modifications of 
the microenvironment, HERV-K expression was accompanied with the 
increase of cancer stem cell markers and with the switching towards 
an invasive malignant phenotype. Notably, the inhibition of HERV-
K restrained cellular plasticity and stem cell markers expression. The 
understanding of the origin of stem-like cells plasticity and of multi-
potent phenotypes in the tumor would help the identification of new 
targets for therapy.
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Introduction: Indian primates, rhesus macaques (Macaca mulatta) 
and langurs (Semnopithecus entellus) are not known to be naturally 
infected by SIVs. The reported ‘SIVmac’ is a variant of SIVsm that nat-
urally infects African sootey mangabeys (Cerocebus atys). Cases of 
monkey bites are routinely reported from different parts of India, a 
potential source for zoonosis, or antropozoonosis, but consumption of 
monkey flesh is not common in India.
Methods: Plasma samples from the two common simian species were 
screened by HIV-1 WB assay as serologic tests for SIVs were not avail-
able in India, to investigate natural lentivirus infection of wild simians 
inhabiting north Indian Rajasthan forests. Antibodies cross reacting 
with some HIV antigens including gp120, p66, gp 41, p24 and p17 
were present in a proportion of the plasma samples tested, suggesting 
lentivirus infection.
To molecularly characterise the unknown lentiviruses, DNA extracted 
from PBMCs and RNA extracted from plasma samples of multiple 
rhesus macaques and langurs were amplified by PCR and RT-PCR 
respectively, using pan-lentiviral primers from pol (RT, Protease), gag 
(p24, p17) and env (gp120, gp41) regions as well as LTR, and accessory 
genes nef, vif and vpr. The molecular virology work was conducted in 
the USA. Extensive phylogenetic analyses of the viral sequences were 
conducted independently in Sweden. Multiple sequence alignments 
were performed in AliView v1.17.1. Maximum likelihood phylogenetic 
analyses were performed in FastTreev1 and confirmed by MEGA6.
Results: The viral sequences revealed unexpected homology to 
Subtype B HIV-1, transmitted in some parts of north India. While the 
conserved p24 gag and RT (pol) sequences had exact homology with 
prototype subtype B HIV-1including HXB2, other region of gag (p17), 
partial env (gp120), vpr, nef, vif and LTR had distinct mutations, dis-
counting any unintentional laboratory contamination. Intriguingly 
the sequences were not related to any known SIV, including SIVmac. 
The analysis identified the origin of LTR and gag sequences from HIV-
1B sequences from north India with >80  % bootstrap support (LTR: 
NII_LTRS1; EU659806 and gag: B.IN.11807: EF694037). Lentiviruses 
infecting feral rhesus macaques and langurs clustered together with 
74 % bootstrap support in the p17 gag region. Vif was truncated at the 
3′region while nef at the 5′region. Importantly nef truncation occurred 
at equivalent conserved regions of both HIV-1 and SIV genomes, 
which could be the reason for the observed low to medium viral load 
in the simian plasma samples. The env gp120 sequences of lentivi-
ruses infecting wild langur and rhesus macaques had several distinc-
tive differences compared to HXB2, and were unrelated to equivalent 
sequences from SIVmac.
Conclusion: Reverse transmission of HIV-1 from infected humans to 
the simians through monkey bite is proposed. If the phenomenon is 
more widespread than this specific simian population, it could have 
profound consequences for the reservoirs of HIV-related lentiviruses in 
Asia and the rest of the world.
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Background: Although the introduction of antiretroviral medications 
in resource-limited settings has decreased the number of HIV-positive 
women dying from AIDS, many are still at risk for HIV-related diseases 
including cervical cancer. Offering free cervical cancer screening at 
antiretroviral treatment centers may decrease the incidence of cervical 
cancer in this high-risk population.
Methods: HIV-positive women between the ages of 30 and 39 and 
receiving free antiretroviral treatment at the University of LAGOS 
TEACHING HOSPITAL AND CENTER FOR INFECTOIUS DISEASES were 
eligible for free cervical cancer screening. Eligible subjects were 
offered Pap smears during routine clinic visits. Pelvic examinations 
were performed by trained nurses and Pap smears were obtained 
using a slide, cervical brush and cytology fixative (UNIVERSITY OF 
IBADAN). Women with high-grade lesions were referred to UNIVERSITY 
OF CALABAR for colposcopic biopsy.
Results: Between July 20010 and June 2011, 595 eligible HIV-positive 
women were offered Pap smears, and 261 (44 %) accepted. Of the 261 
women, 125 (48  %) women had normal cytological results, 112 (43  %) 
had abnormal cytological results, and 24 (9  %) had results which were 
indeterminate due to inflammation, inadequate sample collection, or 
insufficient data. Abnormal cytological results included 25 women (10 %) 
with atypical squamous cells of undetermined significance (ASCUS), 66 
(25  %) low-grade squamous intraepithelial lesions (LSIL), and 21 (8  %) 
high-grade squamous intraepithelial lesions (HSIL). Of the 21 women 
with HSIL, 14 underwent colposcopic biopsy. Histology revealed 4 (29 %) 
CIN-I, 4 (29 %) CIN-II, 4 (29 %) CIN-III, and 2 (14 %) invasive cancers.
Conclusions: Among HIV-positive women receiving free antiretroviral 
treatment in Africa, we found significant abnormal cytological results 
and a large number of high-grade lesions. However, less than half of 
all eligible women accepted free screening. Further study is necessary 
to determine barriers to screening and the association of antiretroviral 
treatment and immunological status to cervical lesions
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Question: Feline immunodeficiency virus (FIV) is one of the most sig-
nificant infection agent among wild and domestic cats throughout the 
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World, which belongs to Retroviridae family and also has been used as 
a model for the study of human immunodeficiency virus (HIV). Phy-
logenetic analyses, have been performed to date, indicated that FIV, 
as similar as HIV, has continually been diverged from each other due 
to genetic variations and genome integrations occurred between 
virus and host close interaction. Thus we aimed to investigate current 
molecular evolutionary status of FIV in Turkey.
Methods: The blood samples of 50 domestic cats were examined in 
term of FIV infection and six samples were found positive by Polymer-
ase Chain Reaction (PCR). V3-V6 regions of the envelope gene (env) of 
six positive samples were characterised as well as many performed 
studies previously and Maximum Likelihood (ML) tree was constructed 
to detect diversities using other FIV strains from GenBank database.
Results: Some considerable results were obtained through this analy-
sis. First one, data indicated that new characterised FIV strains has 
localized on separated clade from FIV A–E subtypes. Other one, it was 
found that these six FIV positive samples have been different from 
both by each other and older characterised Turkish FIV strains.
Conclusion: These results have shown that there was existence and 
prevalence of FIV infection among domestic cats in Turkey. Addition-
ally the mentioned differences between FIV strains were required to 
be study with more samples relevant to whether or not using FIV vac-
cine and, choice criteria using vaccine.
Topic 7: Innate sensing & intrinsic immunity
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Question: Human T-lymphotropic virus type 1 (HTLV-1) infects 
between 5 and 10 million people worldwide. It causes the aggressive 
malignancy known as Adult T-cell Leukemia/Lymphoma (ATL), HTLV-
1-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP), and 
infective dermatitis. Although strong immune responses are gener-
ated against the virus, they do not eliminate HTLV-1.
Methods: Primary human monocyte derived DCs were co-cultured 
with a HTLV-1 infected cell line, MT-2 with or without LPS. Morpho-
logical analyses for virus transmission were performed by confocal and 
electron microscopy. Virus binding or LPS-induced activation of DCs 
were analysed by FACS. Signaling pathways were also demonstrated 
by western blots. ALU-PCR or high-throughput integration site map 
analysis was performed by using purified DNA from DCs co-cultured 
with MT-2.
Results: We demonstrate that the contact formed between a DC and 
an HTLV-1-infected T cell can reduce DCs immunological functions 
by reducing TLR responses, IL-12 p40/p70 expression and MHC-II 
expression on the DCs. These DC-T cell contacts induce spleen tyros-
ine kinase-mediated c-Raf/MEK/ERK signaling pathway activation on 
DCs but are independent of DC-SIGN signalling. Furthermore, both 
Alu-PCR and high-throughput integration site analysis of HTLV-1 show 
little evidence of integrated proviruses in DCs. Finally, we show that 
DCs can re-transfer HTLV-1 to target autologous CD4+ T-cells in trans 
(Fig. 16).
Conclusions: These findings suggest that DC/T-cell virological syn-
apses contribute not only to viral cell-to-cell transmission in trans, 
but also to down-modulation of host innate and adaptive immunity 
against HTLV-1. Restoring DC functions in HTLV-1 infection might 
improve the early immune control of the virus and reduce the risk of 
emergence of ATL and other diseases including infective dermatitis.
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Question: AIDS is the deadliest disease due to a single infectious 
agent (i.e. Human Immunodeficiency Virus, HIV-1). Its well-known syn-
ergy with Mycobacterium tuberculosis (Mtb), the etiological agent for 
tuberculosis (TB), places an immense clinical and economic burden in 
resource-limited countries where co-infection with these pathogens is 
highly prevalent, and thus requires a better understanding at the cellu-
lar and molecular level. Interestingly, both pathogens impair the host 
immune response and share monocytes/macrophages as common 
Fig. 16 Transmission of HTLV‑1 from infected cells to DCs via cell‑
to‑cell contact. a, d TEM analysis of DC‑MT‑2 cell‑to‑cell contact or 
control DC. b, c, e SEM analysis of DC‑MT‑2 cell‑to‑cell contact or 
control DC. f–k Confocal immunofluorescence analysis of lectin‑
ConA (green), p19 Gag (red), DC‑SIGN (yellow) or CD3 (yellow) of DCs 
co‑cultured with MT‑2, CD4+ T‑cells from HAM/TSP or a normal 
allogeneic subject. DAPI (nucleus) is shown in blue
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host target cells. Our work aims at deciphering the mechanisms by 
which Mtb exacerbates HIV-1 infection in monocytes/macrophages.
Methods: Primary human monocytes were treated with either pleu-
ral effusions (PE) from TB patients (PE-TB) versus PE from patients 
with other pulmonary infections (PE-nonTB), or conditioned medium 
from Mtb-infected (CmMTB) versus uninfected (CmCTR) human mac-
rophages. At day 3, conditioned cells were infected with HIV-1. Cell 
phenotype was assessed by flow cytometry, and macrophage infec-
tion was qualitatively and quantitatively characterised at day 13 using 
detection of p24 viral protein in confocal microscopy.
Results: We demonstrate that treatment of monocytes with PE-TB 
(or CmMTB) exacerbates HIV-1 infection (i.e. number of infected 
cells, virus entry and replication, formation of multinucleated giant 
cells), in comparison to treatment with PE-nonTB (or CmCTR). This 
increased HIV-1 infection is associated with a deregulator (M2c) acti-
vation program of monocytes/macrophages, characterised by the 
CD16+CD163+MerTK+CD169+ cell-surface marker signature, also 
observed on monocytes from the pleural cavity of TB patients. We 
identified specific molecular mechanisms responsible for these effects, 
including the increased expression of HIV-1 entry co-receptors CCR5 
and CXCR4, and the IL-10/STAT3 signaling pathway.
Conclusion: Collectively, this study improves our understanding of 
how Mtb modulates the differentiation process of human monocytes 
towards a macrophage activation program that increases susceptibility 
to viral infection and formation of cell reservoirs for HIV-1. Finally, it will 
also provide novel target candidates with diagnostic and therapeutic 
potential against the co-morbidity established between AIDS and TB.
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The SAM and HD domain-containing protein 1 (SAMHD1) blocks 
retroviral infection in nondividing myeloid cells and resting CD4+ T 
cells. SAMHD1 acts as a dNTP hydrolase and restricts viral infection 
by depleting cellular dNTPs below the level supporting reverse tran-
scription. In addition, SAMHD1 has been shown to inhibit endogenous 
LINE-1 (L1) elements, the only autonomously active retroelements in 
humans.
In contrast to retroviral restriction, SAMHD1 blocks L1 elements also 
in dividing cells. To determine whether SAMHD1 inhibits HIV-1 and 
L1 through distinct mechanisms, we analysed SAMHD1-mediated 
restriction of L1 using a GFP-based L1 retrotransposition assay. In tran-
siently transfected 293T cells, we found that co-expression of human 
and murine SAMHD1 reduced L1 retrotransposition. The activity of 
SAMHD1 against L1-GFP proofed to be regulated by phosphoryla-
tion of SAMHD1 at Threonine 592. Wildtype or SAMHD1 containing 
the phosphomimetic mutation T592D did not restrict L1, whereas 
the non-phosphorylated SAMHD1 T592A mutant potently inhibited 
L1. SAMHD1 activity was also dependent on the enzymatic active site 
and the allosteric dGTP-binding site. In addition, our data show that 
the intracellular localization of SAMHD1 is not critical for L1 restric-
tion, since the ΔNLS-mutant also blocked retrotransposition. Quanti-
fication of intracellular dNTP levels indicated that the dNTPase activity 
alone might not be responsible for L1 restriction, hinting towards an 
additional mechanism of L1 restriction. Using a luciferase-based L1 
promotor-assay, we found that SAMHD1 does not repress L1 promo-
tor activity. Quantitative RT-PCR experiments suggest that SAMHD1 
does not reduce L1 RNA levels and western blot analysis showed no 
decreased L1 protein levels upon co-expression of SAMHD1.
Together, our results demonstrate that SAMHD1 contributes to 
genome stability by restricting L1 retroelements. The mechanism of L1 
restriction seems similar but not identical to that of HIV-1. In contrast 
to HIV-1, L1 is also blocked in dividing cells. Since neither the dNTPase 
nor the postulated RNase activity seem to contribute to L1 inhibition, 
further analyses of the L1 restriction might identify a previously unrec-
ognized activity of SAMHD1.
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HIV replication requires the successful orchestration of reverse tran-
scription, nuclear entry, and integration while avoiding various antivi-
ral factors and innate immune sensors during early steps of infection. 
The viral capsid and its interactions with cellular factors plays a major 
role during all of these steps. One of these factors, Cyclophilin A 
(CypA), binds the HIV capsid and is essential at these steps, but the 
underlying cellular pathway remained elusive. We identified a family 
of capsid mutants in HIV and SIVmac that are restricted by CypA. This 
antiviral restriction is maintained across species and inhibits nuclear 
import of the viral cDNA. We have demonstrated that the inner nuclear 
envelope protein SUN2 is required for this antiviral activity on HIV and 
SIV capsid mutants. In primary CD4+ target cells, wild-type HIV seems 
to manipulate SUN2 as an essential host factor for viral infection and 
SUN2 is required for the positive activities of CypA on reverse tran-
scription and infection. Thus, these results identify fundamental CypA-
dependent functions of SUN2 in HIV infection at the nuclear envelope. 
We are currently exploring the molecular mechanisms of SUN2 activi-
ties and associated factors at the nuclear envelope in HIV infection. 
The nuclear envelope is increasingly recognized as a highly versatile 
structure and it likely plays critical functions in HIV infection.
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Myeloid cells such as monocytes, macrophages and dendritic cells 
sense virus infection using pattern recognition receptors (PRRs) includ-
ing the toll-like receptors (TLRs) and RIG-I-like receptors (RLRs) that are 
activated by pathogen-associated molecular patterns (PAMPS). Sens-
ing through these receptors activates a variety of antiviral systems 
and induces type-I interferon. In the case of HIV-1, PAMPs are thought 
to include the viral genomic RNA molecules, the reverse transcribed 
viral DNA and viral structural proteins. To determine whether TLRs 
could be further stimulated by small molecule agonists to potentiate 
innate anti-viral mechanisms, we tested a series of TLR agonists for 
their effects on HIV-1 infection of myeloid and T cells. One such mol-
ecule, the TLR7/8 agonist R848, induced a potent block to HIV-1 and 
HIV-2 in myeloid cells. We found that the block was post virus entry yet 
prior to or at reverse transcription. The block could not be overcome 
by packaging the Vpx accessory protein into the virus despite its main-
tained ability to degrade SAMHD1. Agonist treatment of bone marrow 
derived dendritic cells isolated from SAMHD1 knock-out mice also 
prevented HIV-1 infection, further suggesting a SAMHD1-independent 
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restriction mechanism. Activation of TLR7/8 in monocytes caused the 
release of pro-inflammatory cytokines including type-I interferon (IFN). 
However, type-I IFN treatment of monocytes did not block reverse 
transcription in monocytes and IFN-blocking antibodies did not alle-
viate the R848-induced restriction, suggesting that the restriction was 
not caused by type-I IFN. Interestingly, the secreted cytokines blocked 
the infection of bystander cells. We conclude that viral sensing can be 
stimulated by small molecule agonists to both prevent the infection 
of target cells and protect bystanders. In target cells, the block to HIV 
infection is SAMHD1 and type-I IFN independent. This restriction could 
not be accounted for by any of the known restriction factors and thus 
is likely caused by a yet unidentified factor.
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Members of the APOBEC3 (A3) protein family restrict replication of 
reverse transcriptase (RT)-containing viruses and other mobile ele-
ments. The most extensively studied A3 proteins, the human A3G and 
mouse mA3, restrict propagation of retroviruses by inducing deami-
nation of deoxycytidine to deoxyuridine in the transiently single-
stranded, minus-sense DNA (-ssDNA) intermediates during reverse 
transcription. Due to this specificity, the polypurine tract-proximal 
region, which remains single-stranded for the longest period of time, 
accumulates more mutations than the primer binding site-proximal 
region. To counteract A3 activity, retroviruses have evolved several 
strategies. These primarily include prevention of encapsidation of A3 
proteins to virions either by a modification of the C terminus of nucle-
ocapsid protein (HTLV-1) or by employing accessory proteins such as 
HIV-1 Vif and foamyvirus Bet. However, the majority of reverse-tran-
scribing viruses lack obvious A3-neutralising factor and it is unlikely 
that they evade restriction by A3 avoidance like HTLV-1. One of such 
viruses is mouse mammary tumor virus (MMTV) that efficiently pack-
ages deamination-competent mA3 and A3G but is only partially inhib-
ited by both restriction factors. We found that the lower sensitivity 
to inhibition results from a reduced frequency of deamination of the 
MMTV genome during reverse transcription governed by the MMTV 
RT. Specifically, we determined that the balance between the rate 
of DNA polymerization and the rate of RNA cleavage, which defines 
the extent of RNA degradation during the synthesis of the -ssDNA, 
is responsible for the low level of A3-mediated deamination of the 
MMTV reverse transcripts. Hence, the MMTV RT narrows down the 
window of opportunity for A3 to bind substrate. Residual mutagenic 
capacity of A3 proteins does not abolish virus infectivity and may be 
even exploited by MMTV to increase virus diversity and to modulate 
overall viral fitness. To our knowledge, alleviation of the deamination 
activity of A3 proteins, represents a novel mechanism of A3 counterac-
tion and it seems likely that the same strategy is employed by other 
RT-containing viruses lacking Vif-like protein. Understanding of the A3 
evasion mechanisms could be beneficial for improvement of current 
therapeutic protocols.
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Background: Dendritic cells (DCs) play a key role in the induction 
of immune responses against HIV. However, HIV has evolved ways 
to exploit them, facilitating immune evasion and viral dissemina-
tion. Immature myeloid DCs can sustain HIV-1 replication, in contrast 
mature myeloid DC are strongly resistant to HIV infection. Our group 
has recently shown that the cellular factor p21cip/waf potently blocks 
HIV infection in macrophages by reducing the pool of dNTPs through 
the inhibition of RNR2. p21 through its cyclin-dependent kinase 
inhibitory activity might also modulate the phosphorylation state of 
SAMHD1 and its antiviral activity. We wondered whether p21 could be 
involved in the strong resistance of DCs to HIV infection.
Results: We found that the maturation of monocyte derived DCs 
(MDDCs), which strongly blocked HIV-1 replication, was associated 
with a strong increase in the expression of p21. Induction of p21 was 
accompanied by a decrease in the expression of RNR2 but also of the 
Thymidine kinase1 (TK1) and Thymidylate synthase (TYMS), which 
are critical for dTTP synthesis. Accordingly, we observed a decrease 
in the levels of all dNTPs in mature MDDCs. The knockdown of p21 
expression recovered RNR2, TK1 and TYMS and the level of dNTPs, 
and increased infection. Supplementation with exogenous dNTPs 
recovered infection in mature MDDCs but not to the level observed in 
immature MDDCs. Maturation of MDDCs did not change total levels 
of SAMHD1 but was accompanied by a decrease in pSAMHD1 (inac-
tive against HIV). Knockdown of p21 increased levels of pSAMHD1, 
supporting the role of p21 in the regulation of phosphorylation of 
SAMHD1 in DCs. Although degradation of SAMHD1 in the presence of 
VPX increased infection in mature MDDCs at great extent, the addition 
of exogenous dNTPs to MDDCs treated with VPL-VPX was necessary to 
completely rescue HIV infection.
Conclusion: Our results suggest that blocking HIV replication in 
mature MDDCs is due to an induction of p21 during maturation. p21 
then regulates several factors involved in dNTPs synthesis and the 
phosphorylation of SAMHD1, resulting in conditions that allow effi-
cient block of HIV-1 replication through complementary/synergistic 
mechanisms. Overall, p21 appears to be a key regulator of HIV infec-
tion in myeloid cells.
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Interferon induced transmembrane proteins (IFITMs) restrict the cel-
lular entry of a broad range of viruses, but it has been suspected that 
for HIV-1 IFITMs may also inhibit a post-integration replicative step. 
We investigated the effects of IFITM expression on late stage HIV-1 
replication.
We found that the expression of human IFITMs reduces the quantity 
of released HIV-1, HIV-2, SIV and MLV viral particles from transfected 
cells. While knockdown of endogenous IFITMs enhances HIV-1 produc-
tion. This phenotype is apparent during single cycle and multiple cycle 
infections of T-cells. Notably, IFITM-mediated antagonism is more 
potent for HIV-1 in which Nef has been deleted.
We show that IFITM expression reduces HIV-1 viral protein synthe-
sis by preferentially excluding viral transcripts from translation and 
thereby restricts viral production. Codon-optimization of proviral DNA 
rescues viral translation during IFITM expression, implying that IFITM-
mediated restriction targets viral RNA. While RRE-containing viral tran-
scripts are more strongly excluded from translation when IFITMs are 
expressed, in agreement with a greater decrease of Vpu and Gag pro-
teins, compared to multiply-spliced transcript levels and Nef.
IFITMs require cellular proteins to suppress viral production. Screening 
a panel of RNA helicases revealed that siRNA-mediated knockdown or 
expression of a dominant negative mutant of DDX3 impaired IFITM1-
mediated restriction of HIV-1.
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Further, mutation of cysteines in IFITM1 and IFITM2 that perturb their 
palmitoylation, and retention in plasma membrane and endosomes, 
strongly reduces levels of all classes of viral transcripts and potently 
inhibits viral output far beyond the level of restriction already seen for 
wild-type IFITM proteins.
Our studies identify a novel role for IFITMs in inhibiting HIV-1 replica-
tion at the level of translation and for which viral RNA is a determinant. 
Yet we show that this restriction can be overcome by the lentiviral 
countermeasure Nef. Further, we identify the host RNA helicase DDX3 
as a cofactor for restriction of HIV-1 protein synthesis by IFITM1. We 
also show that it is possible to engineer highly active anti-HIV-1 IFITM 
variants by modulating their palmitoylation status.
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In recent years several human proteins have come to light which act 
as restriction factors for HIV-1 infection. Among these Serinc3 and Ser-
inc5, members of the Serinc family of transmembrane proteins could 
recently be shown to have strong anti-HIV-1 activity if expressed in 
virus-producing cells. The exact mechanism by which Serinc3 and Ser-
inc5 restrict HIV-1 is as of yet unknown. Therefore, we have analysed 
different regions of Serinc5, the most potent restriction factor of the 
family, to discover those regions of the protein which are crucial for 
restriction. To achieve this, we systematically examined the protein 
by means of domain deletions, domain swaps, amino acid mutations 
and construction of chimeric proteins. Beyond the extensive mapping 
of the protein’s function, we were able to characterise the membrane 
topology of this 10-transmembrane protein, but most importantly, we 
have devised several assays to define the protein’s function in HIV-1 
restriction: Analysis of surface expression, total expression by Western 
blot and flow cytometry, localisation, infectivity, particle incorpora-
tion, gag and env maturation, and its influence on antibody-mediated 
virus neutralisation. With the help of these methods we collected 
many insights into the protein’s domain structure, localization and 
mechanism of action.
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Background: One of several inhibitory RNA (RNAi) systems is the piwi 
anti-transposon system, which stores short (24–32 nt) concatenated 
transposon copies in genomic DNA. It is especially active during early 
embryogenesis. It is not known if the piwi system is active against 
retroviruses and related retrotransposons in humans. We therefore 
searched for sense and antisense piwi sequences in our collection of 
HERV sequences, and in random sequences of a similar length.
Materials and methods: The following sequence collections were 
used: 3290 proviruses found by the RetroTector program [Sperber 
et  al. NAR (2007); 35:4964–76] in the GRCh 37/hg19 human genome 
assembly (HG19), 3150 random 5000 bp sequences and 23,595 human 
entries of the piRNA database [Lakshmi and Agarwal, NAR (2008); 36: 
D173–D177]. BLASTn was downloaded from the NCBI website. The 
runs were administered by programs written in Visual Foxpro by JB.
Results: Of 3290 proviruses in HG19 870 contained a perfect copy 
(100 % match) of at least one piRNA (558 had one, 166 two, 72 three, 
33 four, 16 five, 14 six, 7 seven, 4 eight, average 2.07 per provirus). Rela-
tive to the ordinary 5′–3′sense of retroviruses (rvsense, s), 42 % of the 
piwi sequences were in rvsense, 58 % in antirvsense (as). None of the 
random sequences contained piwi sequences. The frequency of piwi 
sequences in 5′LTRs was 118 (37 % s and 63 % as); in 3′LTR 94 (42 % s, 
58 % as); in gag 126 (44 % s, 66 % as); in pro 54 26 % s, 74 % as; in pol 
376 (39 % s, 61 % as); in env 132 (35 % s, 65 % as). Proviruses contain-
ing piwi sequences occurred on all chromosomes.
Conclusion: HERVs may participate in piwi-dependent RNAi retroviral 
restriction.
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Low occurrence of HIV-1 infection in sickle cell disease (SCD) patients 
suggests a potential restriction of HIV-1 infection in SCD. Here we ana-
lysed whether ex vivo HIV-1 infection is restricted in SCD PBMCs and 
determined the mechanism of the restriction. We observed reduced 
HIV-1 replication and increased expression of heme and iron-regulated 
genes, including ferroportin. We also observed the induction of sev-
eral HIV-1 regulatory host factors, including SAMHD1. Critically, HIV-1 
restriction was alleviated with hepcidin treatment suggesting that fer-
roportin mediates HIV-1 restriction which might go unsuppressed as 
hepcidin levels were not elevated in serum of SCD patients. Consist-
ent with the increased ferroportin expression, labile iron levels were 
reduced in SCD PBMCs and protein levels of ferroportin and HIF-1α 
were increased. The effect of hepcidin was replicated in HIV-1 infected 
primary and cultured cells, in which HIV-1 inhibition by hemin was 
reversed by hepcidin. Knock down of ferroportin, HO-1 but not HIF-1α 
alleviated the HIV-1 inhibition by hepcidin. Analysis of HIV-1 replica-
tion steps showed inhibition of reverse transcription, implicating 
SAMHD1. SAMHD1 is negatively regulated by CDK2, which is inhibited 
by iron chelation. In SCD PBMCs, CDK2 activity was low and SAMHD1 
phosphorylation was reduced. SAMHD1 expression was induced and 
its phosphorylation decreased with heme treatment further support-
ing its involvement in HIV-1 restriction in SCD. Our findings point to 
the previously unknown role of ferroportin as an HIV-1 restriction fac-
tor in biologically relevant settings, linking reduced intracellular iron 
levels to the inhibition of CDK2, reduction of SAMHD1 phosphoryla-
tion and HIV-1 inhibition.
P58 
APOBEC3G modulates the response to antiretroviral drugs 
in humanized mice
Audrey Fahrny1, Gustavo Gers‑Huber1, Annette Audigé1, Roberto F. 
Speck1, Anitha Jayaprakash2, Ravi Sachidanandam2, Matt Hernandez3, 
Marsha Dillon‑White3, Viviana Simon3,4 
1University hospital Zurich, Infectious diseases, Zurich, Switzerland; 2Icahn 
School of Medicine at Mount Sinai, Department of Oncological Sciences, 
New York City, NY, United States; 3Icahn School of Medicine at Mount 
Sinai, Department of Microbiology and The Global Health and Emerging 
Pathogens Institute, New York City, NY, United States; 4School of Medicine 
at Mount Sinai, Division of Infectious Diseases, Department of Medicine, 
New York City, NY, United States
Correspondence: Audrey Fahrny
Retrovirology 2016, 13(Suppl 1): P58
Viral evolution and diversification in HIV+ patients have been associ-
ated with increased pathogenicity and underlies the rapid appear-
ance of viral variants resistant to antiretroviral drugs. APOBEC3G (A3G) 
restricts HIV-1 by inducing G-to-A mutations in the newly synthesized 
proviral cDNA during RT. The HIV-1 accessory protein Vif counteracts 
A3G restriction and is, thus, critical for productive HIV-1 replication 
in  vivo. Humanized mouse models provide us with an experimental 
system to directly test the extent to which sub-optimal neutralisation 
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of A3G impacts viral fitness, pathogenicity and antiretroviral treat-
ment outcomes. CD34 complemented NSG mice were infected with 
HIV strains that encoded Vif variants differing in anti-A3G activity 
(e.g., WT: 100 %, 45G: 10 % and SLQ: 1 %). In a subset of mice antiret-
roviral treatment with lamivudine (3TC) was initiated after 4 weeks of 
infection. Plasma viremia and T cell subsets were measured for up to 
4 months’ post infection. HIV WT and 45G viruses established produc-
tive infection and displayed comparable levels of plasma viremia at 
4 weeks post infection. In contrast, HIV SLQ failed to infect and spread 
in humanized mice suggesting that counteracting A3G is needed. 
Interestingly, we observed that the WT infected mice maintained 
high levels of plasma viremia while the 45G infected mice displayed 
a significant reduction in plasma viremia over time. As expected, 
3TC treatment decreased viremia in all infected animals but the 45G 
infected mice experienced less overall reduction in viremia and a 
more rapid viral rebound. In summary, viruses engineered to display 
a range of anti-APOBEC3 activities are useful tools to probe for impact 
of APOBEC3 on viral pathogenesis and treatment outcome. Our 
results suggest that partial neutralisation of APOBEC3 impacts viral 
fitness and response to lamivudine. Ongoing and future studies will 
analyze the genotypes (e.g., RT, Vif ) underlying the observed in  vivo 
phenotypes.
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Endogenous retroviruses (ERVs) are genetic elements constituting a 
significant part of the vertebrate genomes. They are generated when 
an exogenous virus integrates into the host germline which leads to 
vertical transfer of ERVs to subsequent host generations. ERVs are 
usually fixed in the host population for millions of years and their 
sequences are damaged by mutations. However, small portion of ERVs 
retains intact genetic information and have been recently shown to 
play a key role in various cellular processes and pathologies. Study of 
the DNA methylation-dependent transcriptional silencing, the main 
mechanism of host defence against uncontrolled virus propagation in 
its genome, is crucial for uncovering the ERV-host interactions. Despite 
the progression in this field, the involvement of epigenetic regulations 
in the defense against active ERVs is still poorly understood.
We study a recently identified ERV present in the mule deer genome, 
CrERV. This evolutionary young virus is extremely polymorphic in its 
integrations suggesting an ongoing invasion into the host genome. 
This makes CrERV a unique model for studying retrovirus endogeni-
sation. In our work, we employed next generation bisulfite sequenc-
ing strategy to determine the methylation pattern of individual CrERV 
integrations in different animals. This method offers new insight into 
the interactions between host and active ERVs.
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Background and question: Endogenous retroviruses (ERVs), descend-
ents of retroviruses integrated into host germline cells which have 
proliferated over millions of years, represent ~5  % of our and other 
mammal genome sequences. Recent research indicate ERVs (and other 
retroelements such as LINEs) may play a role in innate sensing, with 
implications for combating autoimmune disease and viral infection. 
We have previously shown the macaque to have recently integrated 
ERVs belonging to three different lineages. Archived material from 
past macaque/SIV studies provides an ideal opportunity to examine 
the dynamics of ERV and SIV expression in the context of their interac-
tion with the innate immune response. Specifically, we plan to explore 
Volkman & Stetson’s (2014) hypothesis that endogenous retroelement 
expression affects the threshold for the innate response to exogenous 
viral infection.
Methods: Generation of in vitro transcripts and specific oligonulcleo-
tide primer and probe sequences have enabled development of qPCR 
assays for the three ERV lineages in the macaque shown to contain 
recently integrated loci. We have also searched bioinformatically for 
full-length ORFs in the reference rhesus macaque genome sequence 
in order to predict the potential of these lineages to produce virions 
and hence RNA in the plasma.
Results: ERV-specific RNA and DNA signals appear to increase in both 
Mauritian cynomolgus and Indian macaque species during acute 
infection with several wild-type exogenous SIV strains. The relation-
ship between expression of ERV-specific lineages and SIV RNA during 
acute infection is currently being explored, in tandem with induction 
of an innate response detectable during acute infection.
Conclusions: Preliminary elucidation of levels of ERV-specific RNA and 
cell-free DNA in macaque plasma suggest a dynamic relationship with 
exogenous SIV infection. Localised expression of ERV mRNA in cell-
associated SIV infection in conjuction with upregulation of interferon 
stimulated genes in multiple macaque challenge studies will provide a 
fuller picture of the potential dynamic interplay of these parameters in 
the outcome of infection.
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The recent discovery of SERINC3 and SERINC5 as an innate immunity 
factor acting against HIV revealed another example of how virus-host 
interactions control pathogen replication. The current knowledge 
is that SERINC3 and SERINC5 expression leads to markedly reduced 
virion infectivity in the absence of Nef. The exact mechanism of action 
of SERINC restriction and Nef antagonism are currently elusive and 
domains essential for SERINC’s function are unknown.
As SERINC proteins are present in several eukaryotes’ genome, the aim 
of the current work is to assess the ability of rodent and lagomorph 
SERINC orthologs to interfere during HIV-1 replication and to identify 
thereby essential domains and the mode of action, as well as their 
importance for the generation of an animal model for HIV replication/
pathogenesis.
cDNAs of SERINC3 and SERINC5 from mouse, rat and rabbit were 
amplified by PCR and cloned into expression vectors. After co-trans-
fection of SERINC orthologs with HIV-1deltaNef proviral DNA into 
293T cells, the effect on HIV-1 infectivity was assessed by measur-
ing RT activity of released viral particles using SG-PERT, and firefly 
luciferase activity on TZM-bl cells of viral supernatants. Viral entry 
into new target cells was also measured using a FACS-based virion-
fusion assay. In addition, evolutionary analyses were conducted 
to evaluate the existence of selective pressure and to determine 
the mutation rate in SERINC3 and SERINC5 from different mammal 
species.
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Although a certain level of amino acid divergence was observed, all 
SERINC3 and SERINC5 orthologs displayed an anti-HIV activity compa-
rable to the human orthologs. The first results obtained with the FACS-
based virion fusion assay correlate with the data from the infectivity 
assay, showing a lower activity of SERINC3 in restricting HIV infectivity 
when compared with SERINC5. The assessment of the potency by the 
viral antagonist Nef to overcome the imposed restriction is currently 
in progress.
Our results show that rodent and rabbit SERINC3 and SERINC5 inhibit 
HIV-1 infectivity in a different extent but comparable with the human 
orthologs. The antiviral activity of SERINC proteins thus appears to be 
extended to rodents and rabbits, therefore representing a potential 
restriction factor when using these species as an animal model for HIV 
replication.
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The promyelocytic leukemia protein (PML), also named TRIM19, is a 
member of the TRIM protein family. The seven main PML isoforms are 
located both in the cytoplasm and the nucleus. In the nucleus, PML 
is mostly sumoylated and is the main structural component of the 
nuclear matrix structures known as nuclear domain 10 (ND10) or PML 
nuclear bodies (PML-NBs). ND10 structures, in which PML is associ-
ated with Sp100, Daxx and other proteins, have been shown to medi-
ate an intrinsic immune response against various different viruses. In 
this study, we analysed the role of PML during retroviral replication 
in different cell types using cell lines exhibiting a shRNA-mediated 
knockdown of PML, Daxx and SP100. Whilst the permanently ND10 
associated proteins Daxx and SP100 have no restricting effect, PML 
inhibits HIV in a cell type-dependent manner. HIV reporter virus 
infection assays comparing control cells harboring intact PML and 
PML-knockdown cell lines revealed an active PML-mediated block to 
retroviral infection in primary human fibroblasts and murine embry-
onic fibroblasts. However, this block to HIV reporter virus infection was 
not present in T cell lines, e.g. Molt4 or Jurkat, and myeloid cell lines, 
e.g. CEM and HuT78. Quantitative PCR analysis of HIV cDNA in infected 
cells revealed that PML restricts infection at the level of reverse tran-
scription, which occurs in the cytoplasm after virus entry. Indeed, in 
immunofluorescence analysis of infected human fibroblasts we found 
a temporary relocation of PML from the nucleus to the cytoplasm, 
which started 30 min post infection and increased till 4 h post infec-
tion. Overexpression of the PML isoforms I to VI resulted in a moderate 
reduction of HIV reporter virus infectivity, but failed to reveal a particu-
lar isoform responsible for the PML-mediated block to retroviral infec-
tion. Finally, we showed that PML has antiviral activity against other 
members of different genera of the retroviral family, e.g. SIV, MPMV 
and MLV. Our findings shed light on the controversial role of PML dur-
ing retroviral infection and show that PML contributes to the intrinsic 
restriction of retroviral infections in a cell type-dependent manner.
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Endogenous retroviruses (ERVs) originate by germline infection and 
subsequent mendelian inheritance of their exogenous counterparts. 
With notable exceptions, all mammalian ERVs are evolutionarily old 
and fixed in the population of its host species. Broader knowledge 
about the process of endogenization is lacking.
Besides endogenous retrovirus in koalas, ERV in mule deer (Odocoileus 
hemionus) forms new germline insertions in the natural host popula-
tion in the present time and serve as important model of the retrovirus 
endogenization process. Previously, we have determined complete 
genome sequence of the deer ERV, denoted cervid endogenous ret-
rovirus (CrERV). Using next generation sequencing-based approach, 
we have characterised thousands of highly polymorphic CrERV inte-
grations in approximately 50 animals. Notable polymorphism within 
the population of mule deer with integration sites allocated to specific 
area verify the predicted young age of the virus as well as the current 
process of endogenization.
For virological studies, we have obtained an infectious virus by cocul-
tivation with susceptible human cells and performed experiments to 
characterise its biophysical properties. Subsequently, we have con-
structed an infectious molecular clone of CrERV and defined its basic 
replication properties. Surprisingly, CrERV exhibits a xenotropic behav-
iour, where it infects human cells but not original host deer cells. This 
is in contrast with the efficient generation of many new endogenous 
integrations. We are using reciprocal pseudotypes with murine leuke-
mia virus (MLV) and vesicular stomatitis virus envelope (VSV) bearing a 
GFP signal, to characterise the nature of the replication block on mule 
deer cells. The preliminary data point to the block at the receptor level.
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Upon virus infection, cGAS-cGAMP-STING-dependent type I IFN sign-
aling contributes to achieve an antiviral state in the host cells. Work 
from others suggests that cGAMP is transferred intercellularly via gap 
junctions and/or incorporated into newly synthesized viral particles. 
The goal of our study is to investigate whether intercellular transfer of 
cGAMP occurs via HIV-1 Env-mediated cell–cell fusion.
Primary human macrophages that were cocultured with cGAS-pos-
itive CHO cells, but not cGAS-negative Jurkat cells expressing HIV-1 
Env induced human IFN-beta mRNA expression and scored positive 
in a bioactivity assay for type I IFNs. Reduction of cGAS expression in 
CHO cells and reconstitution of cGAS expression in Jurkat cells abol-
ished and rescued the mounting of the IFN response, respectively, in 
cocultured macrophages. Importantly, donor cell line-specific cGAS 
expression levels and abundance of SVPDE-sensitive, IFN-inducing 
small molecules, most conceivably cGAMP, correlated with the ability 
to trigger an IFN response in cocultured macrophages. Additionally, 
an intact STING-TBK1-IRF3 signaling axis, but not the cytoplasmic DNA 
sensor cGAS in macrophages, was essential for the macrophages’ abil-
ity to induce an IFN response upon coculture.
Mounting of an IFN response coincided with a functional antiviral 
state in macrophages and was abolished upon genetic, immunologi-
cal or pharmacological interference with the membrane fusion pro-
cess. Whereas HIV-1 Env-positive donor cells and target macrophages 
interacted via multiple modes, only fusion inhibitor-sensitive cell–cell 
fusion, but not Jasplakinolide-sensitive phagocytosis of donor cells by 
macrophages was required for induction of an IFN response.
In conclusion, we propose that cGAMP transfers horizontally through 
HIV-1 Env-mediated membrane fusion sites from cells with acti-
vated or constitutively active cGAS to cocultured macrophages, and 
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activates an innate immune response. The intercellular transfer of this 
second messenger may have direct implications in the context of cell-
to-cell transmission of HIV-1.
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CD8+ cells from simian immunodeficiency virus (SIV)-infected long 
term non progressors and certain uninfected macaques can suppress 
viral replication in  vitro (CNAR). Analysis of the global transcription 
pattern and additional validation revealed that expression of FAM26F 
distinguished CD8+ cells controllers and non controllers.
However, the studies also indicated that the cell surface protein 
FAM26F might be not necessarily related to CNAR, but to immune 
activation which provided the rationale for further investigations 
into FAM26F expression and its role in SIV-infection. FAM26F was 
also expressed in many cells of the immune system. Its expression 
increased in vitro after IFN-γ treatment of lymphocytes. Ex vivo FAM26F 
RNA levels in PBMCs correlated with plasma IFN-γ but not with IFN-α 
indicating that FAM26F transcription is linked to the IFN-γ pathway. 
Baseline FAM26F expression appeared to be stable for months, albeit 
the individual expression levels varied significantly. FAM26F expression 
in macaques thus might represent an eQTL similar to humans. FAM26F 
transcription was upregulated in SIV-infected monkeys, but did not 
directly correlate with viral load in contrast to MX1 and CXCL10. Nota-
bly, pre-infection levels of FAM26F correlated inversely with overall 
plasma viral load during the acute and post-acute phase of infection 
(AUC wpi 0–8) in naïve SIV-infected from two experiments, and—at a 
lower significance level—even in immunized macaques.
FAM26F transcript levels prior to infection thus can inform about the 
pace and strength of the antiviral immune response during the early 
stage of infection. It has a strong potential to serve as a novel marker 
to investigate innate and adaptive immunological responses limiting 
early retroviral replication.
Topic 8: Adaptive immunity & immune evasion
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Background: T-cell receptor (TCR) transfer is a promising approach for 
boosting the cytotoxic T lymphocyte (CTL) response. Due to the ability 
of HIV-1 to escape from CTLs it is important to use TCRs with broad 
recognition of viral variants. So far, there is a lack of data regarding 
the molecular determinants for the recognition of defined epitopes. 
Therefore, we performed a sequence-function analysis of three differ-
ent TCRs targeting the HLA-A2-restricted CTL epitope SLYNTVATL (SL9) 
in HIV-1 p17.
Methods: Three TCRs were cloned from SL9-specific CTL from three 
HIV-1-infected patients. SL9/TCR-mRNA-constructs encoding the TCR-
alpha and TCR-beta chains were electroporated into peripheral blood 
mononuclear cells (PBMC). TCR functionality with regard to functional 
avidity and cross-recognition of eleven SL9 variants was analysed in 
γIFN-ELISPOT assays using synthetic peptides.
Results: The SL9-specific TCRs consisted of following TCR-alpha 
and TCR-beta chains: TCR #1: AV2S1/BV5S1(Cβ1), TCR#2: AV2S1/
BV5S1(Cβ2). TCR#3: AV2S3/BV22S1(Cβ2). TCR#1 and TCR#2 used the 
same variable alpha and beta chains, but displayed variant amino 
acids in the CDR3-regions of the TCR-alpha and TCR-beta chains. In 
addition, TCR#1 and #2 used different constant beta chains.
All three TCRs showed a similar functional avidity with a half-max-
imal peptide sensitizing concentration ranging between 2  μg/ml 
and 0.2  μg/ml. Recognition of viral variants was similar for TCR#1 
and TCR#2, whereas TCR#3 showed a different pattern of variant 
recognition.
Cross-over exchange of the TCR-alpha and TCR-beta chains from TCR#1 
and TCR#2 did not affect SL9-recognition by the new hybrid TCRs. In 
contrast, hybrid TCRs with combinations of the respective TCR-alpha 
and TCR-beta chains from TCR#1/TCR#3 and TCR#2/TCR#3 failed to rec-
ognize SL9.
Conclusion: Despite their differences in the sequences of their TCR-
alpha and TCR-beta chains, all three HLA-A2-restricted TCRs showed 
a similar functionality with regard to peptide avidity. The efficacy of a 
TCR-based immunotherapy could be enhanced by usage of different 
TCRs targeting the same epitope with a different pattern of recogni-
tion of viral sequence variants.
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Small ruminant lentiviruses persist in infected goats that mount a 
strong humoral immune response characterised by low neutralising 
titers. In this study, we characterised the antibody response to SU5, 
a variable, immunodominant epitope of the envelope glycoprotein 
of SRLV (1,4). The sequence of this epitope is variable between dif-
ferent phylogenetic groups but surprisingly conserved within a 
given subgroup (3,4). We compared the neutralising activity of the 
affinity purified anti-SU5 fraction with that of antibody contained in 
the unfractionated serum, the flow through of the affinity column 
and a negative control serum. While the neutralising activity of the 
flow through associated antibody was not significantly reduced 
compared to the unfractionated serum, the purified anti-SU5 anti-
body was devoid of neutralising activity. Taken together these data 
strongly suggest that anti-SU5 antibody is incapable of binding the 
functional form of Env expressed at the surface of infectious virus 
particles. We concluded that the observed variability does not reflect 
escape from neutralisation but rather indicate a structural tolerance 
of this particular region. To test this hypothesis, we substituted the 
original SU5 of the g6221 molecular clone with a FLAG-Tag (2). Pre-
liminary data indicate that the mutated virus replicates efficiently 
in susceptible cells, confirming the structural tolerance of this par-
ticular region of the envelope gene. Experiment in  vivo will follow 
to confirm the immunodominant nature of this envelope region. 
We propose that SU5 is a decoy epitope exposed on virus debris 
that lures the humoral immune response in committing an “original 
epitopic sin”.
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Paediatric HIV infection is typically characterised by rapid disease pro-
gression in the absence of ART. However, there is a subset (5–10  %) 
of ART-naïve HIV-infected children who remain clinically healthy, 
maintaining normal-for-age CD4 T-cell counts throughout childhood 
defined here as ‘paediatric non-progressors’ (PNPs). To identify mech-
anisms preventing HIV disease progression we studied a cohort of 
170 HIV-1 Clade C infected PNPs recruited from multiple clinical sites 
across South Africa.
In contrast to adults where HIV long-term non-progression is mostly 
associated with low to undetectable viral load levels, paediatric non-
progressors maintained normal-for-age CD4 T-cell counts despite 
persistently high viremia (median 26,000 HIV copies/ml). T-cell 
and monocyte activation was increased in progressor children but 
remained at levels similar to HIV-uninfected children in PNPs. The 
CD4+ and CD8+ T-cell compartment in progressors, but not PNPs, was 
differentiated towards pro-inflammatory effector memory phenotypes 
with high levels of immune exhaustion. HIV specific T-cell responses 
and potent broadly neutralising antibody (bnAb) responses were 
detected in both, progressor and non-progressor children (bnAbs in 
72 % of paediatric subjects versus 19 % of infected adults, p < 0.0001), 
but non-progression in paediatric infection was independent of these 
HIV-specific immune responses.
However, we observed low levels of CCR5 expression and limited 
HIV infection in long-lived stem cell memory and central memory 
CD4+ T-cells in paediatric non-progressors in association with 
higher frequencies of these T-cell subsets (p  <  0.0001 vs. progres-
sor controls), suggesting a mechanism contributing to the mainte-
nance of normal-for-age CD4 T-cell counts despite persistently high 
viremia.
These data indicate that the mechanisms of HIV non-pathogenesis in 
paediatric infection are distinct from those in adults, where disease 
non-progression is typically linked to viremic suppression in the pres-
ence of ‘protective’ HLA class I-mediated immunity; but reminiscent 
of the natural hosts of SIV infection, such as the sooty mangabey, 
in which non-pathogenesis is independent of strong virus-specific 
immunity and characterised by low systemic immune activation 
despite persistently high viremia (Figs. 17, 18).
Fig. 17 Normal CD4 counts for age and low immune activation 
despite high viral loads in paediatric non‑progressors. a–c absolute 
CD4 count, CD4 % and viral load in ART‑naïve paediatric subject 
517‑C over the first 10 years of life. 10th, 50th, and 90th centile of 
absolute CD4 and CD4% are shown in panels A‑B for uninfected chil‑
dren over the first 10 years of life18–19. d Longitudinal viral load data 
from 170 cART‑naïve paediatric non‑progressors. Viral load declines 
with age over the first 5 years (r = −0.34, p < 0.0001) but then pla‑
teaus thereafter. e Current absolute CD4 counts and viral loads in 170 
paediatric non‑progressors. f Lack of correlation between CD4 count 
and viral load in 170 paediatric non‑progressors
Fig. 18 CCR5 expression and HIV infection is lower in central 
memory CD4+ T‑cells in paediatric non‑progressors than in progres‑
sors. a Representative FACS data of CCR5 expression in paediatric pro‑
gressors versus non‑progressors. b CCR5 expression on CD4+ T‑cell 
subsets in ART‑naive children aged >5 years by absolute CD4 count, 
c Absolute C04 counts and viral loads in paediatric non‑progressors 
and adult future progressors did not differ significantly (median 1251 
vs. 1106 cells/mmJ; and 22,075 vs. 31,500 HIV RNS copies/ml plasma, 
respectively; similarly CD4% did not differ between the two groups, 
median 31 versus 36 %, not shown), d HIV infection in Tn, Tscm, Tern 
and Tem in paediatric non‑progressors and adult future progressors, 
determined by qPCR of HIV DNA in sorted CD4 T‑cell subsets
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Topic 9: Novel antiviral strategies
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Introduction: Medicinal plants are the base of traditional medicine 
to fight a diversity of infections and diseases for thousands of years. 
According to estimates, 25  % of the commonly used medicines con-
tain compounds isolated from plants. A variety of herbal products 
have shown potential to treat a number of viral infections and possess 
a broad-spectrum antiviral activity.
Results: We demonstrate that extracts of Cistus incanus (Ci) leaves 
and roots of Pelargonium sidoides inhibit human immunodeficiency 
virus (HIV) infections in vitro. Antiviral activity was highly selective for 
virus particles, preventing primary attachment of the virus to the cell 
surface and viral envelope proteins from binding to heparin. Ci treat-
ment also prevented infection by virus particles containing Ebola and 
Marburg virus envelope, indicating that antiviral activity of Ci extract 
extends to emerging viral pathogens. Antiviral activity was mediated 
by polyphenol-enriched fraction. Using Bioassay-guided fractionation 
of whole Ci extracts, we detected the presence of numerous, separable 
antiviral compounds and we were also able to identify the structure of 
several components with anti-HIV activity.
Conclusion: These results demonstrate a potent and broad in  vitro 
antiviral activity of leaf extracts of Ci against potentially lethal viruses 
for humans and also highlight medicinal plants as a promising source 
of novel antiviral agents.
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Question: Mucosal Th17-polarized CD4+ T-cells are the first targets 
of HIV/SIV infection and contribute to HIV persistence during ART. 
PPARγ agonists negatively regulate RORγt-mediated Th17 functions 
and block HIV replication. Here, we investigated the potential use of 
PPARγ antagonism for viral reactivation and Th17 restoration during 
HIV infection.
Methods: Memory CD4+ T cells were isolated from PBMCs of HIV− or 
HIV+ on ART individuals using magnetic beads (Miltenyi) and stimu-
lated with anti-CD3/CD28 Abs. HIV− cells exposed to replication-com-
petent or VSVG-pseudotyped HIV in vitro and cells isolated from HIV+ 
on ART individuals were cultured in the presence or absence of the 
PPARγ agonist Rosiglitazone (RGZ) or antagonist T0070907 (T007) for 
12 days. HIV-p24 and IL-17A levels were quantified by ELISA and FACS. 
HIV-DNA integration was quantified by real-time PCR. Gene expression 
was quantified by real time RT-PCR. The expression of HIV co-receptors 
CCR5 and CXCR4 was measured by FACS.
Results: RGZ decreased both HIV replication and IL-17A production. As 
predicted, T007 increased IL-17A expression/production. Surprisingly, 
T007 alone or in combination with RGZ inhibited HIV replication by 
reducing CCR5 expression and HIV transcription. The T007-mediated 
effects coincided with the induction of cholesterol-25-hydroxylase, 
an enzyme converting cholesterol to 25-hydroxycholesterol, a mol-
ecule known to broadly inhibit viral infection and recently identified 
as an intrinsic agonist of RORγt. Finally, T007 inhibited HIV reactivation 
and promoted IL-17A production in CD4+ T cells from HIV+ on ART 
individuals.
Conclusions: We demonstrated that PPARγ antagonism interferes 
with HIV replication/reactivation while promoting the Th17 effector 
functions at least in part via the synthesis of 25-hydroxycholesterol. 
Future studies in animal models and human clinical trials should deter-
mine whether PPARγ is an appropriate target for viral eradication and 
immune restoration.
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We analysed a multiresistant (MR) HIV-1 reverse transcriptase (RT), 
subcloned from a patient-derived subtype CRF02_AG, harboring 45 
amino acid exchanges, amongst them four thymidine analog muta-
tions (TAMs) relevant for AZTMP excision (M41L, D67N, T215Y, K219E, 
lacking K70R) as well as four substitutions of the AZTTP discrimina-
tion pathway (A62V, V75I, F116Y and Q151M, lacking F77I). In addition, 
K65R, known to antagonize AZTMP excision in HIV-1 subtype B was 
present. Although MR-RT harbored the most significant exchanges 
T215Y and Q151M of each pathway, it exclusively used AZTTP discrimi-
nation. This indicates that the two mechanisms are mutually exclusive 
and that the Q151M pathway is preferred since it confers resistance to 
most nucleoside inhibitors. A derivative was created, additionally har-
boring the TAM K70R and the reversions M151Q as well as R65K since 
K65R antagonizes excision. MR-R65K-K70R-M151Q was able of AZTMP 
excision, whereas other combinations thereof with only one or two 
exchanges still promoted discrimination. Furthermore, several amino 
acid substitutions present in the ribonuclease H domain correlate with 
TAMs, thus making RNase H a suitable target for inhibitors. All MR-RTs 
exhibited similar sensitivity towards RNase H inhibitors belonging to 
different inhibitor classes, indicating the importance of developing 
RNase H inhibitors further as anti-HIV drugs. Using NMR spectroscopy, 
we were able to identify the binding pocket in the HIV-1 RNase H for 
one of the RNase H inhibitors.
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HIV latency, e.g. in resting CD4+ T-cells, is the cardinal obstacle for 
eradicating the virus and curing an infected individual. Antiretroviral 
therapy (ART) is extremely effective in suppressing viral replication, 
yet fails to effectively diminish latent, transcriptionally inactive cellular 
reservoirs of HIV. Remarkably, very recently it has been demonstrated 
Page 38 of 40Retrovirology 2016, 13(Suppl 1):68
that inhibition of histone deacetylases by chemical compounds is suf-
ficient to reactivate HIV and thus to unmask and sensitize a proportion 
of latently infected cells for killing. These lysine deacetylase inhibitors 
(KDACIs) are used in basic research, and many are being investigated 
in clinical trials for treatment of cancer and other diseases like HIV. 
However, their specificities in cells are incompletely characterised. 
Here we used quantitative mass spectrometry (MS) to obtain acetyla-
tion signatures for 19 different KDACIs, covering all 18 human lysine 
deacetylases. Most KDACIs increased acetylation of a small, specific 
subset of the acetylome, including sites on histones and other chro-
matin-associated proteins. Inhibitor treatment combined with genetic 
deletion showed that the effects of the pan-sirtuin inhibitor nicoti-
namide are primarily mediated by SIRT1 inhibition. Furthermore, we 
confirmed that the effects of tubacin and bufexamac on cytoplasmic 
proteins result from inhibition of HDAC6. Bufexamac also triggered 
an HDAC6-independent, hypoxia-like response by stabilizing HIF1-α, 
providing a possible mechanistic explanation of its adverse, pro-
inflammatory effects. Our results offer a systems view of KDACI specifi-
cities, providing a profound framework for the understanding of their 
effect on latently infected cells and will support future investigations 
towards a combined ART/KDACI therapy.
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SEVI (seminal enhancer of virus infection) forms amyloid fibrils from 
fragments of the abundant semen marker prostatic acidic phos-
phatase in human seminal fluid and enhances HIV infection (Münch 
et  al., Cell, 2007). We recently identified the ability of an abundant 
cleavage product of the E4 protein of mucotropic HPV types ((Δ1–17)
E4) (thereafter referred to as E4) to assemble into cationic, intermedi-
ate amyloid fibrils that can capture and concentrate HIV particles, 
protecting virion infectivity and drastically promoting fusion to pri-
mary HIV target cells. Thus, the concept emerges that combinations of 
aggregating cleavage products originating from body fluids and from 
co-infecting pathogens may enhance the likelihood of HIV transmis-
sion in the anogenital tract. Besides antiretroviral (ART) treatment, 
protection from sexual HIV transmission by broadly neutralising anti-
bodies (bNAbs) could in principle be accomplished by active immuni-
sation with a potent vaccine or, as has been demonstrated in animal 
models, by passive immunisation with bNAbs.
In the present study we explored the capacity of three potent human 
second generation bNAbs, targeting either the CD4 binding site or 
spanning several epitopes in Env, as well as binding and entry inhibi-
tors to block infection of primary CD4 T-cells in the context of infec-
tion-enhancing amyloids, SEVI or E4 from HPV16. We observed that 
the relative and absolute efficacy of drugs and bNAbs was diminished 
to variable degrees in the presence of the infection enhancers with 
increases of IC50 concentrations ranging from 2- to 30-fold (drugs) 
and 2- to 16-fold (bNAbs), respectively. At concentrations of drugs 
or bNAbs, which reduced control infection levels to background, 
infections in the presence of the amyloid peptides were elevated by 
4- to 26-fold (drugs) or 7- to 54-fold (bNAbs). At high bNAb concen-
trations the most potent bNAbs and all drugs tested were capable of 
completely inhibiting infection even when SEVI or E4 were present. 
Taken together and in line with a recent report (Zirafi et al., Sci. Transl. 
Med., 2014), amyloid fibrils that are present at the anogenital tract can 
undermine the inhibitory effect of antiretroviral drugs and the neutral-
ising capacity of bNAbs. These types of studies may impact the drug 
and bNAb candidate selection and may help to define desirable target 
concentrations in the anogenital mucosa for the prevention of sexual 
transmission of HIV.
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Question: (−)lentiginosine (-LENT) is a non-natural iminosugar show-
ing glycosidase inhibitor properties. We have recently shown that 
-LENT exerts a preferential pro-apoptotic activity towards tumor cells 
in comparison with non-tumor cells.
Methods: The effects of -LENT on PBMC from healthy donors infected 
in  vitro with HTLV-1 by co-culture with irradiated MT-2 or C91/PL 
cells, were then evaluated through real time PCR and flow cytometry 
analysis.
Results: LENT inhibited HTLV-1 expression in a dose-dependent fash-
ion, at concentrations of 15, 10 and 5 µM, in HTLV-1 infected cells. Pro-
liferation of MT-2, C91/PL and HTLV-1-immortalized IL-2-dependent 
CD4+ cells (CD4/HTLV-1) were inhibited, in comparison with chemo-
therapeutic agent, after 24  h of treatment, with an IC50 of 327, 113 
and 131 µM, respectively, while stimulated PBMC were inhibited with 
an IC50 of 170 µM. Conversely, cell growth of HTLV-1 infected cell lines 
was more efficiently inhibited after 48–72  h of treatment, with cyto-
toxic concentrations 50 % (CC50) of 50 and 70 µM for MT-2, C91/PL and 
CD4/HTLV-1, respectively. In addition, cell growth of HTLV-1 infected 
cell lines was more efficiently inhibited after long-term treatment 
with -LENT at a concentration of 5 µM in comparison with stimulated 
PBMC and 5 µM AZT-treated HTLV-1-infected cells. Moreover, confocal 
microscopy studies and flow cytometry analysis showed that treat-
ment for 4  h with 20  µM -LENT inhibited by 50  % GLUT-1 receptor 
expression. Actually, GLUT-1 was differently distributed in the cytosol 
of -LENT-treated cells in comparison with untreated cells.
Conclusions: These data suggest that -LENT could interfere with glu-
cose metabolism in HTLV-1 infected/transformed cells, causing a pref-
erential inhibition of cell growth in these cells. The use of metabolic 
inhibitors, in combination or not with other agents, is an interesting, 
potential novel strategy against HTLV-1 associated pathologies. Fur-
ther studies are necessary to verify this hypothesis.
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Background: South Africa remains the leading country highly affected 
by HIV/AIDS, with 6.8 million people living with the disease and at 
least 3.1 million people on ARV(UNAIDS 2015). With the scale-up of 
ARV programme in the country a pragmatic approach to ART pro-
gramme in monitoring and evaluation was developed in the Western 
Cape Province of South Africa.In this study we investigated the change 
in genotypic drug resistance of the Reverse Transcriptase (PR) region 
from our viral load monitoring cohort.
Methods: We analysed the HIV-1 associated drug resistance muta-
tions in plasma samples submitted to the Tygerberg Academic Hospi-
tal National Health Service Laboratoryfor HIV-1 Viral load monitoring. 
Our 205 cohort samples with a viral load above 2000 copies/ml were 
amplified by PCR and sequenced. Viral subtyping was done using 
online tools and drug resistannce mutations were screened using the 
Stanford University HIV Drug Resistance Database for Interpretation 
and the International AIDS Society-USA Guidelines
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Results: We detected resistance associated mutations against RT 
inhibitors in 63.5 % of samples analysed. This includes 34 NRTI muta-
tions (33.9 %) and 71 NNRTI mutations (61.7 %). In addition 93.1 % of 
the virus is subtype C With 6.9  % of other non-C subtypes detected 
A(1.7 %) and B(5.2 %) respectively.
Discussion: As the ARV programme is scaling up in the country, it is 
essential to monitor and evaluate the resistance patterns of HIV-1. 
Our results shows that majority of the HIV/AIDS population around 
the Western Cape are acquiring drug resistance mutation. Our current 
results reflect that most patients harbourmutations that confer resist-
ance to first-line ARV therapy given the highest number of RT muta-
tions detected in this study.
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In the Friend retrovirus mouse model we developed potent adenovi-
rus-based vaccines that were designed to induce strong Friend virus-
specific CD8+ T cell or antibody responses, respectively. In order to 
create an optimal vaccine, we pursued a combination vaccination 
protocol.
While the vectors on their own confer strong protection from a sub-
sequent Friend virus challenge, the simple combination of the vectors 
for the establishment of an optimized immunisation protocol did not 
result in a further improvement of vaccine effectivity. In fact, we found 
that the co-immunisation of a CD8+ T cell-inducing Leader-Gag vector 
with Envelope-encoding vectors abrogated the induction of GagL85–
93-specific CD8
+ T cells, even if the two vaccines were spatially sepa-
rated. In a successive immunisation approach, we found that the order 
of vector administration was crucial for the vaccination outcome, as 
the immunisation with the CD8+ T cell inducing vector had to precede 
the immunisation with an Envelope encoding vector for the efficient 
induction of CD8+ T cells, which would otherwise be suppressed, 
whereas the antibody response to Envelope was in fact enhanced 
when the mice were adenovirus-experienced from a prior immunisa-
tion. Using a rational, two immunisations-based vaccination protocol 
we established an adenovirus-based vaccine regimen that induces 
potent immune responses and confers strong protection of highly 
Friend virus-susceptible mice from a lethal Friend virus challenge. The 
degree of protection from the high-dose challenge FV infection medi-
ated by the optimized vector-based immunisation was comparable to 
the level of protection conferred by an attenuated retrovirus immuni-
sation, which is considered by many the gold standard vector-based 
vaccines have to meet.
Our data highlights the importance to consider the interplay of vac-
cine antigens in simultaneous as well as consecutive immunisa-
tions, and demonstrates the potential of vector-based immunisation 
approaches.
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So far there have been six HIV vaccine efficacy trials, but only the 
RV144 trial provided evidence for some level of protection. The results 
of the RV144 trial showed that protection correlated with a higher 
induction of IgG3 which is the most potent antibody (AB) subclass in 
human with regard to Fc-mediated immune functions like the Anti-
body-dependent cell-mediated cytotoxicity (ADCC). Thus, it seems to 
be important which AB subclass can be induced by a vaccine.
In our previous immunisation experiments, we observed a bias in the 
HIV-1 Env-specific AB response in mice. Upon DNA vaccination with 
Env, mice tend to produce more IgG1 than IgG2a while vaccination 
with structurally comparable viral surface proteins like the Hemagglu-
tinin of the Influenza A Virus (IAV-HA) or the Fusion protein of the Res-
piratoral Syncytial Virus (RSV-F) results in a balanced response. In mice, 
IgG2a has the highest ability to induce Fc-mediated effector functions, 
therefore we want to know which mechanism leads to the differential 
immune response.
Vaccination with plasmids encoding soluble versions of HIV-Env, IAV-
HA, and RSV-F fused to the HIV-1 core protein p24 showed that the 
bias in the Env specific antibody response was transferred to the p24 
specific AB response. The surplus of IgG1 was accompanied by raised 
levels of the Th2 cytokines IL-5 and IL-13. Immunisations of knockout 
mice for MyD88 and TRIF, or Card9 respectively, led as well to a biased 
response suggesting that the bias is neither dependent on Toll Like 
Receptor (TLR) signaling nor the signaling of C-type lectin receptors 
(CLR). Interestingly, vaccination with plasmids encoding truncated ver-
sions of Env revealed that the bias vanishes when the protein is short-
ened as far as C1-V1V2. A longer version including additionally C2-V3 
still led to a bias indicating that the unbalanced response is due to a 
feature of the C2-V3 domain of the protein.
Taken together, our results indicate that Env is able to modulate the 
humoral part of the adaptive immune response via a protein imma-
nent feature within the C2-V3 domain. Further analysis of this protein 
part might improve our knowledge about the underlying mechanism 
of the differentially regulated immune response.
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T-follicular helper cells (TFH) play a central role in the formation and 
maintenance of germinal centers and the establishment of long-lived 
antibody responses. The understanding of TFH induction and develop-
ment during immune responses is crucial to build up novel vaccina-
tion strategies. As a B-cell targeting antigen-delivery system, virus-like 
particles (VLP) are able to provide several unique direct effects on the 
cognate B-cells that cannot be achieved by the monovalent form of 
the antigen. In co-cultures of transgenic T- and B-cells, cognate VLPs 
efficiently induced co-expression of TFH-master regulator transcrip-
tion factor BCL-6 together with follicular marker CXCR5 in up to 40 % 
of the CD4+ T-cells. Production of IL-21 and isotype switching of the 
B-cells to IgG1 further indicated helper functions of the generated 
BCL-6+ CXCR5+ T-cells. Our study confirms the importance of the cog-
nate B- and T-cell cross-talk for the TFH-differentiation process. Pre-
sented robust system to generate TFH cells in vitro, based on natural 
biological background and minimal additional requirements is rel-
evant for both basic scientific research on TFH cell biology and rational 
vaccine design.
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There are lines of evidence that the infection of human immunode-
ficiency virus ype-1 (HIV) causes DNA double strand break (DSB). We 
reported that HIV integrates in the DSB sites without catalytic activ-
ity of HIV integrase (IN) [1]. Here we found that Vpr is recruited to DSB 
sites and protects proviral DNA from nuclease activity during viral inte-
gration into the host genome.
We first observed that Vpr is recruited to DSB sites by FRAP assay, in 
which Vpr was accumulated to DSB tracks that were created by micro-
irradiation (μ-IR). The ChIP assay revealed similar results that Vpr was 
accumulated to the DAB1 locus after expression of I-Ppo I enzyme, a 
rare-cutting endonuclease that recognizes nucleotide sequence of 
15 base pairs, the target site of which is present in the DAB1 locus. 
Interestingly, the recruitment of Vpr to the DSB sites was observed 
even under the presence of inhibitors of ATM and DNA-PKcs, central 
factors of DSB signaling. Data suggested that the DSB sensor proteins 
are involved in the early response of Vpr to the DSB sites. To iden-
tify a responsive cellular factor, we performed μ-IR experiments in a 
patient derived cell line, in which Mre11, a component of a DSB sensor 
complex is deficient (∆Mre11 cells). Interestingly, the recruitment of 
Vpr to μ-IR created DSB sites was completely abolished in the ∆Mre11 
cell, whereas it was restored by complementation of Mre11 gene prod-
uct in the cells. We next compared data of nucleotide sequence of the 
proviral DNA-ends after infection with two types of IN-activity defec-
tive HIV viruses that were proficient or deficient of Vpr. Interestingly, 
the proviral DNA-ends sequence from Vpr deficient virus was suscep-
tible to larger deletion compared to that of proficient virus, implying 
that Vpr protected viral DNA-ends during the IN-independent integra-
tion process. Given that Mre11 and Vpr are physically associated and 
Mre11 is a nuclease that functions in DSB repair by non-homologous 
end-joining (NHEJ), data suggested that Vpr negatively regulates the 
nuclease activity of Mre11 protein, which was confirmed by in  vitro 
nuclease assay. Finally, we tested the inhibitory effect of Mre11 on 
the HIV infection, and several independent experiments revealed that 
Mre11 inhibited HIV infection, implying that Mre11 is a novel restric-
tion factor against HIV infection. Notably, the Mre11-mediated sup-
pression of viral infection was not restored by Vpr, implying that Mre11 
has multiple roles in HIV infection. Taken together with our observa-
tion that Vpr induces DNA damage in resting macrophages, we pro-
pose that Vpr is an important factor that positively functions in viral 
infection into resting macrophages, especially in the presence of inte-
grase inhibitor.
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